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Abstract 
 
I compared the rate of psychiatric comorbidity in children with Non-tic movement disorders to 
children with tics and TS. In addition, this PhD explores whether children with Non-tic movement 
disorders have elevated rates of psychiatry compared to other hospital populations, including 
Emergency patients and other Neurology patients, as well as a healthy community control group. 
My hypothesis was that children with Non-tic movement disorders would have rates of psychiatric 
comorbidities that are similar to children with tics and TS.  
To examine this hypothesis, I recruited children between the ages of 5 and 16 years from Neurology 
clinics at The Children’s Hospital at Westmead, Australia , and Great Ormond Street Hospital, United 
Kingdom, for the following two movement disorder groups: tic movement disorder cohort (consisting 
of patients with tics and Tourette Syndrome, n=158) and Non-tic movement disorder cohort, 
(consisting of patients with all other movement disorders, n=102). An additional 137 patients were 
recruited for two clinical control groups: the Emergency department control cohort (n=100) and the 
Neurology control cohort including children with peripheral neuropathy or epilepsy (n=37). In 
addition, data from 10,438 British children were included as a retrospective community control. All 
patients were screened for psychiatric comorbidities using the Development and Wellbeing 
Assessment Tool (DAWBA).  
My primary outcome was that the difference in the rate of psychiatric comorbidity in the Non-tic 
cohort (39.2%) and the Tic cohort (41.8%) was not statically significant. Importantly, the rate of 
psychiatric comorbidity in the Non-tic cohort was more than four times the rate of psychiatric 
diagnosis observed in the large retrospective community cohort (9.5%) (p<0.00001). This is the largest 
study to date exploring psychiatry in children with paediatric dystonia (n=66) and psychiatric 
comorbidities occurred in 33.3% of these patients.  
In conclusion, this study recognises that children with non-tic movement disorders are just as 
vulnerable to psychiatric comorbidities as children with tics and TS. This new evidence may encourage 
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clinicians to consider screening for psychiatric comorbidities in their movement disorder patients, 
therefore allowing for earlier diagnosis and treatment.  
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1 Introduction 
1.1 Researcher background 
I am an Advanced Trainee in Paediatric Neurology with an interest in the psychiatric and psychosocial 
experiences of patients with neurological disorders. Prior to undertaking my medical degree at the 
University of Sydney, I held a public communications background and worked in health promotion 
with a focus on mental health and adolescents. In 2003 I managed the State-wide implementation of 
a youth mental health promotion program, MindMatters, as part of the Commonwealth mental health 
strategy and this role acquainted me with the impact of psychiatric disease in children, families and 
communities across New South Wales. With this perspective, I commenced clinical medicine with an 
interest in addressing the psychiatric vulnerabilities of children as part of their medical management.  
1.2 Origin of this research project 
During my neurology training I had the privilege of learning from Professor Russell Dale, who is 
regarded an international leader in paediatric movement disorders, neuro-immunology and the 
neuropsychiatry of Tourette Syndrome.  This thesis emerged from our shared appreciation of the 
significance of psychiatry in the lives of our patients, and enthusiasm for the emerging advances in the 
area of neuropsychiatry.   
Having undertaken my paediatric neurology training at The Children’s Hospital at Westmead, a 
quaternary referral service for acute and chronic neurologic disease, I have met many families affected 
by paediatric movement disorders. Conversations with these patients, their parents and their 
physicians, have revealed frequent concerns regarding emotional and behavioural comorbidities, to 
the extent that the impact of psychiatry often outweighs the burden of the movement disorder itself. 
Similar observations have been tested and confirmed in the paediatric literature with respect to 
Tourette Syndrome, and psychiatry is well recognised in the adult diseases of Huntington’s and 
Parkinson’s. However, for paediatric movement disorders in general, the literature is sparse to non-
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existent. When I met Professor Dale early in my paediatric neurology training, he identified this area 
as a deficiency in the medical literature. We subsequently designed a research question, and this 
evolved to form the basis of my higher degree.   
1.3 Ethics approval 
Ethics approval was obtained for the study. A National Ethics Application Form and site-specific 
application was completed in accordance with the National Health and Medical Research Council. 
Applications were also made to the Sydney Children’s Hospital Human Research Ethics Committee 
(HREC/11/CHW/14) and Governance office (SSA/11/CHW/62) to ensure protocols were followed with 
the Hospital. Separate and parallel applications were submitted to the UK Health Research Authority 
(15/LO/0239) for the Great Ormond Street component of recruitment.   
1.4 Context: Movement disorders in children 
Children with movement disorders present a challenging subset of patients in paediatric neurology. 
These can be caused by diverse aetiologies which are divided into two main categories: 
• Primary genetic disorders due to important mutations or deletions of essential brain 
proteins  
• Secondary disorders, due to a brain insult such as encephalitis, stroke or metabolic disorders 
From a physiological process, the understanding of both primary and secondary movement disorders 
requires appreciation of the role of the basal ganglia. The basal ganglia comprise of sub cortical nuclear 
masses that include the caudate nucleus, the nucleus accumbens, the putamen and the globus 
pallidus. These structures have long been understood as integral to the organization of movement 
and as such, basal ganglia disorders have traditionally been described as conditions of abnormal 
movements.  
There are several reasons that make the question of psychiatry in movement disorders a timely and 
important area of research. Increasingly, the basal ganglia have become appreciated as important in 
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the development and integration of psychomotor processes, as well as cognition and behaviour. We 
have learned that rather than operating as an isolated structure, the basal ganglia and cortex interact 
as part of a complex cortico-striatal network to affect movement, cognition and emotion; more recent 
descriptions of basal ganglia disorders include dysautonomia and psychiatric disturbance. From a 
biochemical perspective, we have developed an understanding of the complex role of 
neurotransmitters and their receptors, with an awareness that neurotransmitter disruption, either 
metabolic or immune, may produce psychiatric symptoms in addition to movement disorders. Finally, 
from a molecular level, emerging genotypes have provided the basis for improved diagnosis of rare 
movement disorders and therefore present an opportunity to develop a growing knowledge base of 
psychiatric and cognitive aspects to these diseases.   
1.5 Illustrative cases 
The significance of this research is given relevance and applicability by considering the patients 
affected. 
The following four de-identified cases relay the lived experiences of patients in this study to provide 
context for the reader.   
1.5.1 Case A: Dyskinetic cerebral palsy with generalised anxiety disorder 
Patient A was a 7 yo boy with dyskinetic cerebral palsy following kernicterus. He was impaired by 
severe chorea and has a mild intellectual disability. His mother described a boy who ‘’falls to the floor 
screaming every morning because he is so afraid to go to school. I literally have to pick up him from 
the floor screaming and put him on the bus, every day. It is intolerable.” 
Patient A’s already severe anxiety was exacerbated when the family cat died.   This has resulted in a 
fear of dying that is pervasive and profound. “We have to continually reassure him that we are not 
dying if we get the slightest cold.” 
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1.5.2 Case B: tyrosine hydroxylase deficiency with comorbid separation anxiety and obsessive 
compulsive disorder 
Case B was a 12 yo girl with genetically confirmed tyrosine hydroxylase deficiency. She experienced 
dystonia and bradykinesia requiring dopamine replacement multiple times daily to manage her 
symptoms. Patient B also had comorbid epilepsy and a mild intellectual disability for which she 
received support via a teacher’s aide in a mainstream class. She had been diagnosed with ADHD 
previously and trialled on Ritalin which was found to be ineffective at regulating her attention.  
Her psychiatric problems developed around the time of commencing secondary school. She became 
very rigid in terms of her daily routine and needed to have items ‘just so’ at home. She had developed 
intrusive thoughts concerned with ‘bad things’ happening to people she cared about and was 
particularly reliant on being with her mother. Her mother reported “She gets up in the morning and 
she wants to know what I am doing. She can’t enjoy her day because she is always wondering where I 
am. She will even deliberately not take her medicine in the morning knowing this will cause bad 
dystonia, so that school will call and ask me to pick her up.”  
1.5.3  Case C: Glutaric aciduria type 1 with comorbid generalised anxiety 
Patient C was a 5 yo girl who was diagnosed with glutaric aciduria type 1 in early infancy following 
neonatal seizures and encephalopathy. Her seizures were later well controlled however dystonia 
became her primary neurological symptom. Her intellect was within the normal range. Patient C 
experienced panic attacks when taken to school in the morning. “She finds it difficult to separate. She 
is afraid that she or someone else will die or that she will get her limbs cut off.” Her mother describes 
that she becomes extremely distressed by these thoughts and “she holds back a lot from doing and 
enjoying things.” She also has specific fears about birds which became difficult to manage. “We can’t 
go to parks or even the beach, in case there are seagulls. The older she gets, the harder it is. People 
tolerate a 3yo panicking and having a melt down because of a bird, but it is harder at 5.”  
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1.5.4 Patient D: Paediatric acute-onset neuropsychiatric syndrome (PANS) with comorbid 
separation anxiety 
Patient D was a 5yo boy who experienced an explosive onset of tics and anxiety following a 
mycoplasma infection at 4yo. He was diagnosed with PANS “He is wanting me to be around him all the 
time; he will change position on the couch to be against me.  He gets upset when I leave the room. He 
became very upset at orientation for kindergarten… he said he has worried about being kidnapped.” 
He could no longer participate in activities such as swimming, as simply letting go of his mother to get 
in to the pool had become too traumatic.  
 
These patient descriptions demonstrate the impact of psychiatry to individual patients recruited for 
the study and suggest the need for efficient diagnosis and management. 
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2 Literature Review 
2.1 Introduction  
Psychiatric co morbidities have been well described in adults with movement disorders such as 
Huntington’s disease and Wilson’s disease. Attention has also been directed to behavioural disorders 
and psychiatric symptoms in children with tics and Tourette Syndrome. There is, however, little known 
about the psychiatric and behavioural problems that affect children with a broader range of 
movement disorders including genetic and acquired dystonias, myoclonus, chorea, stereotypies and 
essential tremor.  
I have reviewed the literature pertaining to psychiatric comorbidities in children with movement 
disorders. For the very rare movement disorders consideration has been expanded to include 
publications evaluating adults with these conditions. I have presented these disorders by way of 
aetiological process, including the developmental movement disorders such as tics and stereotypies, 
neurotransmitter disorders, genetic movement disorders, immune mediated disorders and other.  
Each diagnosis is explained and investigated for psychiatric comorbidities within this chapter. A table 
summarising pertinent findings is also following. (Table 2.1) 
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Table 2.1 Psychiatric comorbidities in movements disorders as found in the literature 
Diagnosis Movement disorder phenotype Established psychiatric 
symptoms 
Occasionally 
reported psychiatric 
symptoms 
Developmental 
Tourette and tic 
disorders 
Child onset, abrupt, repetitive 
semi-purposeful movements that 
typically follow a waxing and 
waning course 
OCD, ADHD, other 
anxieties, rage attacks, 
depression 
Psychosis 
Stereotypy Repetitive, rhythmic movements 
(such as hand flapping) that tend 
to occur during excitement of 
stress 
ADHD, OCD, anxiety, 
behavioural disorders 
 
 
Neurotransmitter disorders 
Dopa responsive 
dystonia (DYT 5) 
Child onset progressive dystonia 
responsive to dopamine 
Not established Depression, anxiety, 
OCD, ADHD 
Tyrosine 
hydroxylase 
deficiency 
Type A: Dystonia and hypokinetic 
rigidity 
Type B: Neonatal encephalopathy 
Not established  
6 PTPS deficiency Child onset dystonia and 
parkinsonism if untreated 
Not established OCD, depression, 
panic attacks 
Genetic disorders 
DYT1 (TOR1A) Child onset focal dystonia Not established Depression 
KMT2B dystonia Child onset progressive dystonia Not established ADHD, anxiety 
TBC1D24 
dystonia 
Dystonia and myoclonus Not established Not reported 
Myoclonus 
dystonia (SCGE) 
Child onset myoclonus and focal 
dystonia 
OCD  Anxiety, depression 
GNB1 dystonia Child onset dystonia Not established Not reported 
Glutaric aciduria 
type 1 
Dystonia and choreoathetosis 
following encephalopathy 
Nil specific to Glutaric 
aciduria 
(emotional/behavioural 
issues increased in 
organic acidaemias 
generally 
Not reported 
Paroxysmal 
kinesiogenic 
dystonia (PRRT2) 
Paroxysmal dyskinesia 
precipitated by movement 
Not established  1 case of anxiety 
reported 
Benign 
hereditary 
chorea 
Early onset hypotonia and motor 
delay followed by chorea 
Not established ADHD, OCD 
Wilson’s disease Parkinsonian symptoms with 
dystonia, tremor and bradykinesia 
Personality change, mood 
disorders, psychosis 
 
Juvenile 
Huntington’s 
disease 
Bradykinesia, tremor rigidity Mood disorders, anxiety 
and psychosis 
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Immune 
PANDAS/PANS Acute onset tics following 
infection (with streptococcal for 
PANDAS, less specific for PANS) 
Anxiety, OCD, emotional 
lability, rage attacks 
Eating disorders, 
psychosis 
Sydenham’s 
chorea 
Acute onset chorea OCD, anxiety, depression, 
ADHD 
 
Antiphospholipid 
chorea 
Acute or gradual onset chorea 
that may be associated with other 
signs of systemic autoimmune 
disease 
Not established  
Psychiatry observed with 
APL antibodies but not 
studied in chorea 
patients 
 
Basal ganglia 
encephalitis 
(Dopamine 2 
Receptor 
Antibody 
positive) 
Acute neuropsychiatric syndrome 
with dystonia or chorea and 
encephalopathy 
Not established Agitation, emotional 
lability and anxiety 
described 
Rasmussen 
encephalitis 
Usually associated with epilepsia 
partialis continua however 
hemidystonia or hemiathetosis 
has been described 
Not established Not reported 
Opsoclonus 
myoclonus 
syndrome 
Classical triad of myoclonus, 
opsoclonus and ataxia (or parts of 
this) with severe 
neurodegeneration if untreated 
Rage attacks, ODD, OCB, 
ADHD, depression 
 
Multifactorial 
Dystonic 
cerebral palsy 
Non-progressive dystonia with 
distribution depending on the 
region of cerebral injury 
Not established 
Studies of CP in general 
(not dystonic) show 
increased rates of 
emotional and 
behavioural issues 
Emotional and 
attention difficulties 
ADHD; attention deficit hyperactivity disorder, OCD; obsessive compulsive disorder, OCB; obsessive 
compulsive behaviours, PANDAS; Paediatric acute neuropsychiatric disorder associated with streptococcal, 
PANS; Paediatric acute neuropsychiatric syndrome 
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2.2 Developmental movement disorders 
2.2.1 Tourette Syndrome 
2.2.1.1 Disease overview 
Tics are sudden, rapid, abrupt, stereotyped movements that occur mostly in a paediatric population. 
Tourette syndrome (TS), also known as Tourette’s disorder or Gilles de la Tourette syndrome, is a 
chronic tic disorder in which patients exhibit both verbal and motor tics for at least 12 months. 
Simple tics and transient tic disorders are far more prevalent than TS. (Cavanna and Termine, 2012) 
TS is one of the most studied movement disorders in terms of psychiatric comorbidities, and presents 
an interesting prototype for analyzing the emotional components of movement pathways. Tics merge 
the traditional paradigms that occupy the movement disorder discourse, because the phenomenon 
blurs the distinction between voluntary and involuntary; tics are generally suppressible for a period of 
time at the cost of some discomfort to the patient, similar to trying to overcome an urge to scratch an 
itch (Cavanna and Rickards, 2013). The ‘urge’ sensation is an important part of the ‘tic’ and tics are 
increasingly considered a ‘sensori-motor’ phenomenon. 
The prevalence of tics in childhood is estimated to be between 6 and 21% (Kurlan et al., 2002).  A small 
percentage of children with tics fulfil criteria for TS. The incidence of TS in the general population is 
estimated to be between 0.5 and 2.3% (Cavanna and Rickards, 2013, Schlander et al., 2011)  with most 
experts considering 0.5% being the most accurate incidence. 
Tics primarily occur in males at a rate of four to seven times the rate of females (Comings and Comings, 
1985, Ghanizadeh and Mosallaei, 2009). There is literature to suggest that this trend decreases with 
age, and may even reverse, with TS occurring more frequently in females, in the adults who continue 
to have tics above the age of 30 years (Schlander et al., 2011). 
2.2.1.2 Pathogenesis in brief 
The cause of TS is not entirely understood and is thought to be multifactorial with hereditary and 
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environmental components (State, 2010). Family studies have shown that parents of children with TS 
are more likely to have tics or related comorbidities than adults in the general population (Matthews, 
1988). Twin studies have shown concordance rates of 50-77% in monozygotic twins as compared with 
only 10-23% of dizygotic twins (Price et al., 1985) 
The pathophysiology implicated in tics relates to disorders of neurotransmitters, particularly 
dopamine, involve disruption of pathways between the basal ganglia and the frontal cortical circuits 
(Rizzo et al., 2013, Tamara, 2013, Eddy et al., 2012, Mol Debes, 2013). There is also evidence of other 
neurotransmitter dysfunction including histamine and glutamate. 
2.2.1.3 Clinical course and diagnosis 
Tics are diagnosed on the basis of history and clinical review. Tourette syndrome can be diagnosed 
when a patient fulfils the following criteria as set out in DSM IV (Betancourt et al., 2003).   
1. the patient has both multiple motor tics (ie rapid eye blinking) and one or more vocal tics (ie 
throat clearing),  
2. the tics have been present for at least one year 
3. the tics began before he or she was 18 years of age. 
4. the symptoms are not due to another pathology or medication (ie viral encephalitis or 
amphetamines) 
Tics typically begin in early primary school years (Cavanna and Rickards, 2013) and follow a waxing 
and waning course. 
Approximately one quarter of people with TS find their tics nearly completely resolve as they approach 
adulthood, with a further one half reporting significant improvements (Erenberg et al., 1987). 
The comorbid symptoms of ADHD often occur before the onset of tics, and symptoms such as 
inattention often persist beyond resolution of the tics. The OCD symptoms typically have their onset 
when the tics are most severe however compulsions can be the presenting symptoms (Mol Debes, 
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2013). 
Interestingly, a longitudinal study of children with OCD conducted over nine years found that tics were 
actually protective against persistence of obsessive-compulsive diagnoses (Bloch et al., 2009). 
2.2.1.4 Movement disorder phenotype 
Tics are motor or vocal actions that are typically brief, repetitive without volition, although can often 
be temporarily suppressed. They tend to be preceded by a premonitory sensation and follow a waxing 
and waning course (Tamara, 2013). Exacerbating factors include stress, excitement and inter-current 
illness. The most common tics include eye-blinking, facial grimacing, and throat-clearing, however tics 
can be complex and consist of multiple motions. Whilst the general population often associates TS 
with compulsive swearing (coprolalia), this is an uncommon vocal tic. In a study of 250 cases receiving 
medical input for Tourette syndrome, which in itself is small subgroup of children with tics, only one 
third were found to have coprolalia (Comings and Comings, 1985). Other studies found coprolalia in 
~4% of TS patients, mostly in adolescents and adults with TS. (McMahon et al., 1992) 
2.2.1.5 Summary of associated psychiatric features 
The rates of psychiatric comorbidity are high in tics and TS. The comorbidities include ADHD, ODD, 
OCD, anxiety (including separation anxiety, overanxious disorder, simple phobia, social phobia, 
agoraphobia) rage attacks, panic attacks and mood disorders (including mania, major depression) (Mol 
Debes, 2013, Pollak et al., 2009, Roessner et al., 2007, Gaze et al., 2006, Denckla, 2006, Termine et al., 
2006, Kurlan et al., 2002, Ghanizadeh and Mosallaei, 2009). Pervasive developmental disorder, autism 
and Asperger Syndrome are more common in people with Tourette syndrome (Kerbeshian et al., 
2009). The most commonly studied comorbidities are discussed in more detail below. 
ADHD and tics are commonly occurring comorbidities (Groth et al., 2017a). Tics occur in about 10% of 
children with ADHD (Mol Debes, 2013) (Rizzo et al., 2013). Between 55 and 80% of children with TS 
also satisfy a diagnosis of ADHD (Cavanna and Rickards, 2013, Kerbeshian et al., 2009, Freeman, 2007). 
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Symptoms of tics and ADHD can overlap and  the inattention and impulsivity of ADHD will often 
precede tics by 2-3 years (Rizzo et al., 2013). Children with ADHD tend to be diagnosed with TS earlier 
than children without the comorbidity. Recognition of comorbid ADHD is imperative, as it is the factor 
most related to impairment and poorer psychosocial outcome in children with Tourette (Rizzo et al., 
2013, Eddy et al., 2012, Gorman et al., 2010). Children with ADHD are more likely to receive 
pharmacotherapy than children with TS alone (Debes et al., 2009). 
The role of ADHD in prediciting outcome has been so well described that studies have taken to explore 
neuroanatomical similarities of ‘Tourette and ADHD phenotypes’ and ‘ADHD alone’, finding 
neuroanatomical commonalities that are not present in children with ‘TS alone’ (Denckla, 2006). The 
behavioural components of ADHD and the involuntary movements of Tourette can both be considered 
problems of inhibition. It is proposed that they share common pathways involving fronto-striatal 
structures (Mol Debes, 2013). It could be argued that tics and ADHD occur together by chance given 
that both conditions affect boys at a particular stage in development, however even when analysing 
lifetime risk in adult population, the lifetime incidence of tics was three times as common in adults 
who had ADHD compared with controls (Spencer et al., 2001). 
There are familial studies supporting a hereditary nature to both TS and ADHD, with relatives of 
patients with either or both of these conditions being more likely to have TS and/or ADHD (Freeman, 
2007, O'Rourke et al., 2011). One study of 239 probands and 692 first degree relatives found that for 
patients with TS only, the increased rate of ADHD in relatives was explained by its comorbidity to TS, 
in that there was not a higher rate of ADHD only; instead the ADHD + TS rate was increased. This 
suggests that the genetic component of TS also creates a predisposition to ADHD, rather than the 
conditions representing one genotype (O'Rourke et al., 2011). 
For children with TS, comorbid ADHD is a risk factor for other comorbidities including OCD, 
oppositional-defiant disorder, depression, anger control, sleep issues, and learning disability (Rizzo et 
al., 2014, Freeman, 2007, Roessner et al., 2007). Whilst stimulant treatment for ADHD can exacerbate 
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existing tics when administered at high doses, the increased incidence of tics in children with ADHD is 
independent of stimulant use (Spencer et al., 2001). 
Approximately half of all people with TS have some features of obsessive-compulsive behaviour with 
most observers describing approximately 40% incidence (Como et al., 2005, Lebowitz et al., 2012). 
Parallels can be drawn between compulsions in OCD and the described ‘need to tic.’ The two disorders 
are both associated with dysfunction of the basal ganglia and it has been theorised that both 
conditions may be manifestations of a single pathophysiology with varying complexities (Cummings 
and Frankel, 1985). According to some authors, the main distinction between a tic and a compulsion 
is the complexity of the urge. Compulsions result from more complex feelings of anxiety whereas tics 
involve a different urge; ‘I need to tic’.  The urge associated with the tic tends to be more sensory, like 
an itch, than the psychological process of the compulsion (Cavanna and Rickards, 2013). 
The types of compulsions in Tourette-OCD are considered to be distinct from ‘idiopathic’ OCD. In 
Tourette-OCD, there is a commonly expressed need to have things ‘just right’, with patients feeling a 
compulsion to repeat an action over and over until it is ‘just so’. Symmetry and counting are often 
involved in Tourette-OCD (Cavanna and Rickards, 2013, Neal and Cavanna, 2013, Gomes de Alvarenga 
et al., 2012) (Como et al., 2005). By contrast contamination obsessive-compulsions are uncommon in 
Tourette-OCD unlike ‘idiopathic’ OCD. Comorbid OCD is associated with more severe tics (Lebowitz et 
al., 2012) and higher rates of anxiety, depression, ADHD, conduct disorder, and poorer overall 
functioning (Lebowitz et al., 2012, Wanderer et al., 2012, Gorman et al., 2010, Gomes de Alvarenga et 
al., 2012). 
Depression has been reported to be increased in patients with Tourette syndrome (Robertson, 2006) 
with one study finding that nearly two thirds of patients satisfied diagnosis for major depression at 
least once in their lifetime (Gorman et al., 2010). Risk factors for depression include more severe tics 
and comorbid OCD (Cavanna and Rickards, 2013). In another study of 57 people with TS, 40% had 
engaged in self-injurious behaviour.  
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The association of depression and TS is not reported as consistently as the ADHD and OCD 
comorbidities, and some authors have found no difference in the risk of depressive symptoms 
between TS groups and controls (Termine et al., 2006, Eddy et al., 2013). Anxieties other than OCD, 
such as generalized anxiety disorder and separation anxiety, are not uncommon in Tourettes. OCD 
itself is a risk factor for other anxiety comorbidities (State, 2010, Lebowitz et al., 2012). 
One study of 399 patients with TS found comorbid schizophrenia in 10 people (2%).  Six of these 
children had their onset of positive psychotic symptoms before the age of 13 years and the mean age 
of diagnosis for schizophrenia was 8.2 years. In all but one patient, the onset of tics preceded the 
onset of psychosis (Kerbeshian et al., 2009). Psychosis is therefore considered marginally elevated in 
TS. 
2.2.1.6 Treatment and prognosis 
Most patients with tics will not require medication. There is increasing interest in the use of 
Comprehensive Behavioural Intervention for Tics (CBIT) and Habit Reversal Therapy (HRT), as they are 
non-pharmacological and have a good evidence base (Woods et al., 2000). Severe and persistent tics 
and TS can be managed with several pharmacological approaches. First line therapies are alpha 
agonists, such as clonidine, that act by inhibiting norepinephrine release and turnover (Coffey et al., 
2000). It is worth noting that clonidine can result in sedation. Second line therapies for tics are typically 
anti-psychotics such as risperidone and aripiprazole, although these have a worse side effect profile. 
Other agents such as topirimate, tetrabenazine, benzodiazepines and baclofen can occasionally be 
helpful. Deep brain stimulation has been used for severe refractory tics in adulthood. Botox can also 
be used for localised severe tics such as ‘whiplash’ neck tics. 
Stimulants such as methylphenidate remain a potential therapy for comorbid ADHD and have been 
shown not to aggravate tics except in very high doses (Rizzo et al., 2013). Stimulants do not improve 
comorbid obsessive-compulsive disorder and treatments such as selective serotonin reuptake 
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inhibitors and cognitive behaviour therapy may be incorporated into a therapeutic model when OCD 
is present. 
The common refrain from the TS literature is that psychiatric and behavioral comorbidities are 
common and should be actively screened in patients with tic disorders and Tourette syndrome. As the 
comorbidities are often a greater cause of impairment than the tics themselves, the psychiatric and 
behavioural issues may present the initial treatment priority (Tamara, 2013). 
2.2.2 Stereotypies 
2.2.2.1 Disease overview 
Stereotypies are rhythmic, repetitive movements that tend to occur in moments of stress, excitement 
and fatigue (Muthugovindan and Singer, 2009). They are estimated to occur in about 20-25% of 
neurotypical infants, and almost half of the population diagnosed with autistic spectrum disorder.  
(Singer, 2009, Peter et al., 2017). 
2.2.2.2 Pathogenesis in brief 
The cause of stereotypies is not well understood. The fact that they occur in higher rates of children 
with developmental disorders suggests some disruption of the neurological pathways 
(Muthugovindan and Singer, 2009). Animal studies have suggested that neurotransmitter 
abnormalities are contributory (Peter et al., 2017) and there is evidence to suggest there is a genetic 
cause, as 25% to 39% of typically developing children with stereotypies have a positive family history 
(Harris et al., 2008, Oakley et al., 2015). 
2.2.2.3 Clinical course and diagnosis 
Motor stereotypies are usually noted before the age of 3 years. They are observed frequently in 
children with developmental disorders such as autistic spectrum disorder, however they also occur in 
neurotypical children (Muthugovindan and Singer, 2009). They can be primary (physiological) or 
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secondary (pathological) to conditions such autistic spectrum disorder (ASD) (Singer, 2009, Peter et 
al., 2017). 
2.2.2.4 Movement disorder phenotype 
Stereotypies may present as any of a broad range of repetitive movements. Some of the common 
examples are hand shaking, arm flapping, body rocking and head nodding (Singer, 2011). They have 
been divided into two subtypes including common (such as hair twisting) and complex (hand flapping). 
Primary stereotypies are far more prevalent, and complex stereotypies are often associated with 
developmental disorders (Singer, 2009). 
2.2.2.5 Spectrum of psychiatric symptoms 
The prevalence of psychiatric symptoms is high in children with stereotypies and has been noted as 
greater than 90% in one study (Oakley et al., 2015). Rates of anxiety, ADHD, OCD, tics/TS and 
behavioural problems are all elevated amongst children with stereotypies (Oakley et al., 2015, 
Cardona et al., 2016). Another large study of 100 typically developing children with stereotypy found 
that nearly half have psychiatric comorbidities. ADHD was present in 30%, tics occurred in 18% and 
obsessive-compulsive behaviours/obsessive-compulsive disorder was noted in 10% (Harris et al., 
2008).  
2.2.2.6 Treatment and prognosis 
Treatment is not generally required for children with stereotypies. Parental and patient education as 
to the diagnosis is often sufficient. Parents are often keen to know whether the stereotypies will cease 
over time and studies to date demonstrate that most stereotypies persist into late childhood and 
adulthood, however the children often become cognitively aware of their stereotypies and may do 
them in private, or reduce their visibility as they get older (Harris et al., 2008, Oakley et al., 2015). 
In cases where stereotypies are causing detriment, a cognitive behaviour therapy approach has been 
applied with some success. This requires willing participation on the part of the child and is therefore 
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not practical for children with intellectual disorder or moderate to severe ASD. It is an unfortunate 
paradox that the children who prove most refractory to psychological therapies are often those with 
the most burdensome stereotypies (Peter et al., 2017, Miller et al., 2006). 
There are no well-established pharmacological therapies for children with stereotypies. However, for 
children with self-injurious stereotypies, such as repetitive head banging in ASD, there is an argument 
to trial medication. Both anti psychotics and selective serotonin re-uptake inhibitors (SSRIs) have been 
studied in this context.  They have generally been found to be ineffective, however limited benefits 
have been observed with haloperidol, risperidone, olanzapine and some SSRIs (Doyle and McDougle, 
2012, Peter et al., 2017). 
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2.3 Neurotransmitter disorders 
  
Figure 2.1 Pathways of neurotransmitter synthesis from (Charlesworth et al., 2013) p 2029 
 
Figure 2.1 above is useful in demonstrating the pathways of neurotransmitter synthesis relevant in 
the section. Point A represents GTP-cyclohydrolase (GCH1), a gene essential for dopamine synthesis. 
Mutations in GCH1 lead to dopa responsive dystonia. Point B represents tyrosine hydroxylase (TH), 
Mutations in this gene are responsible for tyrosine hydroxylase deficiency (THD). Point C represents 6 
pyruvoyl-tetrahydropterin-synthase (6PTPS), and deficiency in this enzyme prevents formation of 
tetrahydrobiopterin, an early precursor of tyrosine which later gets converted to dopamine. 
2.3.1 Dopa responsive dystonia 
2.3.1.1 Disease overview 
The dopa responsive dystonias are a group of inherited dystonias that share the feature of marked 
improvement when treated with  exogenous levodopa (Wijemanne and Jankovic, 2015). 
more severe, with complex neurological dysfunction, including de-
velopmental delay, spasticity, seizures and physiological hyperphe-
nylalaninaemia, which is generally picked up on routine screening
of newborn infants (Ichinose et al., 1995). However, atypical pres-
entations have been described with DOPA-r sponsive dystonia
(Hwu et al., 1999), with a neonatal DOPA-responsive extrapyr-
amidal syndrome (Nardocci et al., 2003) or without hyperpheny-
laninaemia (Horvath et al., 2008; Opladen et al., 2011).
TH mutations (DYT5b)
Rarely, DOPA-responsive dystonia can also be inherited as an
autosomal recessive disorder associated with mutations in the
gene encoding tyrosine hydroxylase itself (Ludecke et al., 1996).
It is sometimes referred to as DYT5b. Only !40 cases have been
reported worldwide but with over 30 different pathogenic muta-
tions, scattered throughout the length of the gene, including its
promoter regions (Willemsen et al., 2010).
As shown in Fig. 2, tyrosine hydroxylase is involved in the con-
version of phenylalanine to dopamine, but it is also the rate-limit-
ing enzyme in the synthesis of other catecholamines, such as
norepinephrine and epinephrine. The enzyme thus plays a key
role in norma functioning of both dopaminergic and noradrener-
gic neuronal populations and, indeed, complete loss of tyrosine
hydroxylase activity appears to be lethal in knock-out mice
(Zhou et al., 1995). Patients with biallelic mutations in this gene
tend to present with a more severe disease than is seen in those
carrying heterozygous GCH1 mutations, which presumably reflects
the more profound deficiency of dopamine and norephinephrine.
Two major phenotypes can be discerned: (i) a progressive hypo-
kinetic-rigid syndrome with dystonia beginning in the first year of
life and significant improvement in response to L-DOPA; and (ii) a
more complex encephalopathy, associated with variable degrees
of hypokinesia, bradykinesia, hypotonia, dystonia, myoclonus,
ptosis and eye movement abnormalities that has its onset in the
Figure 2 Schematic illustration of the pathways for the synthesis of catecholamines and serotonin. Breakdown products are indicated by
broken arrows. Enzymes in which defects cause DOPA-responsive dystonia are shown in red with the gene symbol in brackets.
Tetrahydrobiopterin is a key cofactor in some enzymatic reactions.
Table 6 CSF neurotransmitter metabolite profiles in DOPA-responisve dystonia secondary to GCH1, TH and SPR mutations
CSF metabolite GCH1 TH SPR
Biopterin Decreased Normal Normal to slightly raised
Neopterin Decreased Normal Increased
Homovanillic acid Normal to mildly decreased Decreased Very low
5-HIAA Normal to mildly decreased Normal Very low
MHPG Normal to mildy decreased Decreased Decreased
5-HIAA = 5-hydroxyindoleactetic acid; MHPG = 3-methoxy-4-hydroxy-phenylethylene glycol.
The genetics of dystonia Brain 2013: 136; 2017–2037 | 2029
Downloaded from https://academic.oup.com/brain/article-abstract/136/7/2017/277430
by Burkitt-Ford Library user
on 29 November 2017
A 
B 
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2.3.1.2 Pathogenesis in brief 
There are several subtypes of DRD, however the most common form is DYT5 (Segawa disease), which 
is caused by a heterozygous mutation of GTP-cyclohydrolase (GCH1). GCH1 is required in the early 
stages of neurotransmitter synthesis, (see Figure 2.1 above) and mutation of GCH1 results in a 
depletion of dopamine, an essential neurotransmitter in movement regulation. More than 100 
different mutations in GCH1 have been identified (Asmus and Gasser, 2010). 
2.3.1.3 Clinical course and diagnosis 
Whilst the course is variable, DRD typically begins in childhood with lower limb dystonia as the 
presenting complaint. Generalised dystonia can develop over time. There is a strong diurnal 
fluctuation and this pattern (good in the morning, worse in the afternoon, and improvement after 
sleep) should prompt consideration of the DRD. 
Diagnosis can usually be obtained on the basis of clinical findings followed by a trial of levodopa. 
Improvement in this setting is strongly in favour of DRD, and the response to L-Dopa is typically 
complete (in contrast to other dystonic syndromes, where there may be a less dramatic effect). 
Ancillary investigations include abnormal CSF neurotransmitters and genetic investigation 
(Wijemanne and Jankovic, 2015). However, testing for mutations in the implicated genes will yield a 
diagnosis in only 80% of cases and variable penetrance means that asymptomatic patients with a 
mutation in GCH1 may not always develop the clinical syndrome. (Asmus and Gasser, 2010). 
2.3.1.4 Movement disorder phenotype 
The early stage of DRD is characterised by focal dystonia in a single lower limb, typically resulting in 
pes equinovarus, therefore impairing mobility. The dystonia generalises slowly over the following 
decade, (Segawa et al., 2003) resulting in varying severity; some patients become wheelchair 
dependant, whereas other cases remain very mild. In addition to dystonia, patients may experience 
parkinsonism, postural tremor and myoclonus (Asmus and Gasser, 2010, Segawa et al., 2003, Muller, 
2009). 
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2.3.1.5 Spectrum of psychiatric symptoms 
Whilst the motor entity of DRD has been widely reported, only limited studies have explored 
associated psychiatric symptoms. Depression has been the most commonly described psychological 
symptom, (Theuns et al., 2012, Timmers et al., 2017) and anxiety and obsessive compulsive disorder 
have been occasionally reported. A study of a large Belgian autosomal dominant DRD family found 
that out of 12 patients, depression was present in 4, anxiety in 8, and obsessive-compulsive disorder 
was reported in 3 (Theuns et al., 2012). A study of 34 DRD patients found depression requiring 
treatment in 6, and severe mood swings in 12. (Trender-Gerhard et al., 2009). However, one study of 
23 patients found that depression and anxiety were not more common than in healthy controls 
(Bruggemann et al., 2014). 
A recent study focusing on non-motor symptoms in DRD evaluated 28 patients from 10 families (18 
adults and 10 children), and compared this with matched controls. Patients with DRD were more than 
twice as likely to experience a lifetime psychiatric disorder (61% vs 29%), and mood and anxiety 
disorders were most common. ADHD and body dysmorphic disorder were occasionally seen (Timmers 
et al., 2017). 
2.3.1.6 Treatment and prognosis 
DRD responds well to levodopa and this is usually prescribed in combination with a decarboxylase 
inhibitor (DCI). The improvement is typically dramatic and immediate, however residual dystonia can 
persist in some individuals (Wijemanne and Jankovic, 2015). Tolerance can occur necessitating doses 
to be increased with duration of use (Trender-Gerhard et al., 2009), however patients typically remain 
highly responsive to L-Dopa. 
1.1.1. Tyrosine hydroxylase deficiency 
2.3.1.7 Disease overview 
Tyrosine hydroxylase deficiency (THD) is a rare disease with fewer than 70 patients described to date 
(Willemsen et al., 2010, Yeung et al., 2011, Leuzzi et al., 2017)  An autosomal recessive disorder, the 
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phenotype results from a disruption to the synthesis of dopamine, a  neurotransmitter essential for 
movement regulation. (Kurian et al., 2011) 
2.3.1.8 Pathogenesis in brief 
Dopamine, norepinephrine and epinephrine are all catecholamines produced primarily in the brain 
and adrenal medulla (Willemsen et al., 2010). Tyrosine hydroxylase is the rate-limiting enzyme 
required for the biosynthesis of catecholamines (Asmus and Gasser, 2010), specifically the conversion 
of L tyrosine to L-dihydroxyphenylalanine (L-Dopa) (see Figure 2.1 above). L-dihydroxyphenylalanine is 
then the precursor for dopamine. It has been observed in mice, that absence of tyrosine hydroxylase 
is lethal. In humans, the disease state tends to occur with tyrosine hydroxylase activities of 10-20% of 
normal (Asmus and Gasser, 2010). 
Resulting from an autosomal recessive mutation on chromosome 11p.15.5 (Willemsen et al., 2010),  
THD is characterised by a disturbance of neurotransmitter synthesis that results in a deficiency 
dopamine (Yeung et al., 2011). 
A large review of THD patients (n=36) described 24 different TH mutations in the promoter sequence, 
and exons 3, 5-14 and intron 11 of the TH gene. A total of 100 mutated alleles were reported in the 
36 individuals. Five of these involved mutations caused protein truncation, whereas others were 
missense mutations. There have been no patients homozygous for 2 truncating alleles observed, 
suggesting that an absolute absence of tyrosine hydroxylase is incompatible with life (Willemsen et 
al., 2010). 
Studies refute a clear genotype-phenotype correlation. A recent paper describing 12 Chinese patients 
with THD found that those with a previously reported genotype clinically varied from those already 
described in the literature (Yeung et al., 2011).  Willemsen’s study described clinical features of 36 
patients and categorised them into the two main subtypes of THD, described in detail below. They 
also found that patients with the same mutations could develop different subtypes (Willemsen et al., 
2010). 
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2.3.1.9 Clinical course and diagnosis 
Several distinct phenotypes have been described, including a severe early onset encephalopathy, a 
progressive dystonia responsive to dopa therapy (Grattan-Smith et al., 2002, Leuzzi et al., 2017, 
Willemsen et al., 2010) and a phenotype with myoclonus and dystonia (Gardiner et al., 2012). The 
motor component of each type is discussed in further detail in the following section.  
Deficiency of the TH enzyme results in decreased levels of the downstream products beyond the 
enzyme deficiency, specifically decreased metabolites homovanillic acid (HVA) and 3-methoxy- 4 
hydroxyphenylethylene (MHPG) (see figure 2.1). Diagnosis can therefore be confirmed by reduced 
amounts of these metabolites in CSF (Kurian et al., 2011). The parallel metabolic pathway for serotonin 
synthesis does not involve tyrosine hydroxylase as an enzyme, enabling normal levels of this pathway’s 
end metabolite (5HIAA) to form. As such, CSF of patients with THD demonstrates decreased 
concentrations of HVA and MHPG with decreased HVA/5HIAA ratios (Willemsen et al., 2010). Raised 
serum prolactin caused by lack of suppression from dopamine deficiency has been noted but is an 
inconsistent finding (Yeung et al., 2011). 
The clinical picture of the dystonic subtype may be confused with Dopa Responsive Dystonia (Segawa 
Syndrome).  An important diagnostic difference is that CSF biopterin and neopterin will be decreased 
in DRD and normal in Tyrosine hydroxylase deficiency (Yeung et al., 2011). 
Imaging is normal in the majority of patients with THD (Willemsen et al., 2010, Yeung et al., 2011).  
Abnormalities that are occasionally observed tend to be nonspecific, mild white matter changes and 
increased volume of extra cerebral CSF has also been reported. Despite the pathophysiology being 
associated with the basal ganglia, there have been no structural changes in the basal ganglia noted on 
MR (Willemsen et al., 2010). 
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Movement disorder phenotype 
Progressive hypokinetic rigid syndrome with dystonia (Type A): 
These patients tend to have uncomplicated antenatal and neonatal period. Whilst the initial cases 
described onset between 2 to 5 years, it has since been found that many have clinical signs during the 
first 2 years of life. Initial abnormalities are noted in 1 lower limb, then both lower limbs then the 
upper limbs. Manifestations include bradykinesia, rigidity and hypokinesia (Willemsen et al., 2010). 
Patients become hypokinetic and rigid followed by a dystonia of the limbs as described above. Parents 
may report abnormal posturing and regression of the child’s walking ability (Willemsen et al., 2010). 
Untreated the dystonia can be significantly debilitating with patients becoming wheelchair bound or 
bedridden (Yeung et al., 2011). Other parkinsonism features are common including slurred speech and 
mask face.  Oculogyric crisis has been observed. Diurnal fluctuation of dystonia is often noted 
(Willemsen et al., 2010) and in some cases has not been observed until as late as 10 years (Yeung et 
al., 2011). 
Severe early onset encephalopathy (Type B): 
With onset as early as a few weeks of age, (Willemsen et al., 2010) the signs of this subtype may be 
misattributed to antenatal causes and mislabelled as cerebral palsy. Abnormalities are usually noted 
before 6 months of age (Leuzzi et al., 2017, Yeung et al., 2011). Unlike the dystonic subtype described 
above, limb dystonia is uncommon in the encephalopathy form, and when dystonia does occur, it is a 
late sign. Common presentations include truncal hypotonia, global developmental delay, hypokinesia, 
oculogyric crisis and pyramidal tract signs with weakness and hyper-reflexia (Grattan-Smith et al., 
2002, Yeung et al., 2011). 
Syndrome of myoclonus and dystonia due to THD: 
This has recently been described in one set of siblings (Gardiner et al., 2012) with compound 
heterozygosity of a point mutation in the promoter region of the TH gene and a novel nonsynonymous 
substitution in exon 12. The three siblings (2 female and 1 male) had unremarkable births and were 
noted to have poor head control at 6 months. Developmental delay persisted with the children unable 
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to walk or sit. Myoclonic jerks were noted in limbs, neck and trunk. Dystonia was also present, and 
most prominent in upper limbs and the face. There was no diurnal fluctuation (Gardiner et al., 2012). 
2.3.1.10 Summary of associated psychiatric symptoms 
Whilst cognitive deficit has been well described, especially in the encephalopathic subtype (Type B) 
(Willemsen et al., 2010, Giovanniello et al., 2012) psychiatric manifestations in THD have not been 
explored. 
2.3.1.11 Treatment and prognosis 
The neurological deficit from THD is expected to be permanent in the absence of treatment.  L-Dopa 
is the primary pharmacotherapy, usually administered with a peripheral L-Dopa decarboxylase 
inhibitor to prevent loss of dopa in the in the circulation (Willemsen et al., 2010).  Alternatives or 
additions to L-Dopa include a monoamine oxidase B (MAO-B) inhibitor, to prevent breakdown of 
dopamine or an anticholinergic, such as trihexyphenidyl (Singer H. S., 2010). 
Doses are initially conservative as tolerance for L-Dopa is low in THD patients (Singer H. S., 2010), 
especially in the encephalopathic subtype (Willemsen, Verbeek et al. 2010 ). Doses may need to start 
as low as <0.5mg/kg /day, and titrate gradually over weeks or months. Side effect such as dyskinesia 
may be observed. (Willemsen et al., 2010). 
Response to treatment is a point of difference for Type A and Type B patients. Outcomes for Type A 
patients are generally very good with approximately 88% able to walk independently. Type B patients 
have a less promising prognosis both in terms of motor and cognition (Willemsen et al., 2010). The 
siblings with THD associated with myoclonus and dystonia all responded well to L Dopa therapy 
(Carecchio et al., 2017). 
It is suggested that the motor problems are improved more by therapy than the cognitive deficits 
(Giovanniello et al., 2012), and that earlier treatment results in a more favourable prognosis 
(Willemsen et al., 2010).  
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2.3.2 6-pyruvoyl-tetrahydropterin synthase deficiency  
2.3.2.1 Disease overview 
6-pyruvoyl-tetrahydropterin synthase (6PTPS) deficiency is a rare form of hyperphenylalaninemia 
resulting from tetrahydrobiopterin (BH4) deficiency (see Figure 2.1) and this in turn causes reduction 
in neurotransmitters, resulting in dystonia and other movement disorders. Untreated, 
hyperphenylalaninemia leads to encephalopathy, disability and other system disorders.   
2.3.2.2 Pathogenesis in brief 
6PTPS is an autosomal recessive disorder caused by mutations in in the PTS gene, which is located on 
chromosome 11q23.1, and codes for the enzyme 6 pyruvoyl tetrahydropterin synthase (Shintaku and 
Ohwada, 2013). 6 pyruvoyl tetrahydrobiopterin is required for the production of tyrosine hydroxylase 
and tryptophan hydroxylase and these enzymes form part of the pathway for the production of 
dopamine and serotonin. In addition, BH4 is important in the forming of phenylalanine hydroxylase 
and nitric oxidise synthase so that deficiency results accumulation of phenylalanine at toxic levels (Kao 
et al., 2004, Shintaku et al., 2000). 
2.3.2.3 Clinical course and diagnosis 
Untreated, 6PTPS results in parkinsonism and dystonia, axial hypotonia, microcephaly and intellectual 
disability (Kao et al., 2004) and hormonal abnormalities such as delayed or partial puberty.  
Respiratory failure and cardiac arrhythmias have also been reported (Roze et al., 2006). 
6PTPS deficiency can be diagnosed from genetic mutation analyses of the PTS gene. Newborn 
screening can diagnose hyperphenylalaninemia and BH4 deficiency can be differentiated from PKU by 
analysis of the dihydropteridine reductase activity on the blood spot. Other supportive investigations 
include deranged neurotransmitters in CSF (although these may be normal in mild cases) and elevated 
urine pterins (Shintaku and Ohwada, 2013). 
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2.3.2.4 Movement disorder phenotype 
The movement disorder phenotype is consistent with other dopamine deficient disorders and includes 
dystonia and choreo-athetosis. Less commonly bradykinesia, tremor and myoclonus have been 
described (Ye et al., 2013). 
2.3.2.5 Spectrum of psychiatric symptoms 
A study of 18 patients with 6PTPS found psychiatric disturbances in 2, specifically obsessive-
compulsive disorder and depression with panic attacks and it was postulated that these may be 
manifestations of serotonergic disturbance (Leuzzi et al., 2010). 
2.3.2.6 Treatment and prognosis 
Treatment involves exogenous provision of BH4, thereby enabling the degradation of phenylalanine. 
And reducing neurotoxicity. BH4 does not cross the blood brain barrier and therefore additional 
treatment with 5-hydroxytryptophan and levo-dopa are also essential to moderate the symptoms 
resulting from dopamine deficiency (Shintaku and Ohwada, 2013). 
2.4 Genetic disorders 
2.4.1 Torsion dystonia or early onset dystonia (DYT1) 
2.4.1.1 Disease overview 
DYT1 was considered the most common genetic cause of early onset dystonia, although it is possible 
KMT2B is a more common dystonia outside of Ashkenazi Jewish populations.  DYT1 typically presents 
in childhood or adolescence although it can occur in early adulthood. The primary symptom is an 
isolated dystonia of an arm or leg and the clinical spectrum is broad, however, the classical course is 
a slowly progressive dystonia. The prevalence of DYT1 is particularly common in the Ashkenazi Jew 
population (Bressman, 2004, Segawa and Nomura, 2014). 
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2.4.1.2 Pathogenesis in brief 
DYT1 is caused by an autosomal dominant mutation of the TOR1A gene, which is located on 
chromosome 9 and includes 5 exons. The typical mutation is a 3 base pair deletion resulting in the loss 
of glutamic acid (Ozelius et al., 1998, Segawa and Nomura, 2014, Granata and Warner, 2010). 
2.4.1.3 Clinical course and diagnosis 
The classical presenting scenario is a previously well child who presents with a history of arm or leg 
dystonia most notable during an action, such as writing or walking. There may also be an associated 
postural tremor. A positive family history of dystonia makes the diagnosis more likely, but the absence 
of heredity does not exclude the diagnosis. The neurological exam and neuroimaging should be 
otherwise normal (Bressman et al., 2000, Ozelius and Lubarr, 1993). 
Over time the dystonia tends to become more persistent and may progress to a fixed deformity and 
generalise to other limbs.  
2.4.1.4 Movement disorder phenotype 
The dystonia is generally focal or segmental and most noted during activity. Commonly, when a lower 
limb is affected, there may be involuntary muscle contraction causing ankle inversion and impairing 
gait. Upper limb dystonia with involuntary flexion and rotation of the wrist, is another typical pattern. 
Less frequently trunk or cervical dystonia may be the presenting symptom (Opal et al., 2002). Dystonia 
associated with DYT1 usually persists with age, and becomes more constant and generalised 
(Bressman, 2004) . 
2.4.1.5 Spectrum of associated psychiatric symptoms 
The literature reports increased rates of major depression in both symptomatic and asymptomatic 
carriers of TOR1A (Heiman et al., 2004). A single study of 13 patients with DYT1 and 13 healthy controls 
found an increase in risk taking behaviour in the dystonia patients (Heiman et al., 2004). 
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2.4.1.6 Treatment and prognosis 
Symptomatic treatment options include anticholinergics, benzodiazepines and baclofen, which may 
be beneficial (Albanese et al., 2011, Albanese et al., 2006). A trial of levodopa may be indicated during 
the diagnostic process however a marked improvement makes DYT1 unlikely and suggests a diagnosis 
of dopa responsive dystonia. Deep brain stimulation has proved efficacious in severe cases (Panov et 
al., 2013, Miri et al., 2014). 
2.4.2 Myoclonus dystonia 
2.4.2.1 Disease overview 
Myoclonus dystonia (DYT11) is a rare syndrome characterised by sudden “lightening like” jerks that 
tend to occur in the neck and upper limbs. There is often an associated focal dystonia, and symptoms 
have been found to be responsive to alcohol in some patients (Asmus et al., 2005b). Familial cases or 
sporadic cases are associated with mutation on the epsilon sarcoglycan gene (SGCE) (Rachad et al., 
2017, Charlesworth et al., 2013). 
2.4.2.2 Pathogenesis in brief 
More than 50 mutations in SGCE have been described in myoclonus dystonia (Charlesworth et al., 
2013). In familial cases of myoclonus dystonia an autosomal dominant loss-of-function mutation in 
the SCGE gene on chromosome 7q21-22 has been implicated as the most common cause, occurring 
in up to 50% of myoclonus-dystonia patients (Asmus et al., 2005b, Kim et al., 2017, Rachad et al., 
2017). Variable penetrance has been observed, and a maternal inheritance with reduced expression 
of myoclonus dystonia (asymptomatic) is often noted. Most patients with a familial form of myoclonus 
dystonia inherit their mutation from their father (Asmus et al., 2005b). 
2.4.2.3 Clinical course and diagnosis 
The onset usually occurs in early childhood (Asmus et al., 2005b, Peall et al., 2016) and the clinical 
course is thought to be non-progressive (Rachad et al., 2017). Diagnosis is typically made on the 
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characteristic distribution of myoclonus and dystonia. Radiological investigations should be normal. 
The myoclonus is subcortical and therefore an EEG should not show cortical epileptic discharges 
during myoclonic attacks. In terms of genetic testing, finding an SCGE may confirm diagnosis of 
myoclonus dystonia. 
2.4.2.4 Movement disorder phenotype 
Myoclonus of the upper limbs is the dominant feature, and is usually localised to the upper limbs, neck 
or head, and primarily involves the proximal upper limbs or the neck. Cervical or upper limb dystonia 
frequently accompanies the myoclonus. Lower limb myoclonus and dystonia can also occur (Asmus et 
al., 2005b). 
2.4.2.5 Spectrum of psychiatric symptoms 
Psychiatric symptoms have been established as frequent comorbidities in myoclonus dystonia (Kim et 
al., 2017, Peall et al., 2016). Obsessive compulsive disorder and generalised anxiety have been noted 
to occur in higher rates than in the general population (Hess et al., 2007, Peall et al., 2013), and 
depression has been observed in 30% of myoclonus dystonia patients (Hess et al., 2007, Weissbach et 
al., 2013). Patients with myoclonus dystonia are also more likely to be affected by alcohol dependence, 
which can be partly explained by the alcohol responsive nature of the myoclonus (Charlesworth et al., 
2013). In some cases, patients have reported psychiatric symptoms prior to the onset of myoclonus 
(Weissbach et al., 2013). There has been some disagreement in the literature as to whether the 
psychiatric symptoms in myoclonus dystonia are more severe in patients with SGCE mutations or 
whether the genotype is irrelevant to severity (Kim et al., 2017, Peall et al., 2016). 
2.4.2.6 Treatment and prognosis 
Generally, a non-progressive condition, some patients find temporary relief from GABA-ergic agents 
such as benzodiazepines. However, as with alcohol, benzodiazepines are prone to abuse in patients 
that find them beneficial (Charlesworth et al., 2013). There have been limited reports of levodopa 
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proving effective, and some authors advocate a levodopa trial (Luciano et al., 2009). Treatments for 
cortical myoclonus are not useful. (Roze et al., 2008, Charlesworth et al., 2013). Symptomatic therapy 
may be required for impairing psychiatric symptoms. 
2.4.3 Benign hereditary chorea  
2.4.3.1 Disease overview 
Benign hereditary chorea (BHC) is a rare form of chorea that presents in childhood and is very slowly 
progressive, or stable, into adulthood (Gras et al., 2012, Peall and Kurian, 2015). It is associated with 
mutations in the NKX2-1 gene or ADCY5 genes (Chen et al., 2015, Mencacci et al., 2015, Peall et al., 
2014). 
2.4.3.2 Pathogenesis in brief 
BHC has been attributed to autosomal dominant mutations in the NKX2.1 gene (also known as TITF-
1) located on chromosome 14q13 (Kumar and Dixon, 2014, Peall et al., 2014). Studies of BHC suggest 
that approximately 60% of cases are de novo (Gras et al., 2012, Peall et al., 2014). Mutations in ADCY5 
on chromosome 3 have been identified in familial and sporadic cases with child-onset chorea when 
they have been NKX2.1 negative chorea (Mencacci et al., 2015). 
2.4.3.3 Clinical course and diagnosis 
Patients typically present with hypotonia and motor delay within infancy. Chorea occurs within the 
first decade. Myoclonus and dystonia can also occur (Gras et al., 2012). NKX2.1 is required for genesis 
of the brain, lungs and thyroid and haplo-insufficiency of this gene results in respiratory dysfunction 
such as recurrent infections or infant respiratory distress, thyroid disease and movement disorder.  
Various combinations of these disease processes have been described including a classical triad with 
all 3 systems affected. In a study of 10 patients with confirmed NKX2.1 related chorea, only 3 
demonstrated the triad of chorea, pulmonary insufficiency and hypothyroidism (Peall et al., 2014). 
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2.4.3.4 Movement disorder phenotype 
Chorea generally starts within the first decade. Myoclonus may be associated and dystonia, tremor, 
motor tics and ataxia have been reported (Gras et al., 2012) (Peall et al., 2014). The ADCY5 chorea is 
sometimes more severe than NKX2.1 chorea and is exacerbated by stress or action (Mencacci et al., 
2015). Commonly, patients with ADCY5 mutation experience dyskinesias that interrupt sleep or occur 
during drowsiness thereby preventing sleep initiation or increased movements upon waking. (Chang 
et al., 2016).  
2.4.3.5 Spectrum of psychiatric symptoms 
There is limited data on psychiatry in BHC. One study of 28 patients showed ADHD in a quarter of the 
cohort. Symptoms of impairing hyperactivity and aggression have been reported in other studies 
(Kumar and Dixon, 2014). Peall et al studied 10 children and found one to have severe obsessive 
compulsive disorder (Peall et al., 2014). Psychosis has been described (Glik et al., 2008). 
Intellectual disability is not uncommon, occurring in 20 of the 28 BHC patients in the study by Gras et 
al (Gras et al., 2012). Other studies have found intellectual ability to be within the normal range (Peall 
et al., 2014). There are similar studies suggesting a range of cognitive abilities in the ADCY5 cohort 
with intellectual delay and normal development reported (Chang et al., 2016, Mencacci et al., 2015). 
The psychiatric profile of ADCY5 has not been investigated to date.  
2.4.3.6 Treatment and prognosis 
In NKX2.1 associated BHC the chorea has been described as remaining stable or improving into 
adulthood, however accompanying myoclonus or dystonia may continue to impair (Gras et al., 2012). 
In ADCY5 some studies have suggested the chorea may worsen in adulthood.  
Tetrabenazine has been shown to be effective in reducing chorea and improving motor function in 
some studies of patients with NKX2.1 (Gras et al., 2012), and Levodopa has also provided benefit 
(Asmus et al., 2005a). Improvement has been reported from treatment with clonazepam and 
trihexyphenidyl. Sodium valproate and sulpiride have been tried with limited efficacy (Peall et al., 
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2014). There is limited information of treatment for ADCY5 chorea, although tetrabenazine may be 
useful.  
2.4.4 Paroxysmal dyskinesia 
2.4.4.1 Disease overview 
Paroxysmal dyskinesia is the collective name for episodic movement disorders, with the most common 
being paroxysmal kinesiogenic dyskinesia (PKD). PKD is estimated to affect approximately 1 in 150,000 
people (Bruno et al., 2004). 
In PKD, the episodes of dyskinesia are precipitated by a voluntary movement (Charlesworth et al., 
2013, Gardiner et al., 2015). Other subtypes of paroxysmal dyskinesia include paroxysmal non-
kinesiogenic dyskinesia and exercise induced dyskinesia (Bruno et al., 2004, Gardiner et al., 2015). 
2.4.4.2 Pathogenesis in brief 
Paroxysmal kinesiogenic dyskinesia has been linked to mutations in PRRT2 (located on chromosome 
16p11.2). This gene is thought to be important in the release of neurotransmitters at the synapse. 
Other genetic associations include SLC2A1, which is associated with exercise induced dystonia, and 
PNKD which is associated with paroxysmal non-kinesiogenic dystonia (Ebrahimi-Fakhari et al., 2015). 
Genetic mutations are found in approximately half of all families with paroxysmal dyskinesia (Gardiner 
et al., 2015). 
2.4.4.3 Clinical course and diagnosis 
PKD usually presents within the first 2 decades of life (Bruno et al., 2004). Patients experience brief 
and frequent attacks of dyskinesia triggered by voluntary and usually sudden movements, such as 
moving from sitting to standing (Gardiner et al., 2015). Consciousness is preserved during episodes 
and the neurological examination should be otherwise normal. There is often a warning or ‘aura’ 
immediately prior to the onset of dyskinesia which may consist of paraesthesia to the affected limb 
(Charlesworth et al., 2013). 
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2.4.4.4 Movement disorder phenotype 
The dyskinesic episodes in paroxysmal dyskinesia may be dystonia, chorea or athetosis, however the 
movements must resolve between events (hence paroxysmal). Events are brief and usually last 5 to 
10 seconds, although they may last up to 5 minutes in exceptional situations. In PKD, events are 
triggered by voluntary movement (Becker et al., 2013). 
2.4.4.5 Spectrum of psychiatric symptoms 
Psychiatric symptoms have not been well described in conjunction with the paroxysmal dyskinesias. 
There is one case report describing comorbid anxiety in a man with diagnosed and treated PKD (Kunii 
et al., 2017). 
2.4.4.6 Treatment and prognosis 
PKD responds well to antiepileptic medications such as carbamazepine and topiramate. Prognosis is 
excellent (Bruno et al., 2004). Given the paroxysmal nature, and response to anti-epileptics, some 
neurologists consider PKD more akin to epilepsy than a movement disorder.  
2.4.5 Glutaric aciduria type 1 
2.4.5.1 Disease overview 
Glutaric aciduria type 1 (GA 1) is an organic aciduria that manifests as infant onset dystonia, usually as 
the result of a metabolic encephalopathy. It is a rare disorder with an estimated prevalence of 1 in 
100,000 newborns (Lindner et al., 2004, Kolker et al., 2011). 
2.4.5.2 Pathogenesis in brief  
Glutaric aciduria is an autosomal recessive disorder caused be a deficiency in glutaryl-CoA 
dehydrogenase. The gene is located on chromosome 19p13.2 and more than 200 mutations have been 
described. The deficiency of glutaryl-CoA dehydrogenase impairs the catabolism of L-lysine, L-
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hydroxylysine and L- tryptophan and results in elevated glutaric aciduria (Goodman et al., 1998, Boy 
et al., 2017). 
2.4.5.3 Clinical course and diagnosis 
Without treatment, approximately 90% of patients with GA1 develop neurological disease within the 
first 3 years of life. This typically occurs following an encephalopathic crisis precipitated by an infantile 
illness or stress. The sequelae of this crisis may include acute striatal injury, manifesting as dystonia 
and choreoathetosis (Kolker et al., 2011). Seizures may occur during periods of encephalopathy. 
Macrocephaly, subdural haemorrhages and subarachnoid cysts are also associated with GA 1 (Boy et 
al., 2017). Less commonly, a more insidious course has been reported with neurological symptoms 
evolving in the absence of an encephalopathic crisis (Boy et al., 2017). 
In some countries including Australia, GA1 is included in the newborn screening program. This involves 
testing the metabolite glutarylcarnitine in the dried blood spot. Where there is a clinical suspicious of 
GA1, quantitative analysis of organic acid is preferred for diagnosis. Mutation analysis of GHDH gene 
in fibroblasts or leukocytes confirms the diagnosis (Kolker et al., 2011). 
2.4.5.4 Movement disorder phenotype 
As outlined above, the hallmark movement dystonia of GA1 is dystonia, which may be superimposed 
on truncal hypotonia. Athetosis may also be present, and later in life, parkinsonism may be observed 
(Kolker et al., 2011). 
It is not uncommon for patients to be misdiagnosed as has having dystonic or athetoid cerebral palsy, 
particularly in the absence of a careful history and metabolic investigations.  
2.4.5.5 Spectrum of psychiatric symptoms 
There has been limited research in to the psychiatric manifestations of GA1, however some studies 
have considered psychiatric symptoms in organic acidaemias in general. One study found that patients 
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with organic acidaemias are 2.5 times as likely to have an emotional or behavioural problem than 
neuro-developmentally normal children (Jamiolkowski et al., 2016). 
2.4.5.6 Treatment and prognosis 
When treatment is initiated in the newborn period, patients typically remain asymptomatic (Kolker et 
al., 2011, Boy et al., 2017). This treatment includes adherence to a low lysine diet and carnitine 
supplementation as well as emergency treatment during crises (Boy et al., 2017). Supportive 
treatment includes benzodiazepines, baclofen and anticholinergic drugs to treat dystonia as well as 
other pharmacological and allied health treatments for symptoms, as indicated (Kolker et al., 2011). 
2.4.6 Wilson’s Disease  
2.4.6.1 Disease overview 
Wilson’s disease (WD) is an inherited disorder that results in copper accumulation and therefore 
hepatic, haematological, neurological and psychiatric dysfunction (Bandmann et al., 2015, Medici et 
al., 2007). 
2.4.6.2 Pathogenesis in brief 
An autosomal recessive mutation of the WD gene (OMIM 277900), which codes for a copper 
transporting ATP-ase, ATP7B, has been identified as the cause (Bandmann et al., 2015). This ATP-ase 
is essential in excreting copper from the liver for elimination. More than 200 mutations have been 
identified (Ferenci, 2005). 
2.4.6.3 Clinical course and diagnosis 
A disorder of copper accumulation, WD commonly presents anytime from adolescence to the fourth 
decade of life although it can occur at any age. Presenting symptoms vary, with psychiatric, 
neurological and hepatic symptoms all seen at first presentation. The disease may be multi-system (in 
about 25% of patients) or affect one system only (Medici et al., 2007, Bandmann et al., 2015). 
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Neurologic dysfunction typically presents as a parkinsonian type with bradykinesia, dystonia, tremor 
and incoordination. Hepatic symptoms may vary from mild hepatomegaly, to acute hepatitis and 
fulminant liver failure. Haemolysis is relatively common. Endocrine, cardiac and musculoskeletal 
conditions are less frequently observed (Medici et al., 2007). Psychiatric symptoms will be discussed 
in greater detail in section 2.4.6.5. 
Diagnosis is achieved by observing typical clinical features (such as the pathopneumonic Kaiser 
Fleisher rings in the cornea) and biochemical testing. The latter may include serum free copper and 
caeruloplasmin levels, and 24-hour urinary copper excretion. Imaging may demonstrate copper 
deposition within the basal ganglia on MRI Brain. In some patients, hepatic copper concentrations 
may be required. Mutation analysis is complex given the large number of mutations known to cause 
Wilson’s disease and therefore not often practical, although exome sequencing makes this more 
practical recently (Ferenci, 2005). Screening of family members following a positive index case is 
advised.  
2.4.6.4 Movement disorder phenotype 
Up to one third of patients with neurological Wilson’s have dystonia which may be generalised or focal 
(Svetel et al., 2001), and dysarthria with slow tongue movements is typical in Wilson’s. Bradykinesia 
and other parkinsonian symptoms are commonly observed. Patients with WD may also present with 
tremor and classically this is a flapping tremor, however intention tremors and rest tremors may also 
be seen (Bandmann et al., 2015). 
2.4.6.5 Spectrum of psychiatric symptoms 
Psychiatric manifestations of Wilson’s have been well documented, and 30-40% of patients with WD 
have a psychiatric symptom at the time of diagnosis (Zimbrean and Schilsky, 2014). 
 A large study retrospectively analysing 195 patients with WD found psychiatric dysfunction in half the 
cases (Dening and Berrios, 1989). Twenty percent of all the cases required psychiatric input prior the 
diagnosis of Wilson’s disease suggesting the symptoms occurred early in the disease process. Similar 
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rates have been reported elsewhere (Zimbrean and Schilsky, 2014). Specific psychiatric problems 
identified in studies include personality and behavioural change, and mood disorders such as major 
depression (Carta et al., 2012, Portala et al., 2000). Psychosis is less common (Dening and Berrios, 
1989) however there are reports that bipolar disorder occurs more frequently in WD than in the 
general population (Woerwag-Mehta et al., 2011, Carta et al., 2012). Mania was the presenting 
symptom of WD in a single case report (Machado et al., 2008). 
2.4.6.6 Treatment and prognosis 
Treatment options for Wilson’s disease include chelation therapies such as D-penicillamine or 
Trientine and therapies aimed at reducing uptake such as zinc salts (Medici et al., 2007). A paradoxical 
worsening of neurological symptoms following initiation of chelation has been well documented. The 
mechanism of this worsening is unclear but it is thought to be due to toxic effects of free copper and 
it has been suggested that starting chelation at lower doses may decrease the likelihood of this 
iatrogenic deterioration (Bandmann et al., 2015). 
Liver transplant is a definitive treatment for hepatic WD however it is generally contraindicated, or at 
the very least controversial, in patients with neuropsychiatric syndromes. Many patients with 
neuropsychiatric Wilson’s will require symptomatic treatment of their dystonia or psychiatric 
condition (Bandmann et al., 2015). 
2.4.7 Juvenile Huntington’s disease 
2.4.7.1 Disease overview 
Huntington’s disease is a rare neurodegenerative disease caused by an inherited expansion of the HTT 
gene. Juvenile Huntington’s (JH) applies when the onset is before 21 years.  Expansions of HTT gene 
increase with each generation of inheritance and larger repeats generally lead to an earlier onset of 
symptoms. Triplet repeat sizes of more than 60 repeats typically result in Juvenile Huntington’s 
disease (Monrad and Renaud, 2013). 
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2.4.7.2 Pathogenesis in brief 
JH is caused by an autosomal dominant inheritance by way of large triplet repeat expansions at one 
end of the Huntington gene. Expansion leads to neurotoxicity and degeneration of striatal neurons 
(Zuccato et al., 2010). 
2.4.7.3 Clinical course and diagnosis 
By definition, JH is clinically recognisable by 21 years of age. Children and young people with JH 
typically present with parkinsonian symptoms including bradykinesia and dystonia although other 
movement disorders may occur (Gatto et al., 2016). Other symptoms of neurological dysfunction such 
as behaviour change and cognitive decline are common, and seizures may be observed (Wojaczynska-
Stanek et al., 2006). Imaging demonstrates bilateral atrophy of the basal ganglia however this may 
normal in the early stages. The diagnosis is confirmed by genetic diagnosis (Monrad and Renaud, 
2013). 
2.4.7.4 Movement Disorder phenotype 
Whilst chorea is a common presenting disorder in adults with Huntington’s, children tend to present 
with bradykinesia, tremor and rigidity (Monrad and Renaud, 2013) and postural instability and 
dysdiadochokinesia may be present.  Involuntary movements such as chorea and myoclonus also may 
be observed (Gatto et al., 2016). 
2.4.7.5 Spectrum of psychiatric symptoms 
Psychiatric disorders have been widely described in Huntington’s, albeit not specific to JH, with rates 
of lifetime diagnosis being approximately 60% (Vassos et al., 2008). Mood disorders are the most 
common psychiatric feature, and psychotic and anxiety disorders are also seen frequently (Craufurd 
et al., 2001, Vassos et al., 2008). Drug and alcohol addiction have been associated, and apathy and 
loss of energy are regarded as common associated symptoms (Craufurd et al., 2001).  
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There is limited literature pertaining to psychiatry in the JH cohort specifically. One study examined 
data from 29 cases of JH and 9/29 had a psychiatric symptom as their presenting feature. For 3 
patients this symptom was depression, for 3 it was behavioural change (such as psychotic or obsessive-
compulsive behaviour), and for 3 it was addiction. During the course of follow up (mean 11 ±6 years) 
79% demonstrated behavioural disturbance (Ribai et al., 2007). 
An interesting clinical question is whether the gene responsible for HD could independently lead to 
psychiatric problems even in the absence of causing classic motor JH symptoms. Whilst psychiatric 
symptoms can precede the onset of motor symptoms, one study comparing the rates of psychiatric 
diagnosis in pre-symptomatic carriers found they were not significantly different from matched 
controls (Julien et al., 2007). 
2.4.7.6 Treatment and prognosis 
Treatment of JH is supportive. Movement disorder medications such as tetrabenazine may be 
indicated for chorea. Anti-psychotics such as risperidone and quetiapine may be beneficial for 
psychosis and anxiety. Anti-depressants are frequently required and antiepileptic medication may be 
indicated for seizures (Sung et al., 2018). 
2.4.8 Emerging genotypes in paediatric movement disorders  
During the time that this study has been in progress, several new genes for movement disorders were 
discovered and tested in our cohort of patients, including KMT2B, TBC1D24 and GNB1. The literature 
on each is limited, however overviews have been provided below. 
2.4.8.1 KMT2B  
KMT2B was first described in 2016 as a cause of child onset progressive generalised dystonia (DYT28) 
(Meyer et al., 2017, Zech et al., 2016). In a review of 38 patients with KMT2B dystonia, 4 patients had 
psychiatric comorbidities including ADHD and anxiety. (Gorman et al., 2018) 
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2.4.8.2 TBC1D24 
Autosomal recessive inheritance of TBC1D24 has been associated with several epilepsy phenotypes 
however it has more recently been found in patients with myoclonus and dystonia. Disability and 
intellectual impairment are commonly described, however psychiatry has not been established (Ngoh 
et al., 2017). 
2.4.8.3 GNB1 
Neuro-disability has recently been attributed to mutations in the guanine nucleotide binding protein, 
beta 1 (GNB1) gene and dystonia may form part of the phenotype. Hypotonia and seizures are other 
features described however psychiatric comorbidities have not been studied. (Steinrucke et al., 2016) 
2.5 Immune mediated disorders 
2.5.1 Sydenham’s chorea 
2.5.1.1 Disease overview 
Sydenham’s chorea (SC), historically known as St Vitus Dance, is a movement disorder defined by new 
onset chorea following infection with beta haemolytic Group A Streptococcus, and is the brain 
component of the multi-system autoimmune disorder Rheumatic fever. It is broadly accepted that 
Sydenham’s chorea can result in chorea and other motor dysfunction as well as neuropsychiatric 
symptoms (Ridel et al., 2010, Teixeira et al., 2007b, Moore, 1996). Sydenham’s chorea is a sign of acute 
rheumatic fever (ARF), and its presence in isolation can satisfy the major criteria. 
According to the World Health Organisation, the annual incidence of acute rheumatic fever is 0.5 per 
100,000 school aged children (Batzloff, 2004). Current estimates are that between 10-30% of children 
with ARF are affected by Sydenham’s chorea (Ben-Pazi et al., 2011). 
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2.5.1.2 Pathogenesis in brief 
Sydenham’s chorea is an autoimmune disorder resulting from an immunological phenomenon known 
has molecular mimicry. It is hypothesised that antibodies that previously formed in response to Group 
A Streptococcus react with structures in the basal ganglia and disrupt regulation of movement, by 
affecting basal ganglia cortical-circuits (Church, 2002, Stollerman, 1997) (Dale et al., 2004, Ridel et al., 
2010), although the exact immunopathogenesis is not clear. 
2.5.1.3 Clinical course and diagnosis  
Sydenham’s chorea is classically non-degenerative and self-limiting. Time to resolution is thought to 
be between 3 months and 2 years, however chronic cases have been described (Walker, 2010). 
Cardoso reported persistent chorea in 50% (n= 32) of Sydenham’s chorea patients at 2 years. (Cardoso 
et al., 1999). 
Sydenham’s chorea is a clinical diagnosis. It is characterised by purposeless, involuntary and 
unpredictable movements that may affect the limbs, trunk and face. According to the revised Jones 
criteria for ARF, diagnosis requires two major criteria (chorea, carditis, polyarthritis, erythema 
marginatum, subcutaneous nodules) or one major and two minor criteria (fever, arthralgia, elevated 
acute phase reactants, prolonged PR interval on electrocardiogram). For most clinical presentations, 
the diagnosis also requires evidence of a recent streptococcal infection via culture, rapid antigen or 
antibody titres (Special Writing Group of the Committee on Rheumatic Fever, 1992). 
In the case of chorea however, which can present several months after the initial streptococcal 
infection, it is accepted that evidence of recent infection may be difficult to demonstrate and is not 
considered necessary. Diagnosis should involve reasonable exclusion of other causes of chorea such 
as toxins, systemic lupus erythematosus and Wilson’s (Burke and Chang, 2014). 
2.5.1.4 Movement disorder phenotype 
The hallmark of Sydenham’s chorea is the acute onset of involuntary, jerky, non-rhythmic and 
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unpredictable movements. Other motor signs such as hypotonia, dysarthria and slowing of saccades 
may accompany the chorea (Teixeira et al., 2007a, Stollerman, 1997). 
2.5.1.5 Summary of associated psychiatric symptoms 
Sydenham’s chorea has been associated with several neuropsychiatric conditions including obsessive-
compulsive disorder, generalised anxiety disorder, depression, attention deficit hyperactivity disorder 
and psychosis (Ben-Pazi et al., 2011, Fibbe et al., 2012). 
In 1993, Swedo assessed 11 children with Sydenham’s chorea via clinical assessments and structured 
interviews. Of these children, 81% were found to have obsessive-compulsive symptoms and 36% 
satisfied the DSM criteria for diagnosis of obsessive-compulsive disorder (Swedo, 1993). This 
association has been reiterated across several studies undertaken during the two decades that 
followed.   
In one study examining 30 patients with Sydenham’s chorea, a sudden onset of obsessive -compulsive 
symptoms was noted in 21 patients (70%). Five patients (16.7%) had symptoms that were severe 
enough to satisfy diagnosis for obsessive-compulsive disorder (Asbahr, 1998). 
In a separate cohort of 20 patients with acute rheumatic fever without chorea there were no cases of 
obsessive-compulsive symptoms in that group (Asbahr, 1998). This supports the hypothesis that direct 
immunological effect on the brain, as opposed to other systemic involvement, influences emotionality 
in these patients. However, this hypothesis was refuted in the study of 59 ARF patients performed by 
Hounie et al. In this study the rates for obsessive-compulsive disorder were higher in patients with 
and without Sydenham’s chorea, than in control patients from an orthopaedic clinic.  Results between 
the chorea and non-chorea group were not statistically different (Hounie, 2004). 
A further study assessed 72 Sydenham’s chorea patients, and found symptoms consistent with OCD 
in 38.4% (Asbahr et al., 2005). Maia’s 2005 paper involved 156 patients including 56 with Sydenham’s 
chorea, 50 with ARF and no chorea, and 50 healthy controls. Maia reported obsessive- compulsive 
behaviours in 19% of Sydenham’s patients and 11% fulfilled criteria for obsessive-compulsive disorder. 
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Rates in healthy controls were 11% and 4% respectively (Maia, 2005). Dale et al reported OCD rates 
of 10% in their study of 20 patients with Sydenham’s chorea (Dale et al., 2004). 
An important issue is the distinction between Sydenham’s chorea and PANDAS; patients with 
Sydenham’s chorea by definition have chorea and they generally do not have tics. Patients diagnosed 
with PANDAS often have tics and should not have chorea. Both disorders are associated with increased 
rates of OCD however de Alvarenga and Floresi have demonstrated the obsessive-compulsive 
symptoms differ (de Alvarenga et al., 2009). 
It is worth noting that Asbahr and Garvey’s review of 73 children with Sydenham’s chorea found that 
none of these children had tics, although more than one third met DSMIV criteria for OCD.  The 
obsessive-compulsive symptoms in Sydenham’s chorea were also different from the profile of OCD in 
children with tics, and more in keeping with children who have primary OCD (de Alvarenga et al., 
2009).  
Three studies referred to anxiety disorders in Sydenham’s chorea patients. Dale et al found 
generalized anxiety disorder in 25% of the Sydenham’s chorea patients (n=20) (Dale et al., 2004). One 
study of 28 children with Sydenham’s chorea found increased rates of anxiety (panic, separation, 
phobic, avoidant) during and after the onset of movement disorder. Interestingly, there was also an 
increased rate of anxiety compared to the general population before the onset of the movement 
disorder in these children, a question of neuropsychiatric susceptibility in children who develop 
neurological sequelae from streptococcal infection (Ridel et al., 2010).  
The literature provides some evidence of an association with Sydenham’s chorea and depression. 
Ridel found that patients with Sydenham’s chorea have a premorbid prevalence of depression of 13%. 
During the acute episode of chorea this percentage increases to 31% and falls only slightly to 27% 
after the chorea resolves (Ridel et al., 2010). Dale reported increased rates of major depression (20 % 
of n= 20) (Dale et al., 2004). 
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In contrast to these trends, Teixeira assessed 32 patients with Sydenham’s chorea and 32 aged and 
gender matched asymptomatic controls. This study found that depressive symptoms were not 
increased in the Sydenham’s chorea group.  (Teixeira et al., 2007a). 
There are two case reports detailing psychosis following Sydenham’s chorea. One described a 13yo 
diagnosed with Sydenham’s chorea who developed acute comorbid visual and auditory hallucinations 
along with anxiety. The patient was commenced on penicillin and risperidone and the psychotic 
symptoms resolved within 2 weeks. The movement disorder and anxiety settled after a period of 3 
months (Teixeira et al., 2007b). 
The second case report demonstrated a chronic and refractory psychiatric course commencing at five 
years of age with chorea. More than twenty years later, the patient developed auditory hallucinations 
and visions of God, and she was hospitalised ten years later due to delusions of persecution (Casanova, 
1995). Such isolated case studies cannot account for all the confounding factors that may predispose 
an individual to psychosis, and may oversimplify the apparent causality.  
However, given the accepted association between psychosis and other chorea disorders such as 
Huntington’s disease, it seems reasonable to suggest that antibody disruption to the basal ganglia may 
in turn lead to psychotic symptoms in patients with preceding Sydenham’s chorea (Teixeira et al., 
2007b). One further retrospective study has been performed. Medical histories were reviewed for 600 
psychotic and 369 nonpsychotic subjects. There were significantly more past cases of ARF in psychotic 
patients than non-psychotic (Wilcox, 1986).  
Elevated rates of ADHD have been reported in Sydenham’s chorea. Maia described rates of 30.4% in 
patients with Sydenham’s compared to 8% of healthy controls. ADHD was more frequent in patients 
whose chorea was persistent (Maia, 2005). Ridel found that rates of ADHD were not only elevated 
(37%) in patients with Sydenham’s Chorea but that the prevalence was higher than the general 
population prior to, and following resolution of chorea. This again raised the question of biological 
susceptibility (Ridel et al., 2010). 
  63 
2.5.1.6 Treatment and prognosis 
Currently treatment of Sydenham’s chorea remains aligned with general treatment of acute 
rheumatic fever, along with symptomatic therapy for neuropsychiatric symptoms. Patients diagnosed 
with Sydenham’s chorea should be treated with 10 days of penicillin (Walker, 2010). Secondary 
prophylaxis with penicillin (or erythromycin in the case of penicillin allergy) is recommended for 
cardiac protection. Efficacy of ongoing penicillin treatment in preventing relapses of Sydenham’s 
chorea remains controversial (Walker, 2010). The duration of prophylaxis is dependent of several 
factors including age of patient, evidence of cardiac disease and time lapsed since last event (Dajani, 
1995). 
The literature recommends symptomatic therapy aimed at controlling the chorea and associated 
psychiatric or behavioural symptoms. For the chorea, dopamine receptor antagonists such as 
haloperidol are effective but if used, should be commenced slowly due to adverse effects. One study 
demonstrated that patients with Sydenham’s chorea have an increased rate of neuroleptic side effects 
(Teixeira et al., 2003). Valproate, carbamazepine and benzodiazepines remain alternatives (Walker, 
2010).  
Immunotherapy has been gaining increasing evidence, with steroids and IVIG each showing promising 
results in small studies (Fusco and Spagnoli, 2018). Barash treated five children with Sydenham’s 
chorea with a short course of steroids resulting in marked improvement within 24-48 hours and 
resolution by 12 days post treatment without relapse (Barash et al., 2005). A double-blind control 
study of children with Sydenham’s chorea, randomized children to receive 2 mg/kg/day corticosteroid 
for 4 weeks, followed by a gradual discontinuation (n=22), or placebo (n=15). The steroid group 
showed a greater improvement in symptoms at one week and a shorter time to remission. No 
statistical difference was observed with regards to rate of relapse (Paz, 2006). More recently other 
forms of immunomodulation have been recommended for the treatment of Sydenham’s chorea. A 
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randomised study of 18 patients with SC found that patients treated with IVIG or plasma exchange 
received greater clinical improvement than patients treated with oral steroids (Garvey et al., 2005).  
The outcome of psychiatric symptoms is less well understood. In Swedo’s study demonstrating 
increased rates of OCD in Sydenham chorea patients, the cohort improved by 18 months so that none 
of them fulfilled criteria for OCD by this stage (Swedo, 1993). Of the 70% of Sydenham’s chorea 
patients who developed obsessive compulsive symptoms in Asbahr’s study, 28.6% still had obsessive 
compulsive symptoms at 5-6 months (Asbahr, 1998). Asbahr went on to publish a series of 4 cases the 
following year and amongst that cohort of 4 adolescents, symptoms of OCD occurred simultaneously 
with the first episode of chorea in 2 patients. All 4 patients had recurring chorea and associated 
obsessive-compulsive symptoms up to 3 years later posing the question of increased vulnerability with 
repeated chorea episodes (Asbahr, 1999). 
Amid the limited studies of depression, anxiety, psychosis and ADHD in Sydenham’s chorea there is a 
suggestion that the psychiatric symptoms outlast the movement disorder (Ridel et al., 2010, Casanova, 
1995, Teixeira et al., 2007b) however the literature examining this hypothesis is lacking.    
2.5.2 Paediatric autoimmune neuropsychiatric disorder associated with streptococcus  
2.5.2.1 Disease overview 
Of all the disorders featured in this review, the one that attracts the greatest scepticism and 
controversy is paediatric autoimmune neuropsychiatric disorder associated with streptococcus 
(PANDAS).  
As early as 1894 William Osler was commenting on the historical misunderstandings surrounding 
chorea (Osler, 1894) and eventually it became accepted that streptococcus infection could cause 
neuropathology. Over a century later Sydenham’s chorea holds its place as an established post-
infectious entity. However, PANDAS has yet to be established broadly. The existence and classification 
of psychological manifestations occurring after streptococcus continues to attract debate in the 
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medical literature and the topic deserves analysis here, as children with PANDAS typically have both 
movement disorders and psychiatric diagnoses.  
Estimation of the actual prevalence of PANDAS is not well described and this is complicated by the 
inconsistencies of inclusion criteria in various studies. Epidemiological data of related conditions such 
as Tourette’s Disorder and OCD find that 0.3%-3% of children are affected with these conditions 
(Murphy et al., 2010a) suggesting that a smaller subset may fulfil criteria for PANDAS. The criteria for 
PANDAS dictates pre-pubertal onset (Swedo, 2001) and few if any patients are reported under the age 
of 3 years (Pavone et al., 2004). 
2.5.2.2 Pathogenesis in brief 
PANDAS refers to a specific constellation associated with infection due to Group A Streptococcus 
(GAS). GAS is a commonly acquired organism and resulting clinical infections include pharyngitis, 
impetigo, scarlet fever and septicaemia. There are numerous non-suppurative conditions including 
rheumatic fever and glomerulonephritis. (Murphy et al., 2010a). 
PANDAS implies an immune mediated pathophysiology that results in a disorder of the central nervous 
system. The most widely accepted theory refers to molecular mimicry, similar to the mechanism 
described in rheumatic carditis. In PANDAS, it is proposed that antibodies produced in response to 
streptococcal exposure mistake brain tissue for streptococcal antigen and become disease causing 
(Murphy et al., 2010a).  
This hypothetical pathophysiology is supported by several studies demonstrating auto-antibodies 
against the basal ganglia antigens of patients with PANDAS (Murphy et al., 2010a). Various theories 
have been postulated as to the more detailed pathophysiology including direct impact on basal ganglia 
receptors, either stimulating or inhibiting, or forming immune complexes that actually damage the 
brain parenchyma (Lewin et al., 2011, Giedd et al., 1996). Further consideration of anatomic basis is 
given by Giedd et al who compared the MRI brains of 34 children with PANDAS to 82 ‘normal healthy’ 
controls. This study noted that the average sizes of the caudate, putamen and globus pallidus were 
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significantly smaller in the PANDAS group when compared to the healthy controls (Giedd et al., 1996), 
In view of the widespread colonisation of GAS in childhood populations, the question emerges as to 
why certain children develop the PANDAS sequelae. The issue of genetic susceptibility is discussed in 
several studies, both in terms of susceptibility to autoimmunity as well as predisposition to anxiety 
and related disorders. The rate of autoimmunity as determined by a structured medical interview in 
mothers of children with tics, OCD and PANDAS was 17.8%, which was quoted to be significantly 
greater than the general prevalence. Rates of autoimmunity were greater again in the subgroup that 
had features suggestive of PANDAS (Murphy et al., 2010b), 
In terms of genetic predisposition for neurological deficit, one study examined pedigrees of 54 
children with PANDAS and found that 39% had at least one first degree relative with a history of tic 
and 26% had at least one first degree relative with OCD (Lougee et al., 2000).  
A further study illustrated PANDAS in two siblings with the onset of disease separated by 3 years.. 
(Dranitzki, 2007). These familial studies can provide some basis to a multifactorial disease with 
environmental and genetic susceptibility. 
Caution in terms of attributing too great an emphasis to genotype is offered by Lewin and Storch et al 
who analysed 3 children with PANDAS and their genetically identical twin or triplet and found variation 
in the clinical phenotype, from full PANDAS to asymptomatic. This suggests that the pathogenesis is 
more complex than a linear interaction between the organism and genetics, as is true for all 
multifactorial diseases (Lewin et al., 2011). 
Another interesting observation is that when children with PANDAS were analysed retrospectively in 
a study by Murphy and Storch, they were found to have a higher rate of tonsillectomies and 
adenoidectomies than children without PANDAS. (Murphy et al., 2012). A recent epidemiological 
study in Denmark performed streptococcal throat testing in more than 600,000 children.  This study 
found that a positive streptococcal test was associated with increased rates of OCD and tics than 
children without a streptococcal infection. Interestingly children with non-streptococcal throat 
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infections were also at increased risk compared to children without any infection. (Orlovska et al., 
2017). Various interpretations for these associations have been offered including that cumulative 
streptococcal infections were factors in the child developing PANDAS. It has also been suggested that 
the absence of lymphoid tissue post-surgery rendered these children more vulnerable to future 
infections.  
2.5.2.3 Clinical course and diagnosis 
The diagnosis of PANDAS requires a temporal correlation with streptococcal infection and should 
adhere to the 5 point criteria outlined below. This issue deserves emphasis in terms of clinical practice 
as well as research methodology. A recent assessment of children diagnosed with PANDAS found that 
more than half did not strictly meet the NIH criteria for PANDAS (Gabbay et al., 2008). Typically the 
streptococcal infection will precede the onset of OCD by a few days to 2 weeks, however a simple 
demonstration of positive anti-streptolysin O titre does not suffice, as some children are chronic 
carriers  (Murphy et al., 2010a). A correct diagnostic process should thoroughly enquire about the 
onset and sudden presentation of symptoms as well as recurrent infections or suggestions of GAS, 
throat infections or scarlet fever. Streptococcal titres should be taken at symptoms onset and retested 
in 4-6 weeks looking for a rise in titre (Murphy et al., 2010a, Swedo, 2004, Murphy et al., 2012). 
2.5.2.4 Movement disorder phenotype 
The term PANDAS defines a range of brain-related deficits and the symptoms that are most widely 
described include OCD, anxiety and tics.  
In the seminal study by Swedo in 1998 - 5 clinical characteristics were outlined to provide diagnostic 
criteria for PANDAS. These include: 
1. prepubertal onset usually between 3 years and 12 years 
2. obsessive compulsive disorder, a tic disorder (lifetime diagnostic criteria) 
3. sudden explosive onset of symptoms and course of recurrent sudden exacerbations and 
remissions 
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4. temporal relationship of exacerbations with streptococcal infections  
5. presence of neurological abnormalities during periods of symptom exacerbation (tics, 
hyperactivity) 
(Swedo, 1998) 
The tics commonly include eye blinking, tongue protrusion, shoulder shrug, facial grimacing, lip 
sucking and neck jerking (Mabrouk and Eapen, 2009). Distal choreiform movements have been 
described in PANDAS and may occur up to 3 months following a tic exacerbation (Murphy et al., 
2010a).  Choreiform movements have also been seen in general childhood onset OCD, tics, and ADHD 
and it has been raised that the neurological symptoms may simply reflect the comorbidities seen in 
other children with TS and OCD (Hirschtritt et al., 2009). 
2.5.2.5 Summary of associated psychiatric features 
Children with PANDAS typically have psychiatric manifestations that include anxiety, and specifically, 
there is a high rate of obsessive-compulsive disorder. Features that distinguish PANDAS patients from 
other children with OCD include the sudden onset of the disorder, with children who were previously 
unaffected developing a sudden manifestation of psychiatric concerns. Emotionality is characteristic 
with separation anxiety, nightmares, personality changes and rage episodes all observed.  There can 
also be psychotic symptoms although these are atypical (Murphy et al., 2010a). Other symptoms 
include secondary nocturnal enuresis and stuttering which may be anxiety related (Swedo, 1998) as 
well deterioration in handwriting (Mell et al., 2005). 
Several authors have drawn distinctions between the OCD in PANDAS to the OCD seen in other 
children. Bernstein analysed children between 6-14 years and assigned diagnosis of PANDAS-OCD on 
the basis of Swedo et al’s criteria (described in section 2.5.2.4 above). Comparisons were drawn 
between non-PANDAS OCD using several questionnaires including Children’s Yale-Brown Obsessive 
Compulsive Scale and Anxiety Disorders Interview Schedule for DSM-IV. Separation anxiety, 
deterioration in handwriting, and decline in school performance were all more prevalent in the initial 
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episode of children with PANDAS–OCD (Bernstein et al., 2010). Other studies found that the 
neuropsychiatric symptoms of PANDAS patients were in keeping with, and not distinct from, the 
primary neuropsychiatric presentation, such as OCD or Tourette syndrome (Hirschtritt et al., 2009). 
Variations to PANDAS have been offered including PANDAS manifesting as anorexia nervosa (Puxley 
et al., 2008), infantile onset PANDAS and adult onset PANDAS (Pavone et al., 2004). Descriptions 
remain limited with approximately 20 cases of PANDAS anorexia and 3 cases of possible PANDAS in 
children under 3 years, however these entities are not broadly accepted or well studied to date. 
Whilst there is debate in the literature as to the extent to which PANDAS psychiatry can be distinct 
from non-PANDA-OCD and TS, the more accepted point of difference is the fulminant onset and ‘saw-
tooth’ fluctuation. The classical clinical picture of PANDAS depicts a sudden deterioration in a 
previously high functioning and unaffected child with severe changes noted over 24-72 hours, such 
that parents might describe ‘a different child’ overnight (Murphy et al., 2010a). Following the sudden 
change in anxious behaviour, the OCD and tics may improve or completely resolve. There may be 
complete remission or recurrent exacerbations. For the latter group it is not uncommon for the 
interval between exacerbations to become briefer with each episode (Murphy et al., 2010a). 
Murphy and Storch’s study examined 109 patients with tics, OCD or both. They were subsequently 
classified as PANDAS and non-PANDAS via clinical interview, neurological exam, autoimmune 
tendencies and serology. They found that children in the PANDAS group were more likely to have 
definite remissions in neuropsychiatric symptoms and have dramatic onset of symptoms (Murphy et 
al., 2012).  
2.5.2.6 Treatment and prognosis 
Patients with PANDAS should receive conventional therapy for their OCD, tic and other 
neuropsychiatric disorders, including cognitive behaviour therapy and SSRIs for OCD, stimulants for 
ADHD, and clonidine, guanfacine, or a dopamine receptor antagonist for tics (Murphy et al., 2010a, 
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Singer et al., 2012). Cognitive behaviour therapy is regarded as a standard therapy for general OCD 
and success has been demonstrated in 7 patients with PANDAS-OCD (Storch et al., 2006). 
Both penicillin and azithromycin prophylaxis have been studied (Murphy et al., 2010a) and in one 
study, 23 subjects with PANDAS were enrolled in a double blind trial comparing antibiotic prophylaxis 
with penicillin compared to azithromycin over a 12-month period. Both the antibiotic groups 
demonstrated a decrease in neuropsychiatric presentations compared with the previous year, 
however there was no placebo arm to allow for consideration of that effect (Snider et al., 2005). 
Garvey studied 37 children with PANDAS comparing penicillin to placebo and found no difference in 
obsessive compulsive or tic severity, although compliance was problematic (Garvey, 1999). 
Given the hypothesis of autoimmunity as a key factor in PANDAS it is not surprising that IVIG and 
plasmapheresis have been trialled. Perlmutter’s study looked at 29 children with severe, infection-
triggered exacerbations of OCD or tic disorder and randomly assigned them to plasma exchange, IVIG 
or placebo. Follow up was at 1 month and then 12 months. Perlmutter reported improvements in 
obsessive-compulsive symptoms, anxiety and overall functioning (Perlmutter et al., 1999). Singer 
pronounced strong criticism of this study in view of limited control patients; the placebo was only for 
IVIG and after one month these children were placed in open trials. Singer also highlights that several 
of the improved patients continued on their psychotropic medications, several without achieving dose 
reduction (Singer, 1999). Singer articulated the caution that should be applied when considering these 
treatments given the potential adverse effects that are weighed against limited evidence for efficacy. 
Whilst the medical and scientific scholars debate the criteria and mere existence of PANDAS, the 
general community have become intrigued by this post-infectious disorder that seems to change the 
thoughts and emotions of their children overnight. Tanya Murphy outlines the astonishing statistic 
that there are approximately 100,000 Internet sites featuring the streptococcus-OCD association 
(Murphy et al., 2010a). 
During the last decade there has been a broadening of the understanding of acute onset 
neuropsychiatric syndromes similar to PANDAS with a de-emphasis of streptococcal as the causative 
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agent. Childhood acute neuropsychiatric syndrome CANS) (Singer et al., 2012) and Paediatric acute-
onset neuropsychiatric syndrome (PANS), which does not require a streptococcal trigger, (Murphy et 
al., 2014) are now proposed entities, in addition to PANDAS.  
2.6 The auto-immune encephalitis syndromes 
2.6.1 Anti-NMDA Receptor (NMDA-R) Encephalitis 
2.6.1.1 Disease overview 
The autoimmune encephalitis conditions are known to cause a spectrum of clinical syndromes 
involving movement disorder and psychiatric manifestations (Hacohen et al., 2013). NMDA Receptor 
encephalitis is likely to be more common than originally thought, and it has been shown that 
approximately 4% of patients hospitalised for encephalitis are NMDA R Ab positive (Granerod et al., 
2010). Despite initially been described as a para-neoplastic syndrome in adult women with ovarian 
teratoma it is now recognised that up to 40% of patients are 18 years or younger (Florance et al., 
2009). 
2.6.1.2 Pathogenesis in brief 
Anti-NMDA R encephalitis is caused by hypofunction of the NMDA receptor secondary to 
autoantibodies targeting the NR1a subunit (Dalmau et al., 2011). The clinical picture implicates 
dysfunction of cortical subcortical structures, limbic regions, amygdala, and fronto-striatal circuitry 
(Dalmau et al., 2011, Gable et al., 2012).  
2.6.1.3 Clinical course and diagnosis 
The typical clinical course is characterized by a prodrome that may include headache, fever, nausea, 
vomiting and respiratory symptoms. Within two weeks patients commonly develop psychiatric 
symptoms. This is often followed by development of a movement disorder and encephalopathy with 
possible seizures and mutism is common. There is typically progression to a catatonic state, and 
following this, patients may require intensive care for autonomic instability (Dalmau et al., 2011, Gable 
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et al., 2012). 
MRI abnormalities are seen in up to 50% of patients with non-enhancing T2 lesions in the temporal 
lobes, cerebral cortex, cerebellum, brainstem and basal ganglia (Dalmau et al., 2008, Dalmau et al., 
2011, Hacohen et al., 2013). The lesions are usually transient however, and atrophy has been noted 
in follow up at six months in a minority.  EEG demonstrates generalized slowing or less frequently 
epileptiform changes (Hacohen et al., 2013). Commonly in the CSF there is lymphocytic pleocytosis 
with raised protein and oligoclonal bands. Most patients have intrathecal production of anti-NMDA R 
antibodies when tested (Dalmau et al., 2011). 
2.6.1.4 Movement disorder phenotype 
After an initial period of altered level of consciousness and agitation, abnormal movements are 
generally noted and oro-lingual-facial dyskinesia is a hallmark feature. Other movement disorders are 
common, and include choreoathetosis, dystonia, rigidity and oculo-gyric crisis (Baizabal-Carvallo et al., 
2013). Several movement disorders may occur simultaneously and repetitive stereotyped movements 
are often observed (Mohammad et al., 2014, Dalmau et al., 2011). 
2.6.1.5 Summary of associated psychiatric symptoms 
The spectrum of psychiatric symptoms is broad. The psychiatric symptoms that are well established 
in the literature include anxiety and psychosis, specifically delusions of grandeur, hyper-religosity and 
paranoia.  Social withdrawal may be an early symptom. Mood disturbances including mania and 
irritability are frequently described (Dalmau et al., 2011, Maneta and Garcia, 2013, Dalmau et al., 
2008). 
Paediatric patients experience behavioural and personality change as an initial feature, however this 
may be difficult to detect in the younger patient and the diagnosis may be delayed until movement 
disorders or encephalopathy develop (Florance et al., 2009, Dalmau et al., 2011). There have been 
cases of NMDA R encephalitis with psychiatric symptoms only (Kayser et al., 2013). 
  73 
 
2.6.1.6 Treatment and prognosis 
For patients with ovarian tumours, removal of the tumour is the primary treatment. Otherwise first 
line treatment includes immunotherapy such as corticcosteroids, IVIG or plasma exchange (Ingram 
and Robertson, 2013). Some patients require second line immunotherapy including rituximab, 
cyclophosphamide, mycophenolate or azathioprine (Dalmau et al., 2011). Patients who are tumour 
negative are more likely to require second line immunotherapy.  
The clinical course is long, with patients often requiring hospitalization for three months or more. 
Recovery often occurs in reverse order to symptom onset;  patients awake from the catatonia, develop 
autonomic instability and then recover verbal functions (Dalmau et al., 2011). Outcome is variable 
with approximately 50% to 75% of patients demonstrating recovery or mild residual deficits (Dalmau 
et al., 2011, Titulaer et al., 2013, Hacohen et al., 2013, Dalmau et al., 2008). At follow up of 12-60 
months from onset, 50% of patients had ongoing behaviour or cognition issues and 33% had ongoing 
seizures (Hacohen et al., 2013). The mortality rate is estimated to be 3% (Gable et al., 2012).  
2.6.2 Basal ganglia encephalitis 
2.6.2.1 Disease overview 
Basal ganglia encephalitis is a clinic-radiological syndrome with dystonia-akinesia plus radiological 
basal ganglia inflammatory lesions. Antibodies to dopamine 2 (D2) receptors have been implicated in 
basal ganglia encephalitis and may result in this acute neuropsychiatric syndrome. 
2.6.2.2 Pathogenesis in brief 
D2 receptors are expressed in the basal ganglia as well as in the cortex. Autoantibodies targeting these 
receptors are thought to disrupt the basal ganglia circuitry (Dale et al., 2012, Ingram and Robertson, 
2013). 
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2.6.2.3 Clinical course and diagnosis  
Basal ganglia encephalitis is characterized by lethargy, movement disorder (dystonia-akinesia) and 
psychiatry. Brain MRI may be normal or show inflammatory lesions in the basal ganglia and brainstem. 
EEG can be unremarkable or demonstrate changes suggestive of encephalopathy. Antibodies may be 
detected on serum (Dale et al., 2012). 
2.6.2.4 Movement disorder phenotype 
The movement disorders are typically dystonic, possibly with dystonic tremor. Parkinsonism and 
chorea are other common symptoms, and ataxia and oculogyric crisis have occasionally been 
described. (Dale et al., 2012) 
2.6.2.5 Spectrum of psychiatric symptoms 
Psychiatric disturbance occurs in most patients. These symptoms included agitation, emotional 
lability, anxiety and psychotic symptoms. Sleep disorders and mutism have also been observed (Dale 
et al., 2012). 
2.6.2.6 Treatment and prognosis 
Treatment is often commenced empirically during the diagnostic process. Preliminary observations 
have found high dose steroids and intravenous immunoglobulin to be beneficial. Symptomatic 
treatment of motor and psychiatric symptoms is often required. Although small numbers limit 
extrapolation, full recovery has been noted in under half of the D2R patients presented in the 
literature. Chronic sequelae include dystonia, cognitive problems and psychiatric comorbidity. One 
study that followed 4 patients for 3 to 13 years post disease, found all 4 had ongoing executive 
dysfunction, fine motor difficulties and anxiety at final follow up (Pawela et al., 2017). 
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2.6.3 Opsoclonus myoclonus ataxia syndrome 
2.6.3.1 Disease overview 
Opsoclonus-myoclonus ataxia syndrome (OMAS) is a rare and serious neurological disorder of auto-
immune aetiology. Its hallmark features are opsoclonus, myoclonus and ataxia and OMAS may occur 
as a paraneoplastic syndrome, classically associated with neuroblastoma. 
2.6.3.2 Pathogenesis in brief 
Whilst the exact mechanism is not clear, OMAS is understood to be an auto-immune disorder with the 
adaptive immune system targeting CNS structures such as the cerebellar and basal ganglia (Pranzatelli 
and Tate, 2016). This response is thought to be provoked by paraneoplastic or para-infectious 
processes (Galstyan et al., 2017). 
2.6.3.3 Clinical course and diagnosis 
OMAS generally occurs in early childhood, usually before 3 years of age (Brunklaus et al., 2011). It is 
common for the neurological symptoms to be preceded by a prodrome of irritability resembling a viral 
illness. Children then present with ataxia or frequent falls, tremor and myoclonus. Opsoclonus, 
hypotonia and speech difficulties can present later along with behavioural issues (Tate et al., 2005). 
Children lose motor control and deteriorate cognitively (Turkel et al., 2006). The diagnosis is clinical 
with supporting data such as neuro-inflammation evident in the CSF (Pranzatelli and Tate, 2016). 
Unfortunately, the time from first presentation to diagnosis is often several months (Tate et al., 2005). 
If left untreated, and indeed even in the setting of treatment (Pranzatelli and Tate, 2016), long term 
neurocognitive deficits occur frequently.  
Neural crest tumours has been diagnosed in approximately forty per cent of cases of OMAS (Brunklaus 
et al., 2011, Tate et al., 2005) and therefore a crucial step after making the diagnosis is screening for 
occult neuroblastoma or neuroganglioma.  
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2.6.3.4 Movement Disorder phenotype 
The movement disorders seen in OMAS include myoclonus, tremor and opsoclonus the latter being 
essentially pathognomonic for OMAS when occurring in the appropriate clinical setting. The 
myoclonus and tremor are typically generalised (Tate et al., 2005). Families often report dysarthria 
and speech regression.   
2.6.3.5 Spectrum of psychiatric symptoms 
Irritability and mood dysfunction are common in the initial phase of OMAS, and night terrors have 
been observed at or soon after diagnosis (Turkel et al., 2006). Neuropsychiatric symptoms are also 
commonly observed as part of the chronic disease process. An American study of 100 children with 
OMAS found that psychiatric symptoms were present in most patients. Rage attacks were reported in 
79%, oppositional defiant disorder in 65%, obsessions and compulsions in 58% and hyperactivity, 
depressions and ADHD were also more common. Behaviour problems have been recognised in several 
studies (Brunklaus et al., 2011), and impulsivity and emotional instability are noted (Klein et al., 2007, 
Pranzatelli et al., 2005). Aggressiveness and self-injurious behaviour have also been reported (Papero 
et al., 1995, Turkel et al., 2006, Tate et al., 2005). 
2.6.3.6 Treatment and prognosis 
Until recently, publications examining the long-term prognosis of OMAS demonstrated poor outcome. 
Early immunosuppressive treatment has been shown to improve prognosis.  Recommendations now 
direct provision of corticosteroid or ACTH and IVIG, with a disease modifying agent such as Rituximab 
for moderate-severe cases (Galstyan et al., 2017, Pranzatelli and Tate, 2016), and this has been 
associated with better preservation of functioning and cognition. 
2.6.4 Antiphospholipid chorea 
2.6.4.1 Disease overview 
Antiphospholipid chorea is a rare manifestation of chorea that occurs in the presence of 
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antiphospholipid antibodies (Peluso et al., 2012).  
2.6.4.2 Pathogenesis in brief 
The exact pathophysiology involved in antiphospholipid chorea is not well understood. Studies have 
suggested that antibodies cross the blood brain barrier and form immune complexes with antigens in 
cerebral tissue (Bresnihan et al., 1979, Ho et al., 2016, Sokol et al., 2007). Previous suggestions that 
the mechanism was a pro-thombotic assault on basal ganglia vasculature have given way to a 
hypothesis based on endothelial dysfunction, inflammation and direct neural injury caused by aPL 
antibodies (Peluso et al., 2012). 
Antibodies implicated in antiphospholipid chorea include lupus anticoagulant, anticardiolipin 
antibodies, antinuclear antibodies, anti-DNA, anti-Ro, anti-RNP, anti-La, and anti-Sm (Cervera et al., 
1997) (Chapman et al., 2003, Ho et al., 2016). Antiphospholipid syndromes tend to occur mostly 
commonly in systemic autoimmune disease, specifically SLE, however, viral infections such as HIV and 
herpes have also been associated (Peluso et al., 2012). Less frequently antiphospholipid syndrome can 
occur as a primary process without systemic or viral trigger.  
2.6.4.3 Clinical course and diagnosis 
Antiphospholipid syndrome may result in a range of symptoms including thromboembolic events or 
stroke, or broader neuropsychiatric symptoms including migraine, seizures or dementia. 
Antiphospholipid syndrome can either be primary (occurring with no other inflammatory syndrome) 
or secondary to a systemic inflammatory disease such as systemic lupus erythematous. Unlike other 
neuropsychiatric presentations occurring in SLE, which may or may not be associated with raised 
antibody titres, antiphospholipid and lupus chorea is almost invariably associated with 
antiphospholipid antibodies (Benseler and Silverman, 2007). Other neurological symptoms that can 
occur in this syndrome include headache, cerebrovascular disease, seizures, transverse myelitis, and 
ataxia (Sanna et al., 2003, Arnson et al., 2010). The diagnosis relies on clinical recognition of chorea 
and detection of antibodies in serum. Neuro-imaging is not generally useful although can be important 
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to exclude other pathologies.  Because of the implications for treatment it is important to differentiate 
the diagnosis from other causes of chorea such as Sydenham’s chorea, BHC and Wilson’s disease 
(Peluso et al., 2012). 
2.6.4.4 Movement disorder phenotype 
Anti-phospholipid chorea presents as a typical chorea, characterised by random, dance-like 
dyskinesia. It is more often unilateral than bilateral (Benseler and Silverman, 2007), or the chorea may 
start on one side then affects the contralateral side in succession. Interestingly most patients with 
antiphospholipid chorea have only one episode of chorea (Peluso et al., 2012). 
2.6.4.5 Spectrum of psychiatric symptoms 
There have been several studies examining neuropsychiatric symptoms in antiphospholipid 
syndromes with mood disorders, anxiety and psychosis all found to be associated, although there have 
been no dedicated studies to explore psychiatry in antiphospholipid chorea specifically (Sanna et al., 
2003, Hallab et al., 2018, Montero-Olvera et al., 2017, Gris et al., 2015). Anti-phospholipid screening 
may form part of the work-up for new onset psychiatric symptoms, and a study of hospital patients 
with psychosis found that one third had antiphospholipid antibodies, however the significance of this 
is uncertain (Schwartz et al., 1998). One case of pathological gambling has also been described with 
antiphospholipid chorea {Barros, 2011 #1951. 
2.6.4.6 Treatment and prognosis 
Treatment options include immunosuppressive treatment such as steroids and other immune 
suppressants, for example, cyclophosphamide (often in combination, particularly if monotherapy 
does not lead to remission). Symptomatic treatment including neuroleptics such as haloperidol may 
be required for the chorea {Peluso, 2012 #1811}. 
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2.6.5 Rasmussen and dystonia – a rare phenotype in a rare disease 
Rasmussen encephalitis is an uncommon inflammatory process affecting one cerebral hemisphere 
and it most commonly associated with epilepsia partialis continua and progressive cerebral atrophy 
on MRI. Rarely hemidystonia and hemiathetosis have been described.  (Bhatjiwale et al., 1998, Frucht, 
2002) Progressive intellectual impairment may result however psychiatric comorbidities remain 
largely unknown Varadkar, 2014 #2072}. 
2.7 Other 
2.7.1 Essential tremor 
2.7.1.1 Disease overview 
Essential tremor (ET) is one of the most common movement disorders seen by physicians and yet its 
pathophysiology is not well understood. Traditionally described as an isolated tremor syndrome, more 
recently the condition has been expanded to include gait ataxia. Credence has also been granted to 
the concept that essential tremor may actually be an umbrella for several different disease processes 
(Louis, 2014). 
2.7.1.2 Pathogenesis in brief 
The cause of ET is not well understood however it is generally accepted to be a disorder of cerebellar 
dysfunction (Chunling and Zheng, 2016). Studies have strongly supported a genetic basis and several 
genetic loci have been presented (Lorenz and Deuschl, 2007). 
2.7.1.3 Clinical course and diagnosis 
Essential tremor is characterised by a tremor, and this may be accompanied by other symptoms 
including sleep disturbance, mild cognitive and memory impairment (Chunling and Zheng, 2016, 
Chandran and Pal, 2012). The diagnostic approach is primarily concerned with clinical criteria and 
excluding other causes of trauma such as Parkinson’s disease and hyperthyroidism (Lorenz and 
Deuschl, 2007). 
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2.7.1.4 Movement Disorder phenotype 
Essential tremor is typically a kinetic tremor of 4 Hz and 12 Hz occurring primarily in the upper limbs. 
A postural tremor may be noted, however this is less marked than the kinetic tremor.  The tremor 
tends to be exaggerated during voluntary movements such as eating or writing (Louis, 2005). The 
impact is variable with some people describing very subtle symptoms, and patients at the more severe 
end of the spectrum may be unable to dress or feed themselves. Overall the tremor is thought to be 
slowly progressive (Louis, 2005, Benito-Leon and Louis, 2006). 
2.7.1.5 Spectrum of psychiatric symptoms 
Despite its relatively common incidence, essential tremor has not been extensively studied with 
regards to psychiatric symptoms. Depression has been found in 40 to 55% of patients (Louis et al., 
2007, Fabbrini et al., 2012). A prospective analysis also found that people with depression were more 
likely to develop essential tremor, suggesting this may be a primary process rather than a reactive 
mood disorder (Louis et al., 2007). Social phobia, anxiety, sleep disturbance and fatigability have all 
been reported to be increased in people with essential tremor (Schneier et al., 2001, Sengul et al., 
2015). A study of patients who had been treated with deep brain stimulation for essential tremor 
found that the patient’s own perception of tremor severity was the strongest predictor of depression 
and anxiety (Achey et al., 2018). 
2.7.1.6 Treatment and prognosis 
Treatment options for ET include pharmacotherapy options, such as propanolol, topirimate and 
gabapentin. Pregabalin, benzodiazepines, botox injections and zonisamide may also show some 
improvement in tremor. Deep brain stimulation and thalatomy have been found to be effective in 
severe cases (Lorenz and Deuschl, 2007, Zesiewicz et al., 2005). 
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2.7.2 Dystonic cerebral palsy (CP) 
2.7.2.1 Disease overview 
Dystonic CP refers to a group of heterogeneous conditions that result in non-progressive disturbance 
of movement with varying degrees of dystonia. As a subset of cerebral palsy, dystonic CP is far less 
common than spastic CP, and dystonic CP accounts for approximately 15% of the broader cerebral 
palsy cohort (Himmelmann et al., 2005, Lin et al., 2014). 
2.7.2.2 Pathogenesis in brief 
Dystonic CP can result from a range of pathologies although most involve injury to the basal ganglia 
as a common mechanism. Frequent causes include (in order of prevalence) neonatal hypoxic 
ischaemic encephalopathy, prematurity and kernicterus followed by less frequent metabolic and 
infectious processes (Lin et al., 2014). Sometimes there is no apparent cause of dystonic CP, and 
genetic causes are increasingly identified. 
2.7.2.3 Clinical course and diagnosis 
The course of cerebral palsy is, by definition, non-progressive and related to the anatomical 
distribution and extent of brain injury. Patients may be mild or severely affected. Despite the static 
nature of the movement disorder, associated complications from neurological disease such as 
contractures, scoliosis, respiratory infection and gastrointestinal complications may cause impairment 
that worsens over time. In some patients, particularly those with injury extending to the cerebral 
hemispheres, intellectual impairment and epilepsy may occur (Himmelmann et al., 2007). 
2.7.2.4 Movement disorder phenotype 
Patients with dystonic cerebral palsy are affected by dystonia as the name implies. The location of the 
dystonia is related to the underlying pattern of injury and may manifest as hemidystonia or bilateral 
involvement. Athetosis, dysarthria and spasticity may accompany the dystonia (Himmelmann et al., 
2005). 
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2.7.2.5 Spectrum of psychiatric symptoms 
Studies of dystonic CP have explored cognition and quality of life, however few have investigated 
psychiatry. One study of 22 children with dystonic CP found high levels of social and emotional 
difficulties, as well as hyperactivity and attention problems (Adegboye et al., 2017). Literature looking 
at CP in general reports higher rates of psychological problems than in the general population 
(Ramstad et al., 2012, Foster et al., 2010, Parkes et al., 2008). Children with CP are more likely to be 
affected by depression, impulsivity, adjustment disorder and emotional lability than healthy cohorts 
(Foster et al., 2010, Fevang et al., 2017).  
2.7.2.6 Treatment and prognosis 
Supportive and multi-disciplinary treatment (including physiotherapy, orthotics and orthopaedic 
intervention) is important for decreasing the burden of immobility and preventing complications in 
dystonic CP. Symptomatic treatment of dystonia can include clonidine, benzodiazepines, baclofen or 
Trihexyphenidyl. Botox, baclofen pumps and tendon release are sometimes needed. Severe cases may 
benefit from deep brain stimulation, although the benefit is sometimes modest (Cif, 2015).  
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3 Method 
3.1 Aims 
1. To describe the prevalence of psychiatric co-morbidities in children (5-16 years) with 
diagnosed movement disorders from an Australian and British tertiary hospital population 
 
2. To compare the prevalence of psychiatric co-morbidities in children (5-16 years) with a 
movement disorder to children who have no neurological disease or any other chronic disease 
(emergency department hospital control group) 
 
3. To compare the prevalence of psychiatric co-morbidities in children and young people (5-16 
years) with children with a neurological disorder distinct from a movement disorder, 
specifically a peripheral neuropathy or epilepsy (neurology control)  
 
4. To compare within the movement disorder group, the prevalence of psychiatric comorbidities 
of children with Tourette syndrome to children with movement disorders distinct from 
Tourette syndrome including dystonia, chorea, tremor, myoclonus, stereotypy and 
bradykinesia.  
 
5. To identify correlations between specific movement disorders (grouped by aetiology and/or 
clinical patterns) and specific types of psychiatric disorders 
3.2 Hypothesis 
I hypothesised that children and young people with movement disorders were significantly more likely 
to have a psychiatric disorder than children without a movement disorder. I expected that children 
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with movement disorders other than Tourette syndrome (such as dystonia and chorea) will have 
elevated rates of psychiatric comorbidity similar to children with Tourette Syndrome 
3.3 Study design overview 
A multi-centre clinical project, the study systematically compared the prevalence of psychiatric 
diagnoses from children in the study group (children with diagnosed movement disorders) to children 
from distinct control groups (Emergency control and Neurology control). The movement disorder 
study group consisted of patients known to The Children’s Hospital at Westmead, Australia.  To 
increase the size of our study group we also recruited movement disorder patients from Great 
Ormond Street Hospital (GOSH), London UK. All patients from the control groups were recruited from 
the Children’s Hospital at Westmead (CHW), Sydney Australia. Control patients were only sought in 
Australia, as a large UK based normative sample already existed from a previous published study using 
the same assessment tool applied in this study. (Ford et al., 2003) I utilised this existing normative 
data for comparative purpose in our analysis. 
Psychiatric assessment occurred through the use of a structured questionnaire called the 
Development and Wellbeing Assessment (DAWBA) tool and I have described this tool in detail below. 
The psychiatric diagnoses were made in line with DSMV criteria and determined by a Psychiatrist.  
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Figure 3.1 Overview of study design 
 
DAWBA; Development and Well-Being Assessment 
 
3.3.1 Hospital context 1: The Children’s Hospital at Westmead, Sydney, Australia 
The majority of movement disorder subjects and all the control subjects were recruited from the 
Children’s Hospital at Westmead (CHW). CHW is the largest paediatric hospital in New South Wales, 
Australia and services the Sydney area and regional New South Wales. There is a tertiary neurology 
service with a dedicated movement disorder clinic, tic clinic, complex epilepsy service and a peripheral 
neuromuscular clinic. Patients from the movement disorder group and the neurology control group, 
including neuropathy and epilepsy patients, were recruited through these services. The hospital 
Emergency Department services children from birth to 16 years of age with a range of urgent medical 
and surgical needs, and the emergency department predominantly sees children local to hospital with 
acute and emergency conditions. Patients from the Emergency control cohort were recruited through 
this emergency department.  
 
Movement Disorder 
(260)
(Tic  = 158
Non tic = 102)
Emergency
Control
n = 100
Neurology
Control 
n = 37
(Neuropathy = 25, 
epilepsy =12)
DAWBA ALGORITHM DIAGNOSIS
PSYCHIATRIST GENERATED DIAGNOSIS
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3.3.2 Hospital context 2: Great Ormond Street Hospital, London, United Kingdom 
Great Ormond Street Hospital (GOSH) is a large tertiary hospital located in Central London, the United 
Kingdom. In addition to a 24  bed inpatient neurology ward, the hospital runs multiple neurology 
clinics and a multidisciplinary Tourette Syndrome clinic. 
3.3.3 Selection of cohorts 
Three patient groups were selected for the study: 
The study group consisted of patients with movement disorders (n=260). Within that group there were 
patients with tic movement disorders (Tic MD, n=158) and patients with movement disorders other 
than tics (Non-tic MD) such as dystonia, chorea, tremor, myoclonus (n=102). Of the tic patients 75/158 
were recruited in the UK, and 83/158 were recruited in Australia. Within the Non-tic cohort 5/102 
were recruited in the UK and the remaining 97/102 were Australian patients. The decision to define 
patients as Tic or Non-tic was important because cohorts of tics and Tourette have previously been 
the subject of extensive research into psychiatric comorbidities, and served as a positive control group 
against the less common movement disorders.  
The first control group was a Hospital Emergency control group (n=100).  
These are patients who presented to the Emergency Department at The Children’s Hospital at 
Westmead with an acute presentation. These children had no movement disorders or neurological 
conditions, but presented with a range of medical and surgical problems. This group should not be 
considered a ‘normal’ group of children, but instead a ‘hospital’ group without neurological disorders, 
for comparison. 
The second control group was a neurology control group (n=37). 
These patients had a diagnosed peripheral neuropathy (n=25) or epilepsy (n=12) but did not have a 
movement disorder. This group provided an interesting comparator because it crudely controlled for 
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confounding factors such as disability and medical intervention for neurological disease during 
childhood. Patients in this control group had neurological impairments without a movement disorder.  
3.3.4 Inclusion criteria 
All patients recruited for the study were between 5 and 16 years. They were all required to have verbal 
skills, to the extent that they could communicate in sentences and therefore facilitate some 
understanding of their behaviour and psychiatry in the detail required to complete the DAWBA.  
Detailed inclusion criteria specific for each of the subgroups has been outlined in later sections.  
3.3.5 Exclusion criteria 
Patients were excluded if they were outside the age of 5-16 years, if they were non-verbal or if they 
or their parent or guardian were unable to understand English to the extent that an informed consent 
was made difficult or completion of the DAWBA was not possible (see below).  
3.4 The assessment tool – The Development and Well-Being Assessment tool 
Extensive consideration was given to the selection of an assessment tool suitable for the screening of 
psychiatric diagnoses. The Development and Wellbeing Assessment Tool (DAWBA), Child and 
Adolescent Psychiatric Assessment (CAPA), Diagnostic Interview Schedule for Children IV (DISC IV), 
Children’s Interview for Psychiatric Symptoms (ChIPS) and Kiddie Schedule for Affective Disorders and 
Schizophrenia (K-SADS) were identified as potential means of assessment and interrogated for their 
strengths and limitations.  
3.4.1 Description of the DAWBA 
The Development and Wellbeing Assessment Tool is a validated and structured screening 
questionnaire designed to determine psychiatric diagnosis in a population setting. Applicable to 
children between the ages of 2 and 17 years, it consists of multiple choice and open-ended questions 
that investigate psychiatric, emotional and behavioural aspects of a child’s development and 
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functioning. There is a mandatory component for parents to complete and an optional component for 
young people over the age of 11 to complete. (Goodman, 2000) 
Outcomes from the DAWBA are depicted as DSMIV, DSMV or ICD diagnoses. The following disorders 
are screened: separation anxiety, specific phobia, social phobia, panic disorder / agoraphobia, post-
traumatic stress disorder, obsessive compulsive disorder, generalised anxiety disorder, body 
dysmorphic disorder, disruptive mood dysregulation disorder, major depression, ADHD / 
hyperkinesia, oppositional defiant disorder, conduct disorder, eating disorders, including anorexia, 
bulimia and binge eating, autism spectrum disorders, tic disorders, including Tourette Syndrome and 
bipolar disorders (Ford et al., 2003). 
A computer algorithm within the DAWBA determines the probability of diagnoses and a qualified child 
and adolescent psychiatrist reviews the entire questionnaire with responses and provides a final 
diagnosis. These final diagnoses were the basis of psychiatric prevalence examined in the study. The 
emphasis on DSMV diagnosis as opposed to quality of life or functioning domains was one of the 
characteristics of the DAWBA that led us to use the DAWBA for this psychiatric study.  
3.4.2 Description of considered alternatives: CAPA, K-SADS, ChIPS, DISC IV 
The Child and Adolescent Psychiatric Assessment (CAPA) screens for behaviour, mood, anxiety, sleep, 
eating, elimination, substance abuse, tic and psychotic disorders (Angold and Costello, 2000). It 
demands interviewers to be trained to recognise various psychiatric symptoms that have been defined 
in a customised glossary. A combination of open and closed questions form screening, mandatory or 
discretionary probes are used  (Angold and Costello, 2000). Symptoms screened are in accordance 
with DSM III, DSM IV, ICD-10 criteria, and in the case where symptoms are recognised, questions are 
then asked about the level of impact caused (Angold and Costello, 2000) (Angold et al., 2012). The 
intensity of symptoms is generally rated on a 3 or 4 point scale (Angold and Costello, 2000). A 
computer algorithm generates the diagnosis based on coded data that has been derived from the 
interview scoring (Angold et al., 2012). 
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Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS) is a semi-structured interview that 
screens for affective disorders such as anxiety, depression and bipolar disorder (Renou et al., 2004). 
K-SADS is administered by a health professional or trained researcher who can provide interpretation 
of questions and responses.  
Children’s Interview for Psychiatric Symptoms (ChIPS) is a structured interview also to be administered 
by trained interviewers, preferably with at least a bachelor’s degree in mental health.  Symptoms and 
diagnoses are in accordance with the DSM symptom. ChIPS screens for 20 disorders and parallel child 
and parent versions exist. A detailed scoring system requires the interviewer to document responses 
and scores in a scoring booklet, which can then be calculated to determine the presence or absence 
of a DSMIV diagnosis (Weller et al., 2000). 
Diagnostic Interview Schedule for Children IV (DISC IV) is a structured diagnostic tool that contains 
approximately 3000 questions. It is administered by lay interviewers who require training, and screens 
for more that 30 psychiatric diagnoses using DSMIV and ICD-10 criteria. Like the CAPA, a computer-
scoring program generates the diagnosis (Angold et al., 2012). Parallel parent and youth 
questionnaires are combined for analysis (Shaffer et al., 2000). 
3.4.3 Selection of the DAWBA 
As a research screening tool, the DAWBA offered several benefits. Unlike the CAPA, ChIPS, DISC and 
K-SADS, the DAWBA can be self-administered without the need for a trained interviewer. The vast 
majority of patients that we recruited completed the DAWBA remotely on a computer connected to 
the internet. This allowed parents and patients the freedom to participate in the study at their chosen 
time and location, thereby improving acceptability to families, and therefore compliance. Many 
patients completed the study on a hospital iPad during hospital admissions, or following clinic 
appointments. For families who did not wish to complete on the internet, I interviewed them over the 
phone or in-person using the DAWBA format.  All questions included in the DAWBA are listed in the 
appendix (Appendices 2 and 3). 
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The DAWBA has been created to be user-friendly and relatively short. In a comparative study of the 
DAWBA, the DISC IV Diagnostic Interview Schedule for Children Version IV, and the CAPA, the DAWBA 
took significantly less time (33 minutes) than the DISC IV and CAPA for lay interviewers to complete 
(55 minutes and 60 minutes respectively) (Angold et al., 2012). Consisting of simply-phrased questions 
that are mostly multiple-choice, the DAWBA can be completed by the parent and youth without the 
need for a skilled interviewer.  ‘Skip rules’ are included in the DAWBA, allowing the questionnaire to 
‘skip’ ahead if a particular session is deemed irrelevant for the participant on the basis of previous 
responses.  In our study, the time for completion varied depending on the extent of psychological 
impairment depicted in the answers, the time for consideration taken by the participant, and other 
factors such as additional conversation had during face-to-face interview or level of computer literacy 
for those who completed the DAWBA online.  
The DAWBA is a validated and peer reviewed tool that has been widely reported in the medical 
literature, and applied to more than 10,000 children in the United Kingdom (Goodman, 2011) 
(Goodman, 2000). In an early study assessing its validity as a screening tool, the DAWBA was applied 
to a community setting (n=491) and clinic setting (n=39). The DAWBA was found to be excellent in 
differentiating the community and clinic samples. When comparing DAWBA to clinician-based 
diagnoses, the DAWBA demonstrated strong reliability. In cases where the clinician had diagnosed 
one psychiatric disorder, the DAWBA agreed in 93% of cases. The DAWBA had a tendency to diagnose 
more comorbid disorders than the clinician, however on review of the case notes, the clinician 
diagnosed the DAWBA diagnoses as ‘possible’ rather than absent (Goodman, 2000). 
A later study examining the clinical utility of the DAWBA was performed on 270 new referrals to a 
large child and adolescent psychiatric service in Zurich. The DAWBA diagnosis was randomly disclosed 
prior to clinical assessment in approximately half the cases. Diagnostic agreement was noted in 77% 
of disclosed internalising disorders, such as generalised anxiety and major depression, and 68% of the 
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non-disclosed cases. Rates for externalising disorders, such as ADHD and oppositional defiant disorder 
were similar (Aebi et al., 2012). 
Precedent exists to illustrate the utility of DAWBA in assessing psychiatric issues in children with 
neurological disorders such as Sydenham’s Chorea (Dale et al., 2004) and across a range of other 
paediatric studies as described in table 3.1 
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Table 3.1 Utility of DAWBA in previous studies 
Author  Year Area of study Age 
range  
Cohort 
descriptors 
Chief findings 
Halabi et al 
(Halabi et al., 
2017) 
 
2017 Bullying and 
psychosocial 
correlates in 
Lebanese 
population 
11-
17y 
Random 
(geographical 
clustering) 
sample of youth 
in Beirut 
(n=510) 
Anxiety disorder and 
disruptive behaviour 
disorder were 
associated with being 
bullied 
Santos 
et al (Santos 
et al., 2017) 
2017 Gestational 
age at birth 
and 
behavioural 
problems 
6-11y Population 
based birth 
cohort (n=4231) 
No significant 
correlation between 
behaviour problems and 
gestational age at birth 
Jesmin et al 
(Jesmin et al., 
2016) 
2016 Psychiatric 
Disorders in 
children 
attending 
Paediatric 
Outpatients of 
Tertiary 
Hospitals 
5-16y Patients 
attending 
outpatient 
appts at tertiary 
hospital in 
Bangladesh 
(n=240) 
18% had a psychiatric 
disorder 
Groth et al 
(Groth et al., 
2017b) 
2017 Comorbidities 
in Tourette 
Syndrome 
5-19y Patients at a 
Danish National 
Tourette Clinic 
(n=227) 
63% had psychiatric 
comorbidities at a 6 
year follow up 
Maalouf et al 
(Maalouf et 
al., 2016) 
2016 Psychiatric 
disorders in 
adolescents 
among 
Lebanon 
11-
17y 
Cluster 
sampling across 
Beirut (n=510) 
30-day prevalence for 
psychiatric diagnosis 
was 26.1% 
Elberling et al 
(Elberling et 
al., 2016) 
2016 Psychiatric 
Disorders in 
Danish 
children 
5-7y Sample from 
Copenhagen 
Child Cohort 
(n=1585) 
Prevalence of any ICD-
10 disorder was 5.7% 
Alvarenga et 
al (Alvarenga 
et al., 2016) 
2016 Psychiatric 
comorbidities 
in children 
obsessive 
compulsive 
symptoms  
6-12y  
OCD (n=77) 
 
OCS (n=488) 
 
Unaffected 
(n=1947) 
 
Total (2512) 
 
OCD group had higher 
rates of comorbid 
psychiatric disorders 
than the OCS or 
unaffected 
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Xiaoli et al 
(Xiaoli et al., 
2014) 
2014 Prevalence of 
psychiatric 
disorders 
among 
children and 
adolescents in 
north east 
China 
6-17y School students 
in Northeast 
China (9806) 
9.49% of the sample 
had a DSMIV diagnosis 
Machnes-
Maayan et al 
(Machnes-
Maayan et 
al., 2014) 
2014 Psychiatric 
comorbidities 
in children 
with recurrent 
headache or 
abdominal 
pain 
5-17y Children 
attending 
tertiary medical 
centre for  
   Migraine 
(n=32),  
tension 
headache 
(n=32), 
 recurrent 
abdominal pain 
(n=32) 
Healthy 
matched 
controls (f/u for 
brief acute 
illness) (n=33) 
All 3 study groups had 
higher rates of 
psychiatric diagnoses 
than the control group 
(Migraine 65.6%, 
Tension headache 75%,  
abdo pain 52% and 
control 21%) 
 
Rabin et al 
(Rabin et al., 
2013) 
2013 Emotional and 
behavioural 
comorbidities 
in children 
with epilepsy 
5-17y Patients with 
epilepsy in 
Bangladesh 
(n=50) 
Age matched 
controls (n=50) 
Psychiatric disorders 
were noted in 44% of 
children with epilepsy 
and 22% of controls 
Dale et al 
(Dale et al., 
2004) 
2004 Psychiatric 
comorbidities 
in children 
with post-
streptococcal 
dyskinesia  
 Patients with 
post 
streptococcal 
dyskinesia 
presenting to a 
tertiary centre 
(n=40) 
62.65% of patients had 
a psychiatric 
comorbidity 
Ford et al 
(Ford et al., 
2003) 
2003 Prevalence of 
psychiatric 
disorders in 
British children 
and 
adolescents 
5-15y Systematic 
sampling across 
a range of 
postal areas 
from a national 
register 
(n=10438) 
9.5% had a DSMIV 
diagnosis 
ADHD; attention deficit hyperactivity disorder, ODD/CD; oppositional defiant/ conduct 
disorder, TDC; typically developing cohort, OCD; obsessive compulsive disorder, OCS; 
obsessive compulsive symptoms, ICD-10; International Statistical Classification of Diseases and 
Related Health Problems, DSM-IV; Diagnostic and Statistical Manual of Mental Disorders, 4th 
Edition 
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To promote credibility of the research findings in my study, an effort was made to select a tool that 
under-diagnosed rather than over-diagnosed psychiatric disorders (and was therefore more rigorous). 
Angold et al compared the DAWBA to the CAPA and DISC in for children aged 9 to 16 who attended a 
primary care paediatric clinic (n=646) in North Carolina. The DAWBA detected 1 or more diagnoses in 
17.7% of youth, suggesting it was a far more conservative than the DISC and CAPA which diagnosed 
disorders in 47.1% and 32.4% of youth respectively (Angold et al., 2012). 
The DAWBA has the provision for a nominated teacher to participate in a supplementary survey. 
Following significant consideration, I decided not to incorporate this section of the questionnaire in 
this study, as it was hypothesised that a requirement to provide school contact details may reduce the 
number of parents who agreed to participate in the study. The likely outcome of this was that we 
underdiagnosed behaviour disorders that may have been reported by teachers more than parents.  
3.5 Ethics 
Ethics approval was obtained for the study. A National Ethics Application Form and site-specific 
application was completed in accordance with the National Health and Medical Research Council. 
Applications were also made to the Sydney Children’s Hospital Human Research Ethics Committee (H 
REC/11/CHW/14) and Governance office (SSA/11/CHW/62) to ensure protocols were followed with 
the Hospital. Separate and parallel applications were submitted to the UK Health Research Authority 
(15/LO/0239) for the Great Ormond Street component of recruitment.   
3.6 Study cohorts in detail 
3.6.1 Study cohort 1 – Movement disorder: Tic and Non-tic cohorts 
3.6.1.1 Explanation and rationale 
We aimed to have a large group of children 5-16 years with a wide range of movement disorders in 
the study. Due to the established medical literature depicting high rates of psychiatric comorbidity in 
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children with Tourette Syndrome, we were determined to have 2 subgroups – the first being children 
with tics and TS movement disorder (Tic MD cohort) as a positive control given the increased incidence 
of psychiatry has been established in the literature), and the second being children with other 
movement disorders other than Tourette Syndrome (Non-tic MD cohort).  
 An effort was made to recruit all eligible children with diagnosed movement disorders to the study. 
This included all patients with that demonstrated hyperkinetic movements (chorea, dystonia, 
myoclonus and tremor), hypokinetic movement disorders (bradykinesia), tics, or stereotypies. The 
movement disorders included primary (genetic or suspected genetic) and secondary disease 
processes. A concerted effort was made to avoid selection bias so that all eligible patients, not only 
those with suspected psychiatric vulnerabilities, were selected for the study, as they were seen in the 
movement disorder clinics.  
3.6.1.2 Inclusion criteria and exclusion criteria for movement disorder group 
In addition to the general criteria outlined in the study description above, pertaining to age and verbal 
ability, the following criteria applied: 
- patients needed to have a diagnosis of a movement disorder made by a neurologist 
3.6.1.3 Recruitment  
Patients with diagnosed movement disorders were recruited through patient encounters at CHW and 
GOSH from services such as movement disorder clinic, Tourette clinics, general neurology clinics and 
neurology inpatient wards. Within the Australian site, an effort was made to recruit all eligible patients 
with movement disorders that presented to Neurologist and project supervisor, Professor Russell Dale 
between 2012 and 2015. After that time, it became evident that the study had a sufficient cohort of 
patients with Tourette Syndrome (the most common movement disorder), so recruitment of tic 
patients ceased, and recruitment of less common movement disorder patients continued to the end 
of 2017. There was an attempt to recruit all consecutive patients with movement disorders, rather 
than only those suspected to psychiatric symptoms, to minimise selection bias. In the UK, emphasis 
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was placed on recruiting patients with dystonia, as dystonia is the most common Non-tic movement 
disorder in the paediatric population. The Tourette patients from the UK were extracted from a 
previously consented group seen at Great Ormond Street Hospital tic clinic service. 75 patients with 
Tourette from GOSH who were eligible and completed the DAWBA during the same interval as the 
Australian patients (2012-2015) were included in our analysis.  
Record was kept of those patients who were approached who declined participation on the Australian 
site. Overall 239 patients with movement disorders were approached about the study on the CHW 
site, and of them, 180 (75.3%) completed the DAWBA. The majority of patients who did not participate 
were lost to follow up after initially consenting, or their expression of willingness to complete the 
DAWBA did not eventuate into action despite phone calls to remind them. For a very small number of 
patients (n=5) there were stated reasons not to participate, and this was cited as lack of time in all but 
one case. In the latter case the parent described that their child was self-conscious about their 
neurological symptom and the parent did not want to draw greater attention to it by taking part in a 
study.  
3.6.1.4 Administration of the tool 
Patients and their parents were informed of the study by Professor Russell Dale or myself. They were 
provided with written information and written consent was obtained.  Parents were directed to the 
DAWBA website with a de-identified and confidential log-in number and asked to complete the 
questionnaire online. 
The majority of parents of movement disorder patients completed the DAWBA online from home. For 
families where this was difficult due to their computer access or computer literacy, I completed the 
questionnaire with the parent over the phone.  
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For some specific patients, I was able to complete the questionnaire in a face-to-face capacity 
following clinic appointments or on the ward. In these situations, I assisted the parent complete the 
DAWBA on a tablet. 
3.6.2 Study cohort 2 – Hospital Emergency control  
3.6.2.1 Explanation and rationale 
Selection of a hospital control group was one of the most challenging aspects of the study design. The 
purpose of the control group was to ensure that a locally relevant prevalence rate could be compared 
to the rates of psychiatric comorbidities found in the neurological patients. Normative data already 
exists for the DAWBA in terms of British or Norwegian children in population studies. (Aebi et al., 2012, 
Goodman, 2000) However, it was felt that a local and culturally comparable group would be valuable. 
Initial plans for the healthy control group included the children of staff working at the Children’s 
Hospital at Westmead. The intention was to involve staff from varied departments including medical 
officers, nursing staff, clerical staff and allied health. There were two obstacles that prohibited the 
success of this approach. Firstly, it was decided that the children of hospital staff were not an ideal 
representation of children in the general population. There was no way of ensuring that educational 
levels, places of residence and cultural backgrounds would be comparable to the children with 
movement disorders who were the focus of the study. Furthermore, utilising children of hospital staff 
required staff members to provide detailed and potentially sensitive information about their child’s 
strengths and vulnerabilities, social and developmental history, to colleagues within a working 
environment. I was concerned that this may affect the rate of recruitment of healthy controls or the 
accuracy of information provided by the parents.  
An alternative control group that I considered was children with fractures who were waiting to be 
seen in fracture clinic. This option was dismissed due to the concern that a cohort of children with 
fractures was likely to include a high number of active and impulsive boys whose activity may have 
predisposed them to injury. It was felt that this might inflate the rates of ADHD in the control group 
  98 
above what may be expected in the general population. A practical limitation also included the 
efficient processes of fracture clinic with very short waiting times, therefore limiting the opportunities 
to recruit these patients whilst prior to their appointments. Consideration was also given to recruiting 
children through local schools however the logistical issues involved in navigating the various ethical 
and administrative processes required to access school students and parents for research led us 
conclude that such an option was untenable. 
Following extensive discussion and consideration, we decided to recruit patients from the Children’s 
Hospital emergency department. I spent two days each week from January 2015 to December 2015 
in the Emergency Department and approached all eligible patients to discuss the study.  
Use of the Emergency Department population as study group posed several challenges. The first was 
the availability of patients, as the emergency Department is busy with primarily very young and very 
unwell children, and there was frequently a paucity of patients who fit the eligible criteria.  
For those patients with less severe medical conditions there was an arguable overlay of parental 
and/or patient anxiety contributing to the reasons for presentation. For example, a parent who brings 
an 8-year-old child to Emergency for a 24-hour history of a sore throat may be motivated by anxiety 
that prevents them from managing at home or visiting a primary care practitioner. This poses 
questions as to whether the familial rates of anxiety of children presenting to Emergency may be 
higher than the average population. Also, children presenting with chronic but mild medical 
complaints such as a recurrent headache or abdominal pain are perhaps more likely to experience co-
existing anxiety or mood issues.  Chronic headache or abdominal pain are known to be frequent 
somatic presentations of a non-organic paediatric issue.  Common chronic and ‘less-critical’ symptoms 
presenting in children such as headache and recurrent abdominal pain are also known to occur in 
children with anxiety and mood disorders. Overall it seemed that there were definite factors 
suggesting that children in Emergency departments were an imperfect representation of the general 
population. However, they served as a practical and feasible group that can provide an additional 
comparison to the European normative data. However, we felt it was important to note that this group 
  99 
be referred to as the ‘hospital medical control’ group, noting that these patients had medical issues 
rather than a ‘normal paediatric population-based’ control group.  
3.6.2.2 Inclusion criteria and exclusion criteria of hospital Emergency control cohort 
In addition to the general criteria outlined in the study description above, pertaining to age and verbal 
ability, the following exclusion criteria applied: 
- Patients were excluded if they had a significant chronic illness that resulted in frequent 
hospitalisations or time away from school such as severe inflammatory bowel disease or an 
oncological history, or had a syndrome such as velo-cardiofacial syndrome. We created this 
exclusion because the Emergency cohort was ideally a group of otherwise normal children 
who had short-lived medical illnesses, although some patients had ongoing medical issues. 
For example, patients with asthma, allergy or a history of occasional headaches were included 
as it felt these would occur in local general population.  
- Patients were excluded if they presented to Emergency with a critical medical or surgical issue 
that required urgent intervention (within 30 minutes) or if they were experiencing significant 
pain or distress, as it was considered unethical to recruit these children 
- Patients presenting to Emergency primarily for a mental health reason were excluded.  
However, patients who presented with an acute medical condition on a background history 
of a behavioural or psychiatric diagnosis were included in the study, as we felt it would be 
inappropriate to exclude these patients, as it may create bias.  
3.6.2.3 Recruitment  
I approached patients in the Emergency Department and discussed the study with the parents and 
the patient. Written information was provided, and a consent form offered for signature. The majority 
of parents invited were agreeable to completing the DAWBA. A small number (n<10) of patients were 
eligible but refused to participate in the study and they cited being tired and stressed due to their 
child’s illness or they had other young children present who required their attention. 
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3.6.2.4 Administration of the tool 
Following attainment of consent, parents were directed to the DAWBA website with a de-identified 
and confidential log-in number and asked to complete the questionnaire online. The questionnaire 
was then completed by the parent on an iPad or laptop. If the patient was 11 years or older they were 
also invited to participate in the study, and if they agreed they completed the questionnaire on an 
iPad.  
3.6.3 Study cohort 3 – Neurology control group (Charcot Marie Tooth neuropathy and epilepsy) 
3.6.3.1 Explanation and rationale 
A concerted effort was made to ensure that a neurological control group would be included. Children 
with Charcot Marie Tooth (CMT) neuropathy have a chronic illness that impacts their life in similar 
ways to their children with other neurological diseases. A significant distinction between the children 
with CMT and movement disorders is that the children with CMT are less likely to have central nervous 
system involvement. This presents an interesting comparison because the children have similar shared 
experiences of disability or impairment, with different biology.  
We felt it was important to consider how patients with movement disorders compared to children 
with other neurological disorders. As epilepsy is the most common category of disorders seen to the 
Neurology Department at the Children’s Hospital, we included epilepsy in the neurological controls in 
addition to the peripheral neuropathy group.  
3.6.3.2 Inclusion criteria and exclusion criteria 
In addition to the general criteria outlined in the study description above, pertaining to age and verbal 
ability, the following exclusion criteria applied: 
- To be included, patients needed to have a diagnosis of a peripheral neuropathy or epilepsy 
- Patients with a co-existing movement disorder were excluded 
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3.6.3.3 Recruitment  
Recruitment of CMT proved more difficult than initially anticipated, primarily due the small numbers 
of patients presenting to the hospital. Patients were approached at monthly CMT clinics. Typically, 4 
patients with CMT were seen at each monthly clinic. Several patients were outside the eligible age 
range. Initially a target of 100 patients was determined for the CMT group however this was soon 
assessed as unachievable and the goal was reduced to 50 patients. As factors such as researcher 
maternity leave interfered with recruitment, this target was again reduced to 25. A supplementary 
epilepsy subgroup was added, and I was able to achieve 37 neurology controls in total (25 CMT and 
12 epilepsy) until I closed the study. 
Of those neurology control patients that were contacted, all except two agreed to participate in the 
study.  One of those that refused to participate cited having insufficient time to complete the 
questionnaire and the other parent cited being overwhelmed by issues pertaining to CMT. 
I attended monthly peripheral neuromuscular clinics between 2012 and 2017 and approached eligible 
patients and their parents. Epilepsy patients and parents were approached on the wards during 
epilepsy monitoring admissions and clinic reviews in 2016.  
3.6.3.4 Administration of the tool 
Following attainment of consent, parents were directed to the DAWBA website with a de-identified 
and confidential log-in number and asked to complete the questionnaire online. The questionnaire 
was then completed by the parent on an iPad or laptop at the hospital. If the patient was 11 years or 
older, they were also invited to participate in the study and if agreed they completed the 
questionnaire on an iPad.  
  102 
3.7 Data collection 
3.7.1 Data collected across all cohorts 
The following aspects of clinical and demographic information were collected on all patients in the 
study and entered in to a secure database.  
3.7.1.1 Patient demographic details  
-  Gender of patient 
-  Age of patient at the time of DAWBA completion 
- Highest level of education obtained by mother and father performed as a proxy for socio-economic 
status. This question was asked directly as part of the study recruitment process and answers. 
3.7.1.2 Patient intellectual functioning  
Intellectual ability was captured by way of 2 parameters 
- The clinical notes describing as intellectual ability as within normal range or below. Such 
information was obtained from the Neurologist’s letters or correspondence from schools and 
paediatricians, or direct reports of psychometric testing included in the files. 
- Type of schooling and learning support. Options included normal class and normal school, 
normal class with support teacher or aide, support class in normal school, special school. (This 
question was directly asked as part of the study recruitment process and answers were 
documented in the patient file.) 
3.7.2 Data collected from the movement disorder (tic and Non-tic) cohorts 
The following aspects of clinical and demographic information were collected on all patients in the 
movement disorder cohorts. 
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3.7.2.1 Clinical diagnosis  
Initially patients were divided into the Tic on Non-tic subgroups. All patients with tic as their primary 
movement disorder were allocated to the Tic cohort and all patients whose primary movement 
disorder was not a tic were placed in the Non-tic MD cohort.  
The actual diagnosis was extracted by recording the disease name documented in patient notes and 
clinic letters.  A verification meeting was held with the treating Neurologist to confirm the accuracy of 
each diagnosis.  
Diagnoses in the Tic cohort were further defined as follows: 
3.7.2.1.1 Tourette syndrome  
Tourette syndrome referred to patients who had a combination of vocal and motor tics for a duration 
of at least one year and not attributable to another cause. The tics must have started before the age 
of 18 years. (American_Psychiatric_Association, 2013) 
3.7.2.1.2 Tic disorder 
Chronic tic disorder (motor) was defined in context with DSMV 
The patient needed to have vocal or motor tics (but not both) that occur multiple times or daily or on 
and off for at least one year (American_Psychiatric_Association, 2013) 
3.7.2.1.3 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal 
infections (PANDAS) 
PANDAS was used to name acute neuropsychiatric disease following a diagnosed streptococcal 
infection. Patients in this group needed to fulfil the recognised criteria presented by Swedo: 
1. prepubertal onset usually between 3 years and 12 years 
2. obsessive compulsive disorder, a tic disorder (lifetime diagnostic criteria) 
3. sudden explosive onset of symptoms and course of recurrent sudden exacerbations and 
remissions 
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4. temporal relationship of exacerbations with streptococcal infections  
5. presence of neurological abnormalities during periods of symptom exacerbation (tics, 
hyperactivity) (Swedo, 1998) 
3.7.2.1.4 Paediatric acute-onset neuropsychiatric diagnosis 
PANS was used to describe patients with an abrupt onset of obsessive-compulsive symptoms and 
other neuropsychiatric symptoms (motor tics were essential due to the movement disorder focus of 
this study) but without the association with streptococcal infection related to PANDAS above. (Murphy 
et al., 2014) 
 
Patients in the Non-tic group had diagnoses defined as follows: 
3.7.2.1.5 Neurotransmitter disorders 
3.7.2.1.5.1 Dopa-responsive dystonia (DRD) 
DRD referred to patients who had a dystonic syndrome with convincing therapeutic benefit from 
exogenous dopamine, plus evidence of dopamine depletion on CSF neurotransmitter analysis or 
genomic testing (Segawa, 2011) 
3.7.2.1.5.2 Tyrosine Hydroxylase deficiency (THD) 
Tyrosine hydroxylase deficiency (THD) referred to patients who have a hypokinetic rigidity syndrome 
with dystonia, abnormalities in cerebrospinal fluid neurotransmitter profile and a genetic testing 
detecting a mutation in the TH gene. (Willemsen et al., 2010) 
3.7.2.1.5.3 6-pyruvoyl-tetrahydropterin synthase (6PTPS) deficiency  
6-pyruvoyl-tetrahydropterin synthase (6PTPS) deficiency referred to patients with an early onset 
movement disorder and biochemical profile consistent with hyperphenylalaninemia followed by 
genetic testing demonstrating an abnormality in the PTS gene. (Leuzzi et al., 2010) 
 
  105 
 
3.7.2.1.6 Genetic disorders 
3.7.2.1.6.1 DYT1 dystonia 
DYT1 referred to patients who had dystonia and the presence of the common mutation in the TOR1A 
gene. (Ozelius and Lubarr, 1993) 
3.7.2.1.6.2 Myoclonus dystonia 
Myoclonus dystonia referred to patients with myoclonus occurring in the upper limbs, head or neck 
with or without dystonia. Patients also tested positive for the SCGE mutation on genetic testing. (Peall 
et al., 2016) 
3.7.2.1.6.3 Benign hereditary chorea 
Benign hereditary chorea referred to patients with non-progressive chorea and a family history or 
genetic testing consistent with the diagnosis (mutation in TITF1/NKX2.1 gene) or where other causes 
of chorea had been reasonably excluded and genetic testing was pending (Gras et al., 2012) 
3.7.2.1.6.4 Paroxysmal kinesiogenic dyskinesia 
Paroxysmal kinesiogenic dyskinesia referred to patients who have brief (seconds to minutes) episodic 
movement disorders (typically dystonia or chorea) precipitated by voluntary movements such as 
moving from sitting to standing (Gardiner et al., 2015). The syndrome is often associated with PRRT2 
mutations, although gene testing was not essential for a diagnosis of PKD, if fulfilling criteria of Bruno 
et al.  (Bruno et al., 2004) 
3.7.2.1.6.5 Glutaric aciduria 
Glutaric aciduria referred to patients presenting with early onset dystonia, who were diagnosed as 
part of the newborn screening program on the basis of raised glutarylcarnitine in the dried blood spot. 
Diagnosis was confirmed by mutation in the GHDH gene. (Kolker et al., 2015)  
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3.7.2.1.6.6 Wilson’s disease 
Wilson’s disease referred to one patient with dystonia, tremor and dysarthria and abnormalities in 
serum copper, caeruloplasmin and urinary copper excretion. (Ferenci, 2005) 
3.7.2.1.6.7 Juvenile Huntington’s disease 
Juvenile Huntington’s referred to one patient with a progressive dystonia and a degenerative 
discourse and genetic testing confirming a triplet repeat expansion in the Huntington gene. 
(Geevasinga et al., 2006, Gonzalez-Alegre and Afifi, 2006, Monrad and Renaud, 2013) 
3.7.2.1.6.8 Newly recognised genes (KMT2B, TBC1D24, GN1B1) 
A genotypic diagnosis consistent with KMT2B, TBC1D24, GN1B1 was provided for patients who had 
primary dystonias and genetic confirmation (de novo) on testing.  
3.7.2.2 Suspected genetic (gene negative) 
3.7.2.2.1.1 Suspected genetic movement disorder  
A descriptive term of either a gene negative dystonia, gene negative chorea, gene negative myoclonus 
or gene negative tremor were used to label those patients whose disease presented with a typical 
genetic course but without positive gene testing. 
3.7.2.2.2 Immune 
3.7.2.2.2.1 Sydenham’s chorea 
Sydenhams Chorea was applied to patients who presented with new onset chorea (purposeless, 
involuntary and unpredictable movements) in the context of a recent group A beta haemolytic 
streptococcal infection (Ridel et al., 2010). 
3.7.2.2.2.2 Basal ganglia encephalitis 
Basal ganglia encephalitis referred to patients with an acute neuropsychiatric illness in the context of 
a highly specific basal ganglia radiological encephalitis and positive D2 receptor antibodies (Dale et al., 
2012). The clinical syndrome presented as dystonia, parkinsonism, and associated behavioural change, 
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and the MR imaging demonstrated caudate and putamen inflammatory lesions. 
3.7.2.2.2.3 Opsoclonus myoclonus ataxia syndrome (OMAS) 
OMAS referred to one patient with a clinical triad of opscoclonus, myoclonus and ataxia and evidence 
of neuroinflammation as evidenced by cerebrospinal fluid studies and response to immunotherapy. 
(Pranzatelli and Tate, 2016, Tate et al., 2005) 
3.7.2.2.2.4 Rasmussen encephalitis 
Rasmussen encephalitis referred to one patient with dystonia and dystonic tremor and evidence of 
inflammatory hemispheric injury on the basis of MRI abnormalities and raised cerebrospinal fluid 
neopterin. (Granata and Andermann, 2013) 
3.7.2.2.2.5 Anti-phospholipid chorea 
Anti-phospholipid chorea referred to patients with chorea in the presence of antiphospholipid 
antibodies, fulfilling criteria for antiphospholipid syndrome (Peluso et al., 2012). 
3.7.2.2.3 Multifactorial (dystonic cerebral palsy) 
Dystonic CP referred to patients who had experienced a known or presumed cerebral insult in the 
antenatal period or shortly after a birth and who developed subsequent non-progressive impairment 
of movement associated with dystonia. (Himmelmann et al., 2007, Kyllerman et al., 1982) This 
diagnosis was further subdivided into one of the following aetiologies: 
Prematurity defined as cause of CP 
Vascular event (in utero or neonatal) defined as cause of CP 
Kernicterus as cause of CP 
Hypoxic ischaemic encephalopathy or traumatic delivery as cause of CP 
Unknown cause of CP 
 
 
  108 
3.7.2.2.4 Developmental syndromes with movement disorders 
3.7.2.2.4.1 Stereotypy  
Stereotypy referred to a clinical symptom rather than a diagnosis, which featured in a range of 
developmental disorders as well as neuro-typical children. However, the term stereotypy was listed 
as a diagnostic descriptor for children in whom this was the primary movement disorder, namely 
primary motor stereotypy in neurotypical children. Stereotypy was defined as rhythmic, fixed, 
repetitive and suppressible movements including head banging, body rocking, hand flapping 
(Fernandez-Alvarez, 2001). 
3.7.2.2.5 Psychogenic 
Psychogenic referred to patients whose movement disorder has been clinically determined to have a 
psychological cause for their symptoms and whereby other reasonable diagnoses have been excluded. 
3.7.2.3 Movement disorder phenomenon 
In addition to aetiological classification (as above), we also classified patients according to the 
movement disorder subtypes or ‘phenomena’, such as dystonia or chorea. I recorded the chief or most 
impactful movement disorder as the primary movement disorder, and then listed co-existing 
movement disorders as secondary and tertiary. Criteria for categorising the movement disorders were 
derived from the International Parkinson and Movement Disorder Society definitions. There were 2 
categories, specifically stereotypy and mirror movements, for which the IPMDS did not provide a 
definition.  For these categories I referred to the text Movement Disorders in Children by Fernandez 
and Aicardi (Fernandez-Alvarez, 2001). 
3.7.2.3.1 Tic 
Tic described involuntary, stereotypical, and repetitive, abrupt movements that are often preceded 
by an urge or uncomfortable feeling that may be relieved following the movement. (Fernandez, n.d) 
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3.7.2.3.2 Dystonia 
Dystonia referred to involuntary muscle contractions that can result in abnormal posture and often 
repetitive movements that are twisting in nature. 
 (International_Parkinson_and_Movement_Disorder_Society, 2016). 
3.7.2.3.3 Chorea 
Chorea was defined random, ‘dance-like’ movements that are often fast, brief, irregular and 
unpredictable (Ho, 2016). 
3.7.2.3.4 Myoclonus  
Myoclonus referred to a series of very brief, jerk-like or ‘electric shock-like’ involuntary movements 
resulting from contraction or relaxation of muscles (Merello, n.d-a). 
3.7.2.3.5 Tremor 
Tremor was defined an involuntary, rhythmic oscillation in fixed plane (Verhagen, n.d). 
3.7.2.3.6 Bradykinesia 
Bradykinesia described slowness with decrement and degradation of repetitive movement (Merello, 
n.d-b) 
3.7.2.3.7 Stereotypy 
Stereotypy referred to a repetitive and suppressible movement that include, but are not limited to, 
hand waving, arm flapping, body rocking (Fernandez-Alvarez, 2001). The movements are sometimes 
separated according to whether they occur in the context of normally developed children, or children 
with neurodevelopmental delay.  
3.7.2.3.8 Functional 
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The term functional applies to one patient whose moment was thought to have a functional (non-
organic) cause and the movement was unusual and inconsistent so that it could not be defined by the 
above categories 
3.7.2.4 Clinician based psychiatric diagnoses 
The details of any psychiatric comorbidities made by the treating neurologist that was documented in 
the patient letters were recorded. As an additional validation process, I met with the Neurologist to 
confirm my interpretation of his clinical assessments and to check that all clinician diagnoses were 
correctly recorded.  
3.7.2.5 Additional data 
Further clinical details including the age of onset of the movement disorder and significant 
neurological comorbidities were extracted from the patient files and listed in a spreadsheet. Family 
history was obtained in terms of any first degree relative (parent or sibling) with any neurological or 
psychiatric diagnosis. All specific diagnoses were recorded. A list of all medications prescribed for the 
patient at the time of the study was kept. In addition, any previously prescribed psychiatric or 
behavioural medications taken by the patient were also recorded. Note was made if the patient had 
sought psychotherapy or counselling.  
3.7.3 Data collected from the Emergency cohort 
In addition to the demographic data collected across all cohorts, the following were obtained from all 
patients in the Emergency cohort: 
3.7.3.1 Reason for presenting to Emergency 
The reason for presentation was captured and simplified in to one of the following categories:  
3.7.3.1.1 Orthopaedic 
A presenting problem related to fracture, musculoskeletal pain or soft-tissue injury. 
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3.7.3.1.2 Gastrointestinal 
A presenting problem related to abdominal pain, vomiting, constipation. 
3.7.3.1.3 Respiratory 
A presenting problem related to cough, exacerbation of asthma, sore throat, ear pain. 
3.7.3.1.4 Fever 
A presenting problem related to fever or any acute cause. 
3.7.3.1.5 Rash 
A presenting problem related to rash of any acute cause. 
3.7.3.1.6 Head injury 
A presenting problem related to head injury not requiring urgent intervention (mostly minor injuries 
requiring a period of observation). 
3.7.3.1.7 Dental 
A presenting problem related to dental pain or infection. 
3.7.4 Data collected from the Neurology cohort 
In addition to the demographic data collected across all cohorts, the following were obtained from all 
patients in the Neurology cohort: 
3.7.4.1 The type of peripheral neuropathy or type of epilepsy 
The diagnosis as provided by a Neurologist was recorded for each patient. 
3.7.5 Overview of cohorts 
In total, 397 patients participated in the study including 260 movement disorder patients and 137 
hospital control patients. The movement disorder patients were divided into 2 subgroups for analysis; 
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the tic and Tourette Movement Disorder cohort (Tic MD, n=158) and Non-tic Movement Disorder 
cohort (Non-tic MD, n=102). As explained in the method chapter, the Tic cohort was included as a 
positive control because of the established literature of psychiatry in tic patients.  
The Tic MD cohort included patients with Tourette, chronic motor tics, PANDAS and PANS, and the 
Non-tic MD cohort was comprised of patients with all other movement disorders.  
The 137 hospital control patients were also inclusive of 2 separate cohorts; the Emergency control 
patients (n=100) and Neurology control patients (n=37). The specific characteristics of each cohort are 
explained further detail in section 4.1.3. Finally, comparison was made with data from a pre-existing 
community control group comprised of 10,438 British children from a national mental health survey 
using the DAWBA (Ford et al., 2003). 
The majority of patients across all study cohorts (n=318) were patients from CHW, Australia, as 
outlined in the method chapter. As the study was designed to increase cohort sizes via a multicentre 
collaboration, a subset of patients (n=80), were recruited from GOSH, UK. Of these GOSH patients, 5 
had dystonia and formed part of the Non-tic MD cohort, whilst 75 had tic disorders and contributed 
to the tic cohort.  
All study cohorts included patients between the ages of 5 and 16 years, however the UK community 
sample had only surveyed children to 15 years. I had opted to include children to 16 years to extend 
the coverage of rare genetic movement disorders that had not been interrogated previously in the 
literature. The mean age of all 397 hospital patients was 10.6y.   There was a male predominance in 
the tic cohort which was in keeping with tics affecting more males than females in general, and gender 
was otherwise quite evenly distributed across all other groups.  Table 3.2 below presents the basic 
demographic descriptors, including age, gender and Australian versus UK recruitment across each 
cohort.  
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Table 3.2 Demographic data across all cohorts in the study 
 
 
Additional demographic data was obtained at the time of recruitment to capture socio-economic 
status for which tertiary education of at least one parent served as a proxy. As this data was part of 
the recruitment process for this trial, information was unable to be obtained from the 75 tic patients 
that were included from the UK. This data is captured in table 3.3, below. Rate of tertiary education 
in at least one parent ranged from 37.3 to 51%. Gross academic ability was observed by type of 
schooling attended by the patient, with the vast majority of children in all groups attending 
mainstream school. Within the Tic MD and Non-tic MD cohorts there were 1 and 6 children, 
respectively, attending special schools for children with additional needs.  
 
 
Tic cohort  Non-tic  
cohort 
Emergency  
control 
Neurology  
control 
Community 
control (Ford 
et al., 2003) 
Total (n=) 158 102 100 37 10,438 
Australian (n=) 83 97 100 37  
UK (n=) 75 5 0 0 10.438 
Gender Male 127 (80.4%) 46 (45.1%) 56 (56.0%) 19 (51.3%) 5,212 (49.9%) 
Age range 5-16y 5-16y 5-16y 5-16y 5-15y 
Mean age 10.6y 10.9y 9.8y 12.3y 11y 
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Table 3.3 Data across all cohorts with a focus on education 
 
*Data from the 75 UK TIC MD cohort unavailable due to retrospective inclusion 
 
3.7.6 Family history in both MD cohorts 
Parental history of psychological, behavioural or developmental disorders were present in 44.9% of 
patients with tic, and 23.5% of patients from the non -tic MD cohort. Sibling family history was less 
common, with 17.7% of the tic cohort having a sibling with a psychiatric history and 13.7% of the Non-
tic MD cohort. In 10.8% of Tic MD patients, and 6.9% of Non-tic MD patients, both a parent and sibling 
had a history of psychiatric diagnosis. These rates are shown in table 3.4 below.  
 
 
 
 
 
 
 
 
 
 
 
Tic MD cohort  Non-tic MD 
cohort 
Emergency  
control 
Neurology  
control 
Total (n=) 158 102 100 37 
One parent with 
tertiary education 
34/83* (41.0%) 
 
38/102 (37.3%) 
 
51 (51.0%) 17 (45.9%) 
Child’s school 
ability: 
    
mainstream 127 (80.4%) 65 (63.7%) 96 (96.0%) 35 (94.5%) 
support teacher 20 (12.7%) 25 (24.5%) 4 (4.0%) 1 (2.7%) 
support class 6 (3.8%) 11 (10.8%) 0 1 (2.7%) 
special school  2 (1.3%) 1 (1.0%) 0 0 
No school 0 0 0 0 
Schooling not 
known 
3 (1.9%) 0 0 0 
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Table 3.4 Rate of family history in each cohort 
 
3.7.7 Descriptive data for Tic MD and Non-tic MD cohorts 
Both movement disorder cohorts were comprised of children with heterogeneous diagnoses. The Tic 
MD cohort included all patients with tic related movement disorders as their primary diagnosis with 
Tourette being the most common (n=136), following by chronic motor tic, PANDAS and PANS. The 
distribution of each condition with gender and mean age is demonstrated in table 3.5. 
 
Table 3.5 Breakdown of the tic cohort with demographic data including gender and age 
 
The Non-tic cohort were even more diverse in terms of movement phenomenon and aetiologies. 
Patients had, as their primary movement disorder, dystonia (n=66), chorea (n=12), stereotypy (n=11), 
myoclonus (n=6), tremor (n=5), and bradykinesia (n=1). One additional patient (n=1) had an unusual 
 Parent 
history of 
psychiatric 
disorder 
Sibling history of 
psychiatric disorder 
Both parent and 
sibling history of 
psychiatric disorder 
Tic MD cohort (n=158) 71 (44.9%) 28 (17.7%) 17 (10.8%) 
Non-tic MD cohort (n=102)   24 (23.5%) 14 (13.7%) 7 (6.9%) 
    
Tic or Tourette 
Diagnosis 
n = Gender Mean age at 
onset 
Mean age at DAWBA 
Tourette Syndrome 136 109 M (80.1%) 5.6 y 10.7 y 
Chronic motor tic 10 6 M (60.0%) 6.8 y 10.7 y 
PANDAS 7 7M (100.0%) 5.2 y 9.9 y 
PANS 5 5M (100.0%) 4.6 y 7.7 y 
Total 158 130M (80.4%) 5.7 y 10.6 y 
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jerking movement that was inconsistent and appeared functional in nature and difficult to 
characterise by standard movement disorder definitions. In many cases there was a secondary 
movement disorder. Table 3.6 demonstrates the number of patients with each primary movement 
phenomenon, their secondary movement problem (if any), as well as demographic data such as 
gender, age of disease onset and age at the time of completing the DAWBA.  
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Table 3.6 Non-tic MD cohort by movement phenomenon with demographic data 
 
 
Of the 102 Non-tic MD patients, a range of aetiologies were identified as causing their movement 
disorders.  13 patients had an identifiable neurotransmitter pathology, whilst 42 had other genetic 
disease processes (24 patients were proven on genetic testing and 18 were suspected only). There 
were 22 patients with dyskinetic cerebral palsy where the cause was regarded as multifactorial but 
Primary 
movement 
phenomenon 
n = Secondary 
movement 
phenomenon 
n = Gender 
(male) 
Mean age 
at onset (y) 
Mean age 
at DAWBA 
(y) 
Dystonia 66 Chorea 4 2 M 4.5  9.3  
Myoclonus 3 1 M 2.5  14. 3  
Tremor 6 3 M 6  11.3  
Bradykinesia 4 1 M 4.2  10  
Stereotypy 2 0 M 2  12  
none 47 19 M 3.5  10.8  
Chorea 12 Myoclonus 2 1 M 2.7 8  
none 10 5 M 5.5 12.5  
Stereotypy 11 none 11 7 M 2.5  8.5  
Myoclonus 6 Dystonia 3 2M 1.7  8  
none 3 3 M 4  10. 3  
Tremor 5 none 5  2 M 10  12.4  
Bradykinesia 1 none 1 0M 15 15 
Other 
(functional) 
1 none 1 0 M 1 16  
Total 102   46 M(45.1%)  10.9 
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could be described as primarily related to birth related events such hypoxic ischaemic 
encephalopathy, kernicterus or an in-utero vascular event. A further 11 patients were affected by an 
immune neurological disease and the remaining patients had developmental (n=11) or psychogenic 
(n=3) conditions. An outline of the diverse aetiological processes captured in this cohort and the 
corresponding demographic data, including age and gender, are included in table 3.7.  
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Table 3.7 Aetiologies in the Non- tic MD cohort 
 
Type of aetiology 
n = Aetiology n = Gender Mean 
age at 
onset 
(y) 
Mean 
age at 
DAWBA 
(y) 
 
Neurotransmitter 
13 Dopa responsive 
dystonia (GTP 
cyclohydrolase 
deficiency) 
4 1 M 4  11  
Dopa responsive 
dystonia (gene 
negative) 
3 2 M 4.5  8  
Tyrosine hydroxylase 
deficiency 
3 1 M 0 12.7  
6 PTPS deficiency 3 0 M 0 8.3 
Proven genetic 24 KMT2B dystonia 2 1 M 4.5 11 
TBC1D24 dystonia 1 0 M 1 13 
Myoclonus dystonia 
(SCGE) 
7 5 M 2.1  11.4 
GNB1 dystonia 1 0 M 4 11 
Glutaric acidura type 1 2 0 M 0 6y 
Paroxysmal 
kinesiogenic dystonia 
(PRRT2) 
4 3 M  9.5 13.8 
Benign hereditary 
chorea 
5 3 M 0.7 14.7 
Wilson’s disease 1 0 M 11 13 
Juvenile Huntington’s 
disease 
1 0 M  1 17 
Suspected genetic 18 Dystonia gene 
negative 
11 6 M 4.3 11.5 
Chorea gene negative 1 1 M  5 14 
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Myoclonus gene 
negative 
2 2 M  4.2 12.5 
Tremor gene negative 4 2 M 8 11.5 
Immune 11 Sydenham’s chorea 2 0 M 13 14  
Antiphospholipid 
chorea 
1 0 M 12 16  
Basal ganglia 
encephalitis 
(Dopamine 2 Receptor 
Antibody positive) 
4 2 M 33  8.3  
Rasmussen 
encephalitis 
1 0 M 13  14  
Opsoclonus 
myoclonus syndrome 
2 1 M 1.3 11 
Acute immune 
akinetic psychotic 
syndrome 
1 1 M 15 15 
Multifactorial 
neonatal (dystonic 
cerebral palsy 
subgroup) 
22 Prematurity defined as 
cause 
7 1M 0.5 10.9 
Vascular event (in 
utero or neonatal) 
4 1 M 1.5 11 
Kernicterus 3 2 M 0 10 
Hypoxic ischaemic 
encephalopathy or 
traumatic delivery 
4 2 M 0.2 10.3 
Unknown 4 2 M 0 11.8 
Developmental 11 Stereotypy 11 7 M 2.7 8.5 
Psychogenic  
3 
 
Psychogenic 
movement disorder 
3 O M 13.7 14.6 
Total  
102 
 
   
46 M 
 
4.7y 
 
10.9 
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3.7.8 Descriptive data for the hospital control cohorts 
The 100 patients in the Emergency cohort were children between the ages of 5 and 16y who had 
presented to the Emergency department at the Children’s Hospital at Westmead for acute care of a 
routine non-chronic medical issue. Patients were excluded if they had a significant chronic disease or 
if they were very unwell at the time of presentation rendering them inappropriate for inclusion. The 
mean age of this cohort was 9.8y and 56% were male. Almost a third of patients (n=31) presented 
with an orthopaedic issue such as a fracture of soft-tissue injury and close to a quarter (n=24) had an 
acute gastrointestinal problem such as abdominal pain, vomiting or constipation. Other reasons for 
presentation including respiratory concerns, fever, rash, mild head injuries or dental pain. A table 
depicting reasons for presentations is included below (table 3.8) 
Table 3.8 Reasons for presentation to the emergency department in the Emergency cohort 
  
 
 
 
 
 
 
 
The Neurology control cohort comprised of 37 patients who had been treated by the neurology 
department at Children’s Hospital for either a peripheral neuropathy (n=25) or epilepsy (n=12). 
Charcot Marie Tooth 1A was by far the most prevalent peripheral neuropathy (n=17) and temporal 
lobe epilepsy was the most common epileptic diagnosis. The specific diagnoses attributed to all 
patients in the Neurology hospital control cohort are listed in table 3.9.  The mean age of this cohort 
was 12.3y and 51.3% were male.  
 
Type of presentation n= Descriptors and examples 
Orthopaedic 31 Fracture, musculoskeletal pain, soft-tissue injury 
Gastrointestinal 24 Abdominal pain, vomiting, constipation 
Respiratory 22 Cough, exacerbation of asthma, sore throat, ear pain 
Fever 11 Fever of any acute cause 
Rash 6 Rash of any acute cause 
Head injury  5 Head injury without intracranial pathology 
Dental 1 Dental pain and infection 
Total 100  
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Table 3.9 Diagnoses in the Neurology cohort 
 
 
 
 
 
 
 
 
3.8 Data analysis  
For all participants in the study the results of the DAWBA were obtained as a DSMV diagnosis. Each 
diagnosis was recorded in an excel spreadsheet alongside the DAWBA ID and clinical details as 
specified above. The excel cells were combined to demonstrate how many DSMV diagnoses each 
patient fulfilled and what each of these diagnoses were. Data was again sorted to demonstrate the 
rates of DSMV diagnoses in each population cohort. For the Tic MD cohort, a diagnosis of tics was 
obviously not considered a comorbidity.  
Prevalence rates of DSMV diagnoses were measured against the aetiology of the movement disorder, 
as well as movement disorder phenomenology.  
Associations were examined by comparing the rates of DSMV diagnoses in those patients whose 
parents had at least one tertiary degree between them, as well those patients with a family history in 
terms of sibling, parent or both. 
Type of neurology n =  Diagnosis n= 
Peripheral neuropathy 25 Charcot Marie Tooth 1A 17 
Charcot Marie Tooth 4C 1 
Charcot Marie Tooth X3 3 
Brown-Vialetto-Van-Laere syndrome 4 
Epilepsy 12 Genetic generalised epilepsy 2 
Temporal lobe epilepsy 6 
Childhood absence epilepsy with 
frontotemporal spikes 
2 
Juvenile absence epilepsy 1 
Panayiotpoulos epilepsy 1 
Total 37  37 
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3.9 Statistical analysis 
Prevalence rates were compared with the assistance of the hospital biostatistician and use of SAS 
software. Chi square probabilities were calculated to determine statistical validity of prevalence rates 
between groups. As the Non-tic cohort was the primary cohort of interest, for the reason that these 
disorders have not previously been interrogated for psychiatric comorbidities in the literature, 
statistical analysis concentrated on differences between the Non-tic cohort and each of the other 
cohorts respectively.  
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4 Results 
4.1 Primary outcome 
4.1.1 Primary outcome: rate of psychiatric comorbidity across cohorts 
The rate of psychiatric comorbidity, in terms of any DSMV diagnosis determined by the DAWBA, across 
all 260 patients with movement disorders was 106/260 (40.8%).   
Of the 158 patients within the Tic MD cohort, 66 (41.8%) satisfied at least one DSMV diagnoses and 
36 (22.3%) qualified for 2 or more.  Within the 102 patients with a Non-tic MD cohort, 40 (39.2%) were 
found to have at least 1 psychiatric diagnosis and 14 (13.7%) had 2 or more. The rate of psychiatry 
comorbidity was not statistically significant between the two movement cohorts (Tic MD v. Non-tic 
MD). 
Importantly, the rate of psychiatric comorbidities across all movement disorder patients and across 
both tic and Non-tic patients, was more than four times the rate of psychiatric diagnosis observed in 
the large-scale community British study in 10,438 children (9.5%). (Ford et al., 2003) 
Within the Emergency control cohort, 18/100 (18%) satisfied one or more psychiatric comorbidities 
and only 3% were found to have two or more diagnoses. The Neurology control rate was higher than 
the Emergency group, but lower than both MD cohorts, with 11/37 (29.5%) patients fulfilling a 
psychiatric diagnosis, and in the Neurology control group (16.2%) had 2 or more DSMV diagnosis. 
Table 4.1 outlines the rate of DSMV diagnoses across each cohort and includes the large community 
control for comparison.  
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Table 4.1 DSMV diagnoses across all cohorts 
*(Ford et al., 2003) 
 
Figure 4.1 depicts the rate of any psychiatric diagnosis across each cohort, demonstrating similar rates 
between the Tic MD and Non-tic MD cohorts. As the Non-tic cohort represents the primary group of 
interest in this thesis, statistical comparisons have been made between the Non-tic cohort and the 
other cohorts.  The difference between the Non-tic MD cohort and the Tic MD cohort was not 
statistically significant. The difference between the Non-tic cohort and Emergency cohort was 
statistically significant (p<0.001). The difference between the Non-tic and Neurology cohorts was not 
statistically significant, and the difference between the Non-tic and Community control was 
statistically significant (p<0.00001). 
Overall, when comparing the Non-tic cohort to the other cohorts in terms of any DSMV disorder, only 
the difference between the Non-tic to Emergency, and Non-tic to Community were statistically 
significant.  
  
 
 
Tic MD cohort  Non-tic MD 
cohort 
Emergency  
control 
Neurology  
control 
Community 
control* 
Total (n=) 158 102 100 37 10 438 
Any DSMV 66 (41.8%) 40 (39.2%) 18 (18.0%) 11 (29.7%) 983 (9.5%)   
1 diagnosis 30 (19.0%) 26 (25.4%) 15 (15.0%) 5 (13.5%) 691 (6.7%) 
2 diagnoses 23 (14.6%) 10 (9.8%) 3 (3.0%) 4 (10.8%) 222 (2.0%) 
3 diagnoses 10 (6.3%) 2 (2.0%) 0 2 (5.4%) 49 (0.5%) 
4 diagnoses 3 (1.9%) 1 (1.0%) 0 0 17 (0.2%) 
5 diagnoses 0 1 (1.0%) 0 0 4 (< 0.1%) 
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Figure 4.1 The percentage of patients from each group who had any psychiatric diagnosis  
.  
 
4.2 Secondary outcomes 
4.2.1 Secondary outcome 1: Types of DSMV diagnoses found in each cohort 
The type of psychiatric disorders identified across each cohort were calculated and compared. Due to 
the varying denominators, this data is presented by percentage as opposed to patient numbers. 
The most common type of psychiatric disorder in the Tic MD cohort were anxiety disorders inclusive 
of OCD (32.3%), oppositional and conduct disorder (17.7%) and disruptive disorders such as ADHD 
(8.9%). In the Non-tic MD cohort, anxiety disorders (separation anxiety, generalised anxiety, social 
phobia and specific phobia) were the most frequent psychiatric diagnoses (28.4%). Disruptive 
disorders such as ADHD were the second most frequent (13.7%). There were no patients in the study 
who satisfied criteria for psychosis.   
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All psychiatric diagnoses established in both MD cohorts, and the number of patients affected by each, 
are listed in table 4.2. 
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Table 4.2 Specific diagnoses found in each cohort 
 
Tic cohort  Non-tic 
cohort 
Emergency 
control 
Neurology 
control  
Community 
healthy 
control 
Total (n=) 158.0 102.0 100.0 37.0 10 438 
Any disorder (%) 41.8 39.2 18.0 29.7 9.5 
Any Anxiety disorder (%) 32.3 28.4 11.0 27.0 3.8 
Sep Anxiety 11.4 7.8 3.0 2.7 1.2 
Social phobia 1.3 4.9 2.0 5.4 0.3 
Agoraphobia 0.6 0.0 0.0 0.0 0.1 
OCD 8.9 0.0 0.0 0.0 0.3 
Gen anxiety 3.2 5.9 0.0 8.1 0.7 
Specific phobia 3.8 3.9 4.0 2.7 1.0 
Panic disorder 2.5 1.0 1.0 2.1 0.1 
PTSD 0.0 1.0 1.0 0.0 0.1 
Other anxiety 1.9 3.9 0.0 5.4 0.9 
Depressive disorder (%) 3.2 4.9 1.0 2.7 0.9 
Major depression 3.2 4.0 0.0 2.7 0.7 
Other depression 
 
0.0 0.0 0.0 0.2 
Disruptive disorder (%) 8.8 13.7 5.0 13.5 5.9 
ADHD combined 0.0 3.9 4.0 5.4 1.4 
ADHD hyperactive 5.1 1.0 1.0 8.1 0.2 
ADHD inattentive 3.8 9.8 0.0 0.0 0.7 
Oppositional/conduct 
disorder (%) 
17.7 2.9 4.0 2.7 3.8 
ODD 17.7 6.9 4.0 2.7 2.3 
Conduct 1.3 2.9 0.0 0.0 1.5 
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Tic cohort  Non-tic 
cohort 
Emergency 
control 
Neurology 
control  
Community 
healthy 
control 
Social (%) 0.0 0.0 0.0 0.0 0.0 
Selective mutism 0.0 0.0 0.0 0.0 0.0 
Attachment 
disorder 
0.0 0.0 0.0 0.0 0.0 
PDD/Autism (%) 3.8 2.0 0.0 5.4 0.3 
Eating disorders (%) 0.0 0.0 0.0 0.0 0.1 
      
 
 
The following graphs demonstrate the different rates of each category of disorders across all cohorts. 
The Non-tic cohort represents the primary interest group that has been largely unexplored in terms 
of psychiatric comorbidities in the past. Therefore, statistical comparisons have been performed only 
between the Non-tic cohort and the other cohorts.  
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Figure 4.2 The percentage of any anxiety disorder across all cohorts 
 
 
The rate of any anxiety diagnosis is shown in figure 4.2 above. Of the Non-tic MD cohort, 28.4% had 
any anxiety disorder, compared to 32.3% in the tic cohort. The difference between the Non-tic and Tic 
cohort was not statistically significant. Within the Emergency cohort 11.0% of patients had an anxiety 
disorder. The difference between Non-tic cohort and Emergency cohorts was statically significant 
(p<0.005). The rate of any anxiety disorder in the Neurology cohort was 27.0% and this was not 
statistically significant to the Non-tic cohort, however the rate of anxiety disorder in the community 
cohort was 3.8%, and this was statistically significant to the Non-tic cohort (p<0.00001). Overall when 
comparing the Non-tic MD cohort to the other cohorts, only the difference between the Non-tic 
cohort to Emergency cohort, and Non-tic cohort to Community cohort were statistically significant.  
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Figure 4.3 The percentage of any depressive disorder across all cohorts 
 
 
Figure 4.3 shows the rate of any depressive disorder. The rate of depressive disorder in the Non-tic 
cohort was 4.9%, and in the Tic cohort it was 3.2%. The difference was not statistically significant. 
Within the Emergency cohort the rate of depressive disorder was 1.0% and this was not statistically 
different to the Non-tic cohort. The rate of depressive disorder in the Neurology cohort was 2.7% and 
the difference with the Non-tic rate of depression (4.9%) was not statistically significant. The rate of 
any depressive diagnosis in the Community control was 0.9% and the difference between this cohort 
and the Non-tic was statistically significant. (p<0.00005). Rates for depressive disorders in all cohorts 
were generally much lower than the anxiety disorders, and the differences between the Non-tic 
cohort and the other cohorts were not statically significant with the exception of the community 
cohort.  
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Figure 4.4 The percentage of any disruptive (ADHD) disorder across cohorts 
 
 
 
The rate of any disruptive (including ADHD) diagnosis across all cohorts is shown in Figure 4.4. The 
rate of any disruptive disorder in the Non-tic MD cohort was 13.7%, compared to 8.8% in the Tic MD 
cohort and this difference was not statistically significant. Within the Emergency control cohort the 
rate of any disruptive disorder was 5.0% and when comparing this the rate of 13.7% in the Non-tic 
cohort, the difference was statistically significant (p<0.05). The rate of any disruptive diagnosis in the 
Neurology control cohort was 13.5% and this was not statistically significant to the Non-tic cohort. 
The rate of any disruptive diagnosis in the community control was 5.9% which was statistically 
significant to the Non-tic cohort (13.7%) (p<0.001).  
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Figure 4.5 The percentage of any oppositional or conduct diagnosis across all cohorts 
 
The rate of any oppositional or conduct diagnosis is shown in figure 4.5. The rate of any oppositional 
or conduct disorder in the Non-tic cohort 2.9%, compared to 17.7% in the Tic cohort. The difference 
between the Non-tic and Tic cohort was statistically significant (p<0.0005) Within the Emergency 
control cohort the rate of any oppositional or conduct diagnosis was 4.0% and the difference between 
this and the Non-tic cohort was not statistically significant. The rate of any oppositional or conduct 
diagnosis in the neurology control cohort was 2.7% and the difference between this rate and the rate 
in the Non-tic cohort was not statistically significant. Within the community control, the rate of any 
oppositional or conduct diagnosis was 3.8% and this was not statistically significant in difference to 
the Non-tic cohort. Overall, with respect to the rate of opposition or conduct disorders across all 
cohorts, the only statically significant difference was that between the tic and Non-tic cohorts.  
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4.2.2 Secondary outcome 2: Prevalence and type of DSMV diagnoses by tic disorder 
Rate of psychiatry was examined within the different diagnostic entities of both Tic MD and Non-tic 
MD cohort. Within the Tic MD cohort, psychiatric comorbidities were found in all patients with 
PANDAS and PANS, and 40.0% of those diagnosed with chronic motor tic disorder.  Of those patients 
with TS, 36.7% satisfied criteria for DSMV diagnosis. The range of specific diagnoses present were 
similar across the subgroups of diagnosis, with anxiety disorders, depression, disruptive and 
oppositional disorders seen most commonly. PDD/autism was demonstrated in the tic and chronic 
motor tic patients but absent in PANDAS and PANS subgroup, although the numbers of these latter 
subgroups are small, and so statistical comparisons were not performed. These findings are outlined 
in table 4.3. 
Table 4.3 Rate of psychiatry and specific psychiatric diagnoses seen by tic disorder 
Tic or Tourette 
Diagnosis 
Patients with 
psychiatry  
Specific diagnoses present 
(%) 
Tourette 
Syndrome 
(n=136) 
50 (36.7%) ODD, (24), Separation anxiety (9), OCD (9), ADHD hyperactive (6), 
PDD/autism (5), specific phobia (4), panic disorder (3), other 
anxiety (3), social phobia (2), ADHD inattentive (2), conduct 
disorder (2), generalised anxiety (1), major depression (1) 
Chronic motor 
tic 
(n=10) 
4 (40%) Separation anxiety (2), generalised anxiety (2), OCD (2), ODD (2) 
specific phobia (1), major depression (1), ADHD inattentive (1), 
PDD/autism (1) 
PANDAS 
(n=7) 
7 (100%) Separation anxiety (5,) generalised anxiety (2), OCD (2), ADHD 
hyperactive (1) 
PANS 
(n=5) 
5 (100%) Separation anxiety (4), ADHD inattentive (2), specific phobia (1), 
OCD (1), panic disorder (1), major depression (1), ODD (1) 
Total 
(n=158) 
 66 (41.8)  ODD (27), Separation anxiety (20), OCD (14), ADHD hyperactive 
(7), PDD/autism (6), specific phobia (6), ADHD inattentive (5), 
other anxiety (3), generalised anxiety (3), social phobia (2), , 
conduct disorder (2), major depression (3), panic disorder (1) 
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4.2.3 Secondary outcome 3: DSMV prevalence and diagnoses by movement disorder 
phenomenon 
When analysed by movement disorder phenomenon, and excluding the single functional 
patient, patients with chorea had the highest rate of psychiatric comorbidity (66.7%) followed 
by tremor (60.0%) then, stereotypies (45.5%) and dystonia (33.3%).  
Within the dystonia subgroup of 66 children, anxiety disorders were the most common 
psychiatric comorbidity, including separation anxiety, generalised anxiety, social phobia and 
specific phobia. ADHD (including the hyperactive, inattentive and combined subtypes) was 
also found in the dystonia subgroup, along with ODD and major depression.  
Patients with chorea were also found to have anxiety and mood disorders and 
disruptive/ADHD disorders. Only one patient with myoclonus as a primary movement disorder 
had a psychiatric comorbidity and this was ADHD combined. Patients who had myoclonus as 
a secondary movement disorder, with dystonia or chorea as their primary movement 
problem, were found to have anxiety disorders, ADHD and ODD. 60% of patients with tremor 
had a DSMV diagnosis, although the group was small (n=5 only). Anxiety disorder and mood 
disorders were also observed in the functional subgroup and this was also the only category 
in which PTSD was diagnosed. 
The rates and specific types of psychiatric comorbidities are outlined in table 4.4 below.  
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Table 4.4 Rates and types of DSMV diagnoses by movement disorder in the Non-tic cohort 
Primary 
movement 
disorder 
Secondary 
movement 
n = Patients with 
DSMV 
psychiatry (%) 
Specific diagnoses present 
All dystonia   66 22 (33.3%) separation anxiety (5), social phobia 
(5), specific phobia (4), ADHD 
combined (3), ADHD inattentive (3), 
ODD (3), generalised anxiety (2), 
other anxiety (1), Major depression 
(1), ADHD hyperactive (1) 
Dystonia 
 
Chorea 4 1 Major depression (1), ADHD 
combined (1), ADHD inattentive (1) 
Dystonia Myoclonus 3 2 Other anxiety (1), specific phobia (1), 
ADHD inattentive (1) 
Dystonia Tremor 6 4 Separation anxiety (2), social phobia 
(1), ADHD combined (1), ADHD 
hyperactive (1) 
Dystonia Bradykinesia 4 1 Separation anxiety (1) 
Dystonia Stereotypy 2 1 Generalised anxiety (1), specific 
phobia (1) 
Dystonia none 47 13 Separation anxiety (2), social phobia 
(4), specific phobia (2), generalised 
anxiety (1), ADHD combined (1), 
ADHD inattentive (1), ODD (3) 
All chorea  12 8 (66.7%) Separation anxiety (1), other anxiety 
(1) bipolar/mania (1), major 
depression (2), ADHD inattentive (1), 
ODD (3) conduct disorder (1 
Chorea Myoclonus 2 1 ODD (1) 
Chorea none 10 7 Separation anxiety (1), other anxiety 
(1) bipolar/mania (1), major 
depression (2), ADHD inattentive (1), 
ODD (2) conduct disorder (1) 
All myoclonus  6 1 (16.7%) ADHD combined (1) 
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In addition to analysing the rate of psychiatric comorbidities by movement disorder 
phenomenon, I also evaluated the Non-tic cohort with respect to aetiology.  
Within in the Non-tic cohort, psychiatric comorbidities were most common in patients with 
disorders caused by genetic mutations, both suspected and proven. The rate of DSMV 
diagnosis in the proven genetic group was 54.2% and within the suspected genetic group the 
rate of DSMV diagnoses was 50.0%. The specific psychiatric disorders across both the proven 
and suspected genetic disorders were similar, with anxiety disorders the most commonly 
reported, as well as disruptive disorders and ODD also found.  
The group least affected by psychiatric comorbidities in this cohort were patients with 
neurotransmitter disorders, although the prevalence in this group remained above expected 
norms, with a rate of 23.1%. The patients who had psychiatric comorbidities in the 
neurotransmitter subgroup had anxiety disorders, as well as one patient who had conduct 
disorder.  
Myoclonus Dystonia 3 0 - 
Myoclonus none 3 1 ADHD combined (1) 
All tremor none 5 3 (60.0%) Generalised anxiety (1), panic 
disorder (1), major depression (1) 
All 
bradykinesia 
none 1 0 (0%) - 
All stereotypy none 11 5 (45.5%) Generalised anxiety (1), ADHD 
inattentive (3), ODD (1) PDD/Autism 
(2) 
All other 
(functional) 
none 1 1 (100%) Generalised anxiety (1), PTSD (1), 
major depression (1) ADHD, conduct 
disorder 
 
 
102 40 (39.2%) 
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DSMV diagnoses occurred in 22 patients (27.3%) with dyskinetic cerebral palsy. Within the 
multifactorial cerebral palsy subgroup, the psychiatric comorbidities included anxiety and 
disruptive disorders. 
Psychiatric comorbidities were detected in 36.4% of the immune subgroup and the specific 
diagnoses were quite varied, including social phobia, major depression, bipolar/ mania, ADHD 
combined and ODD.  
The rates and types of psychiatric comorbidity found across the aetiological entities are shown 
in table 4.5.  
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Table 4.5 Rate of psychiatry and specific psychiatric diagnoses by movement disorder aetiology 
Aetiology n = Patients with 
psychiatry (%) 
Specific diagnoses present 
All neurotransmitter 13 3 (23.1%) Generalised anxiety disorder (2), 
separation anxiety (1), conduct disorder (1) 
Dopa responsive dystonia 
(GTP cyclohydrolase 
deficiency) 
4 0   
Dopa responsive dystonia 
(gene negative) 
3 2 Generalised anxiety (2), conduct disorder (1) 
Tyrosine hydroxylase 
deficiency 
3 1 Separation anxiety (1) 
6 PTPS deficiency 3 0 -          
All proven genetic  24 13 (54.2%) Separation anxiety (4), ADHD inattentive 
(3), ODD (3), other anxiety (2), social phobia 
(1), specific phobia (1), major depression 
(1), ADHD combined (1), ODD (1) 
KMT2B dystonia 2 2 Separation anxiety (1), social phobia (1), 
ADHD combined (1), ADHD inattentive (1) 
TBC1D24 dystonia 1 0 -          
Myoclonus dystonia (SCGE) 7 3 Specific phobia (1), other anxiety (1), ADHD 
inattentive (1) 
GNB1 dystonia 1 0   
Glutaric acidura type 1 2 1 Separation anxiety (1) 
Paroxysmal kinesiogenic 
dystonia (PRRT2) 
4 2 Major depression (1), ODD (1) 
Benign hereditary chorea 5 4 Separation anxiety, (1) other anxiety (1), 
ADHD inattentive (1), ODD (2) 
Wilson’s disease 1     
Juvenile Huntington’s 
disease 
1 1 Separation anxiety (1) 
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All suspected genetic  18  9(50%) Separation anxiety (2), generalised anxiety 
(2), social phobia, (1), specific phobia (1), 
major depression (1), panic disorder (1), 
ADHD combined (2), ADHD hyperactive (1), 
ODD (1) 
Dystonia - gene negative 11 6 Separation anxiety (2), generalised anxiety 
(1), social phobia, (1), generalised anxiety 
(1), specific phobia (1), ADHD combined (1), 
ADHD hyperactive (1), ODD (1) 
Chorea - gene negative 1 0   
Myoclonus - gene negative 2 1 ADHD combined (1) 
Tremor gene negative 4 2 Generalised anxiety (1) panic disorder (1), 
major depression (1) 
All immune 11 4(36.4%) Social phobia (2), major depression (2), 
Bipolar/mania (1) ADHD combined (1), 
ODD (1) 
Sydenham’s chorea 2 2 Bipolar/mania (1), major depression (2) 
Antiphospholipid chorea 1 0   
Basal ganglia encephalitis 
(Dopamine 2 Receptor 
Antibody positive) 
4 2 Social phobia (2) ADHD combined (1), ODD 
(1) 
Rasmussen encephalitis 
with hemidystonia 
1 0 - 
Opsoclonus myoclonus 
syndrome 
2 0 - 
Acute immune akinetc 
psychotic syndrome 
1 0 - 
All multifactorial (dyskinetic 
CP group) 
22 6 (27.3%)  ADHD inattentive (2), specific phobia (2), 
separation anxiety (1), generalised anxiety 
(1), social phobia (1) 
Prematurity defined as 
cause 
7 4 Separation anxiety (1), social phobia (1), 
specific phobia (1), ADHD inattentive (2) 
Vascular event (in utero or 
neonatal) 
4 0   
Kernicterus 3 1 Generalised anxiety (1) 
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Hypoxic ischaemic 
encephalopathy or 
traumatic delivery 
4 1 ADHD inattentive (1), specific phobia (1) 
Unknown 4 0 -          
Stereotypy (All 
developmental) 
11 4(36.4%)  Generalised anxiety (1), ADHD, inattentive 
(2) ODD (1), PDD/autism (2) 
 
3 1(33.3%)  Generalised anxiety (1), PTSD, (1), major 
depression (1), ADHD inattentive (1), 
conduct disorder (1) Psychogenic movement 
disorder  
 
102 40 (39.2%) 
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4.2.4 Secondary outcome 5: Correlation between diagnosis made by clinician and DAWBA 
diagnoses 
For those patients recruited at CHW, Australia (n=180), (inclusive of both Tic MD and Non-tic 
MD patients), DAWBA psychiatric diagnoses were compared to clinical diagnoses attributed 
by the patient’s treating Neurologist. Overall, the Neurologist had diagnosed a DSMV 
diagnosis in 48.3% of patients with movement disorders, compared to 46.1% diagnosed by 
the DAWBA.  
Table 4.6 below demonstrates the number of patients with and without clinician diagnosis 
that received positive or negative for DAWBA psychiatric diagnosis. 
Table 4.6 Clinician versus DAWBA diagnosis in all Australian movement disorder patients 
 
 
Of the 180 MD patients recruited at CHW, Australia, 87 were diagnosed with a DSMV diagnosis 
by their treating Neurologist. Of those 87, 56 (64.3%) were also diagnosed with a psychiatric 
diagnosis by the DAWBA. Presented alternatively, of the 180 MD patients recruited at CHW, 
Australia, the DAWBA diagnosed a psychiatric comorbidity in 83. Of those 83 DAWBA positive 
patients, the treating Neurologist had diagnosed a psychiatric disorder in 56 (67.5%). Within 
the 180 MD patients recruited at CHW, the DAWBA was negative for psychiatry disorder in 
97. Of those 97, the treating Neurologist had been in agreement that no psychiatric diagnosis 
applied in 66 cases (68.0%). 
 
 Clinician findings for all movement 
disorder patients 
DAWBA positive for DSMV DAWBA negative 
for DMSV 
Clinician diagnosis (n=87) 56 31 
No clinician diagnosis (n=93) 27 66 
All Australian cohort (n=180) 83 97 
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4.2.5 Secondary outcome 6: Relationship between clinical and DAWBA OCD findings 
Special consideration was allocated to diagnosis of OCD as the prevalence rates found in this 
study were lower than anticipated. Across both Tic and Non-tic patients the Neurologist had 
diagnosed 36 cases with OCD. The DAWBA also diagnosed OCD in 12 (33.3%) of these cases, 
however an additional 11 (31.4%) of clinician rated OCD patients, the DAWBA diagnosed an 
alternative anxiety diagnosis such as separation anxiety or specific phobia. In 13 (36.0%) of 
cases of clinician diagnosed OCD patients, the DAWBA did not attribute any psychiatric 
diagnosis. Rates of positive and negative DAWBA vs clinician diagnose are outlined in table 
4.7. 
 
Table 4.7 Clinician versus DAWBA OCD diagnosis in all Australian movement disorder patients 
 
 
Of the 180 MD patients recruited at CHW, Australia, the DAWBA diagnosed OCD in 16 patients. 
The treating Neurologist had also diagnosed OCD in 12 of those 16 patients (75.0%). Within 
the same Australian 180 MD patients, the treating Neurologist had diagnosed OCD in 36, and 
the DAWBA agreed in 12 (33.3%) of cases. Interestingly however, of the remaining 24 who 
were clinician positive and DAWBA negative for OCD, 9 were diagnosed with a different 
anxiety disorder by the DAWBA.   
 Clinician findings for all movement 
disorder patients 
DAWBA positive for OCD DAWBA negative for OCD 
Clinician diagnosis (n=36) 12 24 
No clinician diagnosis (n=144) 4 140 
All Australian cohort (n=180) 16 164 
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4.3 Secondary outcome 7: Description of therapeutic interventions  
With respect to all MD patients, both with and without DSMV diagnoses, pharmacological 
therapies for psychiatric symptoms had been prescribed for 40.5% of the Tic MD cohort and 
15.7% of the Non-tic MD cohort. Medications included fluoxetine, fluvoxamine, risperidone, 
quetiapine, clonidine, methylphenidate and atomoxetine. Psychological therapy had been 
recommended for 37.3% of all Tic MD patients and only 14.7% of Non-tic MD patients. 
Interestingly, for patients with a DAWBA DSMV diagnosis, 45.5% of patients in the Tic MD 
cohort had taken psychiatric medications compared to only 22.5% of Non-tic patients. In 
terms of psychological therapy in the DAWBA DSMV positive subgroup, 43.9% of the Tic 
patients had accessed therapy, compared to only 15.0% of Non-tic patients with a psychiatric 
diagnosis. 
4.4 Associations  
4.4.1 Impact of parental tertiary education 
I analysed whether parental tertiary education could be a confounder and influence the rate 
of psychiatric diagnoses in offspring. There was no clear difference in parental tertiary 
education in the different cohorts. In the children with movement disorders (both Tic and 
Non-tic movement disorder), of the patients with a DAWBA rated DSMV diagnosis, 40.0% of 
parents had tertiary education, whereas in patients without a DAWBA rated DSMV diagnosis, 
25.9% of parents had tertiary education. The difference was not statically significant (p= 
3.871). 
4.4.2 Impact of neurological comorbidities in the Non-tic cohort 
A further factor which may have influenced the DSMV psychiatric diagnosis was the presence 
or absence of neurological comorbidity. As outlined in table 4.8 below, neurological 
comorbidities were noted in 45.1% of patients with Non-tic MD patients and included 
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hypertonia or hypotonia, bulbar or cranial nerve dysfunction, ataxia and epilepsy. In the Tic 
MD cohort neurological comorbidities were only reported in 1.9%. Overall, neurological 
comorbidities were not associated with increased rates of psychiatric comorbidities, however 
the smaller subsets of these study cohorts with neurological are not ideal for allowing 
extensive extrapolations regarding these associations.    
Table 4.8 Neurological in each cohort and rate psychiatric diagnosis 
  
 Neurological comorbidities  Patients 
(n=) 
Rates of DSMV 
diagnoses in 
patients with 
specific 
comorbidities 
Tic MD 
(n=158) 
All neurological comorbidities   3 30.0% 
 
Epilepsy  3 30.0% 
Non-tic MD 
(n=102)   
All neurological comorbidities  46 34.8% 
 Hypertonia  28 27.5% 
Bulbar/crania nerve dysfunction  8 7.8% 
Ataxia  4 3.9% 
Epilepsy   4 3.9% 
Hypotonia  4 3.9% 
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5 Discussion 
5.1 Important novel finding of psychiatric prevalence 
This study demonstrates that children with movement disorders are four times as likely to 
have a psychiatric diagnosis than children in the general community. More importantly, this 
is the first large study that specifically examines children with Non-tic movement disorders, 
including dystonia and chorea, and describes that whilst there has long been concern about 
elevated rates of psychiatric comorbidities with tics and TS, children with other movement 
disorders such as dystonia and chorea have almost the same rate of psychiatric comorbidities 
as children with tics (39.2% in the Non-tic MD cohort: 41.8% in the Tic MD cohort). Of the 102 
Non-tic patients in this study, greater that 1/3 (39.2%) satisfied criteria for a DSMV diagnosis.  
This is the largest study of psychiatry in paediatric dystonia performed to date, comprising of 
66 patients with dystonia secondary to primary and secondary aetiologies.  One third of these 
children (33.3%) had a psychiatric comorbidity. These comorbidities represent a burdensome 
aspect of the patient’s neurological disorder. The psychiatric diagnoses may often be 
unrecognised, and therefore untreated. These new insights into the high rates of psychiatric 
comorbidities provide an important contribution to our understanding of paediatric 
movement disorders, and opportunities to improve patient care. 
5.2 Psychiatry in the Non-tic cohort 
This study included 102 patients with Non-tic movement disorders, and 39.2% had a 
psychiatric diagnosis. This rate was not statistically significant to the tic movement disorder 
cohort.  
The rates of psychiatric comorbidities in dystonia patients (33.3%), our largest Non-tic 
movement disorder subgroup, were in keeping with anecdotal reports of troubling anxiety 
disorders in this population. Children with chorea had rates of psychiatry (66.7%) elevated 
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above the other movement disorder types, although the chorea subgroup was small (n=11). 
The high rates of psychiatric problems were expected within the Sydenham’s chorea patients, 
however the elevated rate of psychiatry in patients with genetic chorea had not been 
anticipated.  
In terms of aetiology, patients with suspected genetic disorders had similar rates of psychiatric 
conditions to those with proven genetic conditions. Interestingly, patients with strictly 
neurotransmitter diagnosis were lower than those in the broader genetic subgroup. It is 
possible that larger multicentre studies may be needed to evaluate psychiatric comorbidities 
of the rare neurotransmitter disorders with greater accuracy.  
Psychiatric comorbidities were less frequent in the dyskinetic cerebral palsy sub-group. 
Anecdotal discussions with treating clinicians of these patients had led to a suspicion that 
psychiatric problems were a very common problem for children with dyskinetic cerebral palsy. 
The method of this study, however, was not purpose built for evaluating children with cerebral 
palsy, many of whom have communication or intellectual disabilities. As children who were 
non-verbal were excluded from this study, the patients with cerebral palsy represent a 
particularly high functioning subgroup and this is likely to have impacted on the psychiatric 
profile.  Moving forward, a study of psychiatric comorbidities for children with dyskinetic 
cerebral palsy by way of a tool not relying on verbal responses would be a valuable 
contribution to our understanding of psychiatry in dyskinetic cerebral palsy.  
5.3  Differences in treatment patterns between the Tic and Non-tic cohort 
One of the most pertinent and surprising findings in this study related to therapies provided 
to patients in the Tic and Non-tic cohorts.  Whilst the rates of DSMV diagnosis were similar in 
both MD cohorts, the rate of treatment was very different. Essentially, patients with tics and 
psychiatric diagnoses were far more likely to have received therapy than patients with Non-
tic movement disorders and psychiatric diagnosis. Of all the patients with tics who had a 
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psychiatric comorbidity, 45.5% were either receiving or had received psychiatric medications, 
and 43.9% had received psychological therapy. These numbers are far greater than the Non-
tic cohort, where only 22.5% had taken psychiatric medications and 15.0% had undergone 
psychological therapy. Of course, these are crude comparisons that do not take in to account 
the severity of each patient’s comorbidity, or other factors affecting treatment such as 
treatment adherence or parental insight, however it is likely that these numbers are 
influenced by the difference in our understandings of these movement disorders. Tic disorders 
and TS have been well researched with respect to psychiatric comorbidities and screening for 
these comorbidities is generally considered best practice for these patients. However, Non-tic 
movement disorders have remained largely unexplored in terms of psychiatric comorbidity 
until now, suggesting many patients have gone undiagnosed and untreated in terms of their 
psychiatry.  
5.4 Prevalence of psychiatry in the various tic disorders  
It was interesting to note that the rate of psychiatry in chronic motor tics (40.0%) was elevated 
above those with definite Tourette (36.7%). One possible reason for this was that children 
with motor tics are primarily looked after by general paediatricians. The patients recruited for 
this study with chronic motor tics were all being managed at a specialised tic clinic at a 
quaternary paediatric hospital. They had all been reviewed by paediatricians and referred on 
for specialised care, mostly in view of their severe tics or other complexities (therefore 
representing referral bias). With that in mind it is not surprising that this most severe subgroup 
of patients with a chronic tic would have an elevated rate of comorbidities.  It was not 
surprising to find 100% rates of comorbidities in PANDAS and PANS, as these conditions both 
have emotional symptoms as part of their diagnostic criteria.  
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5.5 Specific psychiatric comorbidities detected 
The most common comorbidities across all groups were anxiety disorders, with ADHD also 
commonly observed. ODD was seen frequently in the Tourette group and oppositional and 
conduct problems have been observed in other studies of patients with TS (Khalifa and von 
Knorring, 2006). Our rates of ADHD (13.7% in the Non-tic MD and 8.8% in the tic MD cohort) 
were lower than previously published rates of 21-90% (Mol Debes, 2013) and it is expected 
that the absence of school teacher responses in our study lowered the reported symptoms 
and impact. The option of seeking teacher responses, was considered during the study design 
however it was considered that this would be logistically difficult and potentially reduce the 
level of uptake of parents who may not want to draw school-based attention to their child’s 
psychiatric profile. Another comorbidity that was lower than anticipated in the tic cohort was 
OCD, with other studies showing rates of obsessive compulsive symptoms in approximately 
40% (Como et al., 2005, Lebowitz et al., 2012). During the comparison between DAWBA and 
clinician diagnosis it became evident that of the 36 patients that had been diagnosed with 
OCD by their treating Neurologist, 9 (25.0%) were attributed an alternative anxiety diagnosis 
by the DAWBA, but not OCD. This occurred most commonly with patients being diagnosed 
with separation anxiety by the DAWBA. When I spoke to parents of children who experienced 
OCD it was often the case that the family had so effectively adjusted to the OCD conditions, 
that the impact was negligible within the family unit (negating the significant impact required 
for the DAWBA diagnosis) but that the child avoided being away from their main carer as a 
result, and was therefore allocated a diagnosis of separation anxiety.  
The DAWBA determines diagnosis by impact or ‘burden’ and does not count prevalence on 
the basis of symptoms only. During the DAWBA interviews many parents seemed to respond 
to the questions about impacts and burden by replying with a variation of “He/She will never 
be a burden. We have just needed to adjust to it.” This observation was made during the paper 
that reported UK Mental Health Survey in which the DAWBA was initially utilized and several 
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studies have shown that tools relying on impact for diagnosis produce lower prevalence rates 
(Anderson et al., 1987, Ford et al., 2003, Shaffer et al., 1996). Furthermore several psychiatric 
comorbidities such as obsessive-compulsive disorder and depression tend to increase in later 
adolescence and the mean age of the population (10 years) would likely lead to a lower rate 
of psychiatric comorbidities captured (Ford et al., 2003).  
5.6 The DAWBA as a screening tool 
Overall the rates of psychiatric comorbidities in children with tic movement disorders children 
were lower than other studies where comorbidities have been described in up to 90% 
(Cavanna and Termine, 2012). The DAWBA has been described as more conservative than 
other psychiatric screening tools such as the DISC and CAPA; in one study the DAWBA detected 
1 or more diagnoses in 17.7% of patients in paediatric care clinics, whilst the DISC and CAPA 
diagnosed disorders in 47.1% and 32.4% respectively (Angold et al., 2012). Several papers 
have confirmed that the DAWBA tends to under diagnose emotional disorders. In the study 
by Groth that examined comorbidities in Tourette, the DAWBA was used along with several 
other tools and compared to clinical assessment. The rates of OCD were significantly lower in 
the DAWBA assessments than the clinical assessments (6% vs 24%). (Groth et al., 2017b) 
Another paper looking at the clinical utility of the DAWBA against clinical assessment in 
patients with suspected ADHD (n=86) found there was a high rate of false negatives of 
emotional disorders when using DAWBA (13 false negatives) and suggested emotional 
disorders were conservatively diagnosed by the DAWBA. (Foreman et al., 2009) For my study, 
it was felt than a tendency to under-diagnose, rather than over-diagnose, would lend to a 
study of greater validity. In this context it was important to use the Tic MD cohort as a positive 
control, and this study showed similar rates of psychiatric comorbidity between tic MD and 
Non-tic MD patients.  
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In this study, assessment of the Australian subgroup of movement disorder patients revealed 
that the DAWBA was slightly more conservative than the treating clinician, attributing a DSMV 
diagnosis to 45.9% of patients compared to the treating Neurologist who had diagnosed 48.1% 
of patients with psychiatry. 
5.7 The control cohorts 
The hospital control groups both consisted of patients recruited in a quaternary hospital and 
both hospital control groups were elevated in their rate of psychiatry when compared to the 
community control. The Emergency control group was comprised of children between 5 and 
16 years who presented to the Emergency Department at CHW for an acute medical condition. 
The prevalence of psychiatry in this cohort (18.0%) was within the range of 18-21% found in 
previous studies that utlised the DAWBA in a tertiary hospital outpatient (Jesmin et al., 2016, 
Machnes-Maayan et al., 2014).  
Whilst patients with significant chronic illness were excluded from the study, there were 
several factors that led to suspicion that psychiatric prevalence in these patients would be 
greater than the community prevalence. First of all, these patients were being recruited at a 
time of illness and therefore family stress, which may have influenced their view of recent 
behaviour and resulted in recall bias. Secondly, the study excluded children who were critically 
unwell or in pain for obvious ethical reasons. This exclusion criteria meant that patients who 
remained eligible had been brought to a quaternary Emergency department for non-critical 
acute medical concerns including fevers, rashes, upper respiratory tract infections and 
abdominal pain. Whilst several patients in this control cohort required hospital interventions 
such as plastering fractured limbs or nebulized treatment for asthma, many patients attended 
hospital with medical issues that could have been seen by general practitioner or outpatient 
clinic. There are numerous  reasons why families may chose care from an Emergency 
department as opposed to a local primary care setting, and some of these include parental 
  152 
anxiety, previous negative experiences in accessing local health services, socio-economic 
barriers to seeking outpatient care (including difficulties in making or attending appointments 
or being unable to afford services and medications) and factors relating to the child 
themselves including the child’s own level of anxiety about their symptoms or pre-existing 
developmental issues. Therefore, it is not unreasonable to suggest that psychiatric conditions 
may be elevated in this cohort. Another reason that parents reported bringing their child to 
Emergency throughout the recruitment process was that relatively benign complaints had 
occurred for a concerning amount of time. This was specifically the case with headaches and 
abdominal pain. It is well understood in the paediatric discipline that chronic headaches and 
chronic abdominal pain frequently co-exist with mood and anxiety problems, which may 
explain the elevated psychiatric diagnoses in the emergency cohort when compared to the 
community control.  
The 27% rate of psychiatry in the Neurology control is likely explained by the incorporation of 
epilepsy where rates of psychiatric comorbidity have been reported to be at least 40% 
(Grabowska-Grzyb et al., 2006, Verrotti et al., 2014). In addition, patients in the neurology 
cohort have been dealing with chronic illness that may potentially contribute to psychiatric 
vulnerabilities not found in healthy populations. I attempted to avoid recruitment bias in this 
cohort by recruiting all patients who fulfilled the inclusion criteria, rather than those who were 
recognised as having psychiatric problems. The Neurology control group represented the most 
challenging aspects of recruitment for this study, due to the small number of patients affected 
by peripheral neuropathies in the hospital, and the high rate of moderate to severe 
intellectual disability in the epilepsy group making them ineligible. A limitation of the study 
was the small size of this Neurology cohort, and the subsequent difficulty in statistically 
comparing rates from this group (due to the small cohort size). The difference between the 
rates of psychiatry in the Non-tic cohort and the Neurology cohort was not statistically 
significant for all comparisons, which may be a reflection of the prevalence of psychiatry in 
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those groups being similar, however it may also reflect the fact that larger numbers are 
needed, particularly in the Neurology cohort, to interrogate any differences more completely.   
5.8 Limitations 
Obviously, a larger study cohort, especially of the Neurology control group, would have been 
advantageous to the study. In actuality the initial study method included plans for 100 
neurology control patients with CMT. As the study unfolded it became evident there were not 
enough CMT patients eligible in the age range to recruit. The study was then amended to aim 
for 50 patients with CMT. It was disappointing to find that even 50 patients became 
unattainable; patients with peripheral neuropathies are generally managed out of hospital 
and contact with them was limited as they attend one appointment every one or two years. 
As such the study was amended to include epilepsy patients in the neurology cohort.  
However, despite epilepsy being a relatively common condition, recruiting patients with 
epilepsy also proved more difficult than initially anticipated. Children with epilepsy who 
frequently attended the hospital, generally had significant intellectual impairment which 
rendered them ineligible for the study. Those patients with mild epilepsy were not often 
attending a tertiary hospital and therefore not available for recruitment.  
A further limitation is that this study examined a heterogenous group of movement disorders 
and within the Non-tic cohort there are multiple small subgroups. Each of these individual 
diagnoses provide interesting questions as to the relationship between neurology and 
psychiatry, and larger cohorts of each genetic and neurotransmitter subtype would be useful 
to better understand these disorders. Equally, as our genetic diagnoses of movement 
disorders continues to improve, detection of the genes responsible for suspected genetic 
conditions in this cohort will allow for meaningful comparisons and phenotyping of these 
disorders with respect to their neuropsychiatric profiles. 
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Throughout the study there was a definite attempt to avoid recruitment bias, with an effort 
made to recruit every eligible patient with a movement disorder, as opposed to targeting only 
those suspected to have a psychiatric comorbidity. However, in real life clinical practice there 
are some consultations that are harder than others, with occasional opportunities for 
recruitment being missed due to factors beyond this study.  Despite these theoretical 
recruitment biases, it is anticipated that in a study with >100 patients in both the tic and Non-
tic cohorts respectively, a relatively accurate picture of these patient groups has been 
obtained. During the recruitment process, there were 70 patients from all groups (who had 
initially agreed to participate in the DAWBA who did not complete the questionnaire (n=467, 
including participants and non-participants). This rendered the completion rate to be 85.0%. 
It is possible that the patients who did not complete the DAWBA may have had different 
psychiatric profiles to the patients included, and this may have impacted on the findings.  
The study is also limited by the use of only one psychiatric screening tool and every tool has 
its limitations. In this case it is likely the DAWBA has under diagnosed some disorders, 
especially given that the teacher questionnaire was not included. A best-case study would 
have used several tools and a clinical screening process to ensure diagnostic accuracy, but this 
would have not been practical with the cohorts of these sizes. A local, out of hospital 
community control would also have been advantageous in supplementing the UK community 
control however this was not logistically possible.  
This study examined the rate of psychiatric comorbidities in children with movement 
disorders, however it has not interrogated the aetiology of these disorders or their prognosis 
over time. Equally, further research into the treatment options for psychiatric comorbidities 
in this specific group as well as analysis of the protective factors that prevents some patients 
from experiencing these comorbidities provide opportunities for further research.  
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6 Conclusion 
 
Children with Tourette Syndrome are well known to have elevated rates of psychiatric 
comorbidities, well above community cohorts. This study contributes new information by 
demonstrating that children with other movement disorders such as dystonia and chorea have 
almost the same rates of psychiatric comorbidities as those with tics and Tourette Syndrome.  
These findings may modify the clinical approach to children with movement disorders by 
suggesting that psychiatry is prevalent and impactful in all patients with movement disorders. 
Screening for, and managing psychiatric comorbidities, as recommended in TS patients should 
therefore be considered for patients with other movement disorders.  
This study includes a total of 260 patients affected by movement disorders, and for more than 
a third of these patients, their difficult movements are compounded by additional psychiatric 
disease. It is hoped that this study contributes to the field in a way that informs future 
directions and enhances the current care of families who took hope from this research.      
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